<SEC-DOCUMENT>0001193125-20-203325.txt : 20200730
<SEC-HEADER>0001193125-20-203325.hdr.sgml : 20200730
<ACCEPTANCE-DATETIME>20200730070004
ACCESSION NUMBER:		0001193125-20-203325
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200730
DATE AS OF CHANGE:		20200730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		201059128

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d919859d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:md="http://www.mednax.com/20200630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-Q</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
 <div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="hidden13911539" contextRef="P01_01_2020To06_30_2020">false</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="hidden13950822" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden13950823" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF">0.01</ix:nonFraction><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="hidden13911545" contextRef="P01_01_2020To06_30_2020">Q2</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="hidden13911547" contextRef="P01_01_2020To06_30_2020">0000893949</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="hidden13911549" contextRef="P01_01_2020To06_30_2020">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntitySmallBusiness" id="hidden13913753" contextRef="P01_01_2020To06_30_2020">false </ix:nonNumeric><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="hidden13913752" contextRef="P01_01_2020To06_30_2020">false </ix:nonNumeric><ix:footnote id="FN_52647" xml:lang="en-US">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.</ix:footnote ><ix:footnote id="FN_52648" xml:lang="en-US">Due to a loss from continuing operations for the six months ended June 30, 2020, no incremental shares are included because the effect would be antidilutive. </ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="md-20200630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_24_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:TwoThousandTwentyThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >md:HospitalsContractsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >md:ContractedManagedCareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:GovernmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis" >us-gaap:SelfPayMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:ExecutiveOfficerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:DivestitureOfMeddataMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-25</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-27</xbrli:startDate> <xbrli:endDate>2020-03-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis" >md:CovidNinenteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis" >md:RuralAreaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >md:CreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-25</xbrli:startDate> <xbrli:endDate>2020-03-25</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-06</xbrli:startDate> <xbrli:endDate>2020-05-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis" >md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_13911053" toRefs="FN_52647"/><ix:relationship fromRefs="Fact_13911054" toRefs="FN_52647"/><ix:relationship fromRefs="Fact_13911059" toRefs="FN_52647"/><ix:relationship fromRefs="Fact_13911060" toRefs="FN_52647"/><ix:relationship fromRefs="Fact_13911218" toRefs="FN_52648"/><ix:relationship fromRefs="Fact_13911219" toRefs="FN_52648"/><ix:relationship fromRefs="Fact_13911225" toRefs="FN_52648"/><ix:relationship fromRefs="Fact_13911226" toRefs="FN_52648"/></ix:resources></ix:header></div><div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em; line-height: 12pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 4pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2020To06_30_2020">10-Q</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="P01_01_2020To06_30_2020" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2020To06_30_2020" format="ixt:datemonthdayyearen">June 30, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2020To06_30_2020">2020</ix:nonNumeric><span style="-sec-ix-hidden:hidden13911545"></span></ix:nonNumeric> </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2020To06_30_2020" format="ixt:booleanfalse">&#9744;</ix:nonNumeric><span style="-sec-ix-hidden:hidden13911539"></span></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the transition period from <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> to <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div></div></div> </div> </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Commission File Number: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2020To06_30_2020">001-12111</ix:nonNumeric></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 18pt; font-size: 18pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 18pt;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2020To06_30_2020">MEDNAX, INC.</ix:nonNumeric></div></div><div style="line-height: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 18pt; font-size: 18pt; background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 18pt; background: none; text-decoration: none;;display:inline;"> </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8pt; font-size: 8pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto; width: 21%; text-align: center; line-height: 6pt; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px; line-height: 6pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2020To06_30_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2020To06_30_2020">26-3667538</ix:nonNumeric></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div></div> <div><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Incorporation or organization)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/> Identification No.)</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2020To06_30_2020">1301 Concord Terrace</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2020To06_30_2020">Sunrise</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="P01_01_2020To06_30_2020" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2020To06_30_2020">33323</ix:nonNumeric></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Address of principal executive offices)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Zip Code)</div></div></td> </tr> </table> <span style="-sec-ix-hidden:hidden13911549"></span><span style="-sec-ix-hidden:hidden13911547"></span> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2020To06_30_2020">954</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2020To06_30_2020">384-0175</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not Applicable </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Former name, former address and former fiscal year, if changed since last report) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 0%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: 'Times New Roman';"></td>
<td style="width: 1%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; width: 34%; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 32%; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Symbol</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 32%; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 34%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2020To06_30_2020">Common Stock</ix:nonNumeric>, par value $.01 per share</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 0%;">&#160;&#160;</td>
<td style="vertical-align: top; width: 32%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2020To06_30_2020">MD</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: top; width: 32%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2020To06_30_2020" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2020To06_30_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-T</div> (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2020To06_30_2020">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 58%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 20%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 17%;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2020To06_30_2020" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 58%;">&#9746;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 20%;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 17%;">Non-accelerated filer</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 58%;">&#9744;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 20%;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td>
<td colspan="2" style="height: 6pt;;width:;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 17%;"></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 58%;"></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; width: 20%;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#9744;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2020To06_30_2020" format="ixt:booleanfalse">&#9746;</ix:nonNumeric><span style="-sec-ix-hidden:hidden13913753"></span><span style="-sec-ix-hidden:hidden13913752"></span></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;24, 2020, the registrant had outstanding<div style="display:inline;">&#160;</div><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn07_24_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">85,461,731</ix:nonFraction> shares of Common Stock, par value $.01 per share. </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PART I - FINANCIAL INFORMATION</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 1.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Statements</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_3">Consolidated Balance Sheets as of June&#160;30, 2020 and December&#160;31, 2019 (Unaudited)</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_4">Consolidated Statements of Income for the Three and Six Months Ended June&#160;30, 2020 and 2019 (Unaudited)</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_5">Consolidated Statements of Equity for the Three and Six Months Ended June&#160;30, 2020 and 2019 (Unaudited)</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_6">Consolidated Statements of Cash Flows for the Six Months Ended June&#160;30, 2020 and 2019 (Unaudited)</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_7">Notes to Consolidated Financial Statements (Unaudited)</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_8">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 3.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_9">Quantitative and Qualitative Disclosures About Market Risk</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 4.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_10">Controls and Procedures</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#tx919859_11">PART II - OTHER INFORMATION </a></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 1.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_12">Legal Proceedings</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_13">Risk Factors</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 2.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_14">Unregistered Sales of Equity Securities and Use of Proceeds</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Item 6.</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#tx919859_15">Exhibits</a></div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td colspan="3" style="height: 6pt;">&#160;</td>
<td colspan="4" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><a href="#tx919859_16">SIGNATURES </a></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div><div id="tx919859_3" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,151</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">345,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">498,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes receivable</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,083</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">688,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">731,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">91,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,165,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,165,020</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">200,408</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">209,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75,817</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,227</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,827</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">97,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets held for sale</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">682,312</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,387,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">360,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">453,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of finance lease liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,485</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,039</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities held for sale</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">383,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">541,819</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt and finance lease liabilities, net</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,737,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,730,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">260,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">226,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income tax liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">52,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,899</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Liabilities held for sale</div></div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,560,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,646,905</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock; $<span style="-sec-ix-hidden:hidden13950822">.01</span> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock; $<span style="-sec-ix-hidden:hidden13950823">.01</span> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">200,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">85,536</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></ix:nonFraction> shares issued and outstanding, respectively</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,004,786</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Retained (deficit) earnings</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">179,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">826,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,387,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx919859_4" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except per share data) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.7pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">509,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">561,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,071,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,104,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">349,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">361,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">748,715</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSalariesAndBenefits" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">731,571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Practice supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,433</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PracticeSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">165,232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">165,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,393</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,792</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">474,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">501,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,020,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">992,357</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">111,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment and other&#160;income</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,265</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity in earnings of unconsolidated affiliates</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">55,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from continuing operations before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">31,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,109</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,047</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">42,593</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">680,036</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">293,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin-bottom:0.0001pt; text-align:right; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></div></div></div> </td>
<td style="padding: 0in; white-space: nowrap;;vertical-align:bottom;"> <div style="margin-bottom:0.0001pt; line-height:normal; margin-top:0px; font-family:Calibri,sans-serif"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">691,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">251,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Per common and common equivalent share data:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from continuing operations:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.09</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.14</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.12</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">8.32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 67%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average common shares:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 67%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> </div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx919859_5" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF EQUITY </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;;width:;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional</div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnings</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">987,942</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,498,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,712</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax <div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_13911053">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_13911054">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">and conversion of restricted stock units to common stock</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">968</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2020To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">852</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">995,257</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">491,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,487,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,436</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 1pt; margin-bottom: 0pt; margin-left: 1em; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on </div></div> <div style="line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investments, net of tax</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,078</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,078</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">277</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,541</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,544</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">200</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,489</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,004,786</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">179,071</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">826,570</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January&#160;1, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">87,820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">992,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,094,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,087,884</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">242,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding loss on investments, net of tax <div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1) </div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_13911059">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_13911060">194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,541</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock swaps</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodSharesStockSwaps" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="md:StockIssuedDuringPeriodValueStockSwaps" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,525</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,740</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P01_01_2019To03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">86,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">977,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,801,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,779,812</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized holding gain on investments, net of tax</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">123</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeitures of restricted stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,080</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchased common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,196</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,527</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 63%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2019</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,096</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">841</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">967,429</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,756,757</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,725,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 6pt;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div>&#160;</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial. </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div></div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> </div> <div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div> <div id="tx919859_6" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;Months&#160;Ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">691,148</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">251,117</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,999</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">293,710</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income to net cash from operating activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,792</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,584</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of premiums, discounts and issuance costs</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,785</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,934</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,819</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,853</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,812</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,378</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,092</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,284</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">44,296</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,703</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,281</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,715</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long-term assets</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,560</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,233</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">86,609</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">52,307</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">/<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>receivable</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">49,757</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,181</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of contingent consideration liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">418</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,931</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,628</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,888</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,212</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,893</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,031</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities - discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,658</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,184</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by operating activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,551</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63,215</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition payments, net of cash acquired</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,450</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,335</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from maturities or sales of investments</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,135</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,180</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,326</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,926</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of business</div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">, net of cash sold</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">476</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,125</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,196</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">provided by (</div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">used&#160;in<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div> investing activities</div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,466</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,438</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,659</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,634</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings on credit agreement</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">898,500</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on credit agreement</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,500</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,286,500</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of senior notes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="width: 6%; height: 15px; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500,000</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments for credit facility amendment and financing costs</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">510</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,194</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of contingent consideration liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,248</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,171</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance lease obligations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,376</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,551</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchases of common stock</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,043</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">144,509</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities &#8211; continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">611</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,421</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities</div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">discontinued operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction> &#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in financing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">611</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,421</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">increase</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">(</div>decrease<div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div> in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,281</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,840</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at beginning of period</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,870</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">40,774</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents&#160;at end of period</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,151</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,934</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%; background-color: rgb(255, 255, 255);"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these Consolidated Financial Statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX, INC. </div></div></div><div id="tx919859_7" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30, 2020 </div></div></div><div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and New Accounting Pronouncements: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors. </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">37.5</ix:nonFraction>% economic interest and a second joint venture in which it owns a <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn06_30_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">49.0</ix:nonFraction>% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. </div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the &#8220;Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;).</div> </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology medical group. The operating results of the Company&#8217;s anesthesiology medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2020, the Company announced the initiation of a process to divest its radiology services medical group when market conditions are appropriate in order to refocus the business as a dedicated pediatrics and obstetrics organization. However, there can be no assurance that this process will result in a transaction. The Company&#8217;s radiology services medical group is reported within continuing operations for all periods presented as the accounting criterion for assets held for sale was not met as of June&#160;30, 2020. </div></div></div></div><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New Accounting Pronouncements</div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 14pt;"><div style="font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_14126975">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology medical group on May&#160;6, 2020. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, the Company&#8217;s operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020. </div></div></div></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">&#160;</div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_14126975"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including <ix:nonFraction name="md:PercentageIncreaseDecreaseInSalaryAndWage" contextRef="P01_01_2020To06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company also divested its anesthesiology medical group in May 2020, where operating results were significantly impacted by COVID-19. </div></div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In response to the anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $<ix:nonFraction name="md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">139.2</ix:nonFraction>&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</ix:nonNumeric> to <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</ix:nonNumeric> for the second and third quarters of 2020 and <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</ix:nonNumeric> for the fourth quarter of <ix:nonNumeric name="md:SupplementaryLeverageRatioRequired" contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</ix:nonNumeric>, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">300.0</ix:nonFraction>&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At June&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To06_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.25</ix:nonFraction>% senior unsecured notes due 2023<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and its <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2020To06_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction>% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2020, the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $<ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn06_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million which reduced the amount available on its Credit Agreement to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">899.8</ix:nonFraction>&#160;million at June&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. </div></div></div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction>&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $<ix:nonFraction name="md:ContributionsInAidOfReimbursementOfLostRevenue" contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction>&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices received an aggregate of approximately $<ix:nonFraction name="md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue" contextRef="PAsOn06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction>&#160;million during the second quarter of 2020.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of the deferred amount due December&#160;31, 2021 and the remaining <ix:nonFraction name="md:PercentageOfDeferredPaymentOfSocialSecurityTaxes" contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020.</div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company currently expects that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Equivalents and Investments: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction>&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at June&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; padding: 0px;"></td>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td>
<td style="padding: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn06_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn06_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn06_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,537</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn06_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">8</div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/>Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MoneyMarketFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,775</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,549</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:MutualFundsFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments were measured at carrying value as of December&#160;31, 2019. See table below. </div></div></td></tr></table><ix:nonNumeric name="md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">744,375</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">766,875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableFairValueDisclosure" contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,025,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. </div></div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="md:AccountsReceivableAndNetRevenueDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_13913850">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,386,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,943,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,040,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,444,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">345,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">498,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">9</div><div style="text-align: center;"></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_13913850"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs<br/>within&#160;30&#160;to&#160;60&#160;days of billing. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div></div></div><ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">428,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">486,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">919,431</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">956,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">129,698</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">136,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,442</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">509,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">561,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,071,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,104,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">67</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">66</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">65</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:PercentageOfNetPatientServiceRevenueByTypeOfPayor" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div></ix:nonNumeric></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_14118574">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discontinued Operations: </div></div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of Anesthesiology Medical Group </div></div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest&#160;the Company&#8217;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $<ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.0</ix:nonFraction>&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">0</ix:nonFraction> to $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $<ix:nonFraction name="md:MaximumConsiderationReceivable" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction>&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated $<ix:nonFraction name="md:AccountsReceivableRetained" contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction>&#160;million at March&#160;31, 2020. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The operating results of the anesthesiology medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. </div></div></div></div><div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-size: 10pt; line-height: 115%; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The preliminary loss on sale recorded during the three months ended June&#160;30, 2020 was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">644.2</ix:nonFraction>&#160;million. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of a valuation for the contingent economic interest and working capital true-up, final net proceeds will be determined, and the Company will adjust the loss on sale at that time. As a result of the sale, the Company currently estimates that it will generate an approximately $<ix:nonFraction name="md:CapitalLossCarryForward" contextRef="PAsOn06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-7" scale="9" format="ixt:numdotdecimal">1.68</ix:nonFraction>&#160;billion capital loss carryforward which expires in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">419.0</ix:nonFraction>&#160;million valuation allowance against this deferred tax asset in its financial results for the three months ended June&#160;30, 2020. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_14118580"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology medical group for the three and six months ended June&#160;30, 2020 and 2019 (in thousands): </div></div></div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_14118574"><ix:continuation id="TextSelection_14118580">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">90,894</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">307,072</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">374,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">615,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">95,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">247,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">348,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">498,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">30,964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,571</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,034</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,771</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,616</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,721</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">644,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">640,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">773,002</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">285,959</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,059,938</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">568,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">682,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">682,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">47,066</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,561</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">677,004</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">679,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> </ix:continuation> <div style="text-align: center;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div></div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and six</div> months ended June&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and </div>$<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P01_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction>&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </ix:continuation> <div style="font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="text-align: center; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses:&#160;</div></div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">131,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">223,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="md:AccruedPayrollTaxesAndBenefitsCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,466</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,869</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">46,956</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">360,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">453,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div></ix:nonNumeric> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $<ix:nonFraction name="md:IncreaseDecreaseInAccruedSalariesAndBonuses" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">92.1</ix:nonFraction>&#160;million, from December&#160;31, 2019 to June&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June&#160;30, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div></ix:nonNumeric></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_14126433">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div></div></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true" continuedAt="TextSelection_14126249">The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June&#160;30, 2020 and 2019 is as follows (in thousands):</ix:nonNumeric> </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_14126249"><ix:continuation id="TextSelection_14126433">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">83,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">84,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_13911218">83,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_13911219">83,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_13911225">83,061</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_13911226">85,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,335</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:numdotdecimal">713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the six months ended June&#160;30, 2020, no incremental shares are included because the effect would be antidilutive. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> </ix:continuation></ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> </div> <div style="font-size: 8pt; margin-top: 0px; margin-bottom: 0px; line-height: 12pt;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-align: center;"> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div></div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric> upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the six months ended June&#160;30, 2020, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2020To06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction>&#160;million shares of restricted stock to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan. At June&#160;30, 2020, the Company had <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction>&#160;million shares available for future grants and awards under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">85</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To06_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the six months ended June&#160;30, 2020, approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction>&#160;million shares in <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>aggregate were issued under the ESPP and SPP. At June&#160;30, 2020, the Company had approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction>&#160;million shares in <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and six months ended June&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To06_30_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.9</ix:nonFraction>&#160;million, respectively. </div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="md:CommonStockRepurchasesTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div></div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the six months ended June&#160;30, 2020. </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn08_31_2018" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">500.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $<ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.2</ix:nonFraction>&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the six months ended June&#160;30, 2020, the Company withheld approximately <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">159,000</ix:nonFraction> shares of its common stock to satisfy minimum statutory withholding obligations of $<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction>&#160;million in connection with the vesting of restricted stock. </div></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> <div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;">&#160;</div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2020To06_30_2020" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></div></div></ix:nonNumeric></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc">Table of Contents</a></div></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx919859_8" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December&#160;31, 2019, filed with the Securities and Exchange Commission on February&#160;20, 2020 (the &#8220;2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;).</div> As used in this Quarterly Report, the terms &#8220;MEDNAX&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, &#8220;MDX&#8221;), together with MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (&#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company&#8217;s 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> including Item 1A, Risk Factors, and Item 1A. Risk Factors below, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see &#8220;Caution Concerning Forward-Looking Statements&#8221; below.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is a leading provider of physician services including newborn, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in all 50 states, the District of Columbia and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides radiology services including diagnostic imaging and interventional radiology, through a network of affiliated physicians, as well as teleradiology services through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through a consulting services company. MEDNAX divested its anesthesiology medical group on May&#160;6, 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by our affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, we experienced a significant decline in the number of elective surgeries at the facilities where&#160;our affiliated clinicians provided anesthesia services. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology service line, orders for radiological studies have declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. Our affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, we have not experienced, nor do we currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, our operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020. We also divested our anesthesiology medical group in May 2020, where operating results were significantly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We implemented a number of actions to preserve financial flexibility and partially mitigate the significant impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to our transformational and restructuring programs, limiting these expenditures to those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;we temporarily reduced executive and key management base salaries, including 50% reductions in salaries for our named executive officers through June&#160;30, 2020; (ii) our Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) we enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;we enacted significant operational and practice-specific expense reduction plans across our clinical operations.</div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also implemented a variety of solutions across specialties to support clinicians and patients during this pandemic, including </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinician Shortage Support </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pediatric clinicians are lending their expertise to help fulfill the need for added adult care. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strengthening of Supply Chain </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MEDNAX is helping to address the shortage of personal protective equipment (PPE) by partnering with vendors across industries to source high filtration respirators, surgical masks and other forms of PPE for protective use. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expanded Virtual Care Offerings </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">Utilizing VSee, an internationally recognized telehealth platform, MEDNAX has deployed a national multi-specialty virtual clinic to expand its telehealth offerings and make virtual care available to its clinical workforce, enabling continued patient consults and clinician collaboration while minimizing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> exposure.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early Virus Detection Using Cutting-Edge Imaging Diagnostic Tools </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">MEDNAX Radiology Solutions is leading early detection efforts through chest imaging. vRad, a MEDNAX company, diagnosed one of the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients in the United States via chest computed tomography (&#8220;CT&#8221;), which showed findings consistent with a severe acute respiratory viral infection. In the absence of laboratory testing kits, chest CT can serve as a diagnostic tool. In addition, MEDNAX Radiology Solutions is refining natural language processing (&#8220;NLP&#8221;) to identify the incidence of viral pneumonia and typical findings of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus in the lungs via chest CT across the proprietary MEDNAX Imaging Platform and inference engine, which is connected to more than 2,000 partner facilities across the country. The NLP is run retrospectively to monitor the amount and rate of increase of suspected chest CT findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and viral pneumonia, supporting faster treatment. If successful, this cutting-edge diagnostic tool could serve as an effective tracker of the disease&#8217;s progression throughout the country and provide new insights for imaging findings for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> patients.</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Virtual Forum to Provide Clinician Support </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;">To support frontline clinicians while abiding by social distancing recommendations, MEDNAX has created a virtual doctors&#8217; lounge for clinicians across specialties to connect and socialize in the absence of typical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> lounges, helping to boost morale and preserve a sense of normalcy.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We currently expect that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will materially impact our financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> we are unable to predict the ultimate impact on our business, financial condition, results of operations, cash flows and the trading price of our securities at this time.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act our affiliated physician practices will qualify for and receive. &#160;&#160;&#160;&#160;The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which our affiliated physician practices received an aggregate of approximately $12&#160;million during the second quarter of 2020. We have applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. We intend to utilize this deferral option throughout 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of the Anesthesiology Medical Group </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, we entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest our anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, we received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The operating results of the anesthesiology medical group were reported as discontinued operations in our consolidated statements of income for the three and six months ended June&#160;30, 2020 and 2019, and the net assets sold were presented as assets and liabilities held for sale in our consolidated balance sheet for the year ended December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Planned Divestiture of MEDNAX Radiology Solutions </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2020, we announced our initiation of a process to divest our radiology services medical group when market conditions are appropriate in order to refocus the business as a dedicated pediatrics and obstetrics organization. However, there can be no assurance that this process will result in a transaction. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassifications </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassifications have been made to certain prior period financial statements and footnote disclosures to conform to the current period presentation, specifically to reflect the impact of the anesthesiology medical group being classified as assets held for sale and discontinued operations. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General Economic Conditions and Other Factors </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our operations and performance depend significantly on economic conditions. During the three months ended June&#160;30, 2020, the percentage of our patient service revenue being reimbursed under government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) decreased slightly as compared to the three months ended June&#160;30, 2019. Economic conditions in the United States (&#8220;U.S.&#8221;) have deteriorated, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> and patient volumes have declined. We could experience shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients&#8217; inability to pay for certain services.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transformation and Restructuring Initiatives </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. We have broadly classified these workstreams in four broad categories including practice operations, revenue cycle management, information technology and human resources. We have included the expenses, which in certain cases represent estimates, related to such activity on a separate line item in our consolidated statements. In our shared services departments, we were focused on improving processes, using our resources more efficiently and utilizing our scale more effectively to improve cost and service performance across our operations. Within our operational infrastructure, we developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We intended to make a series of information-technology and other investments to improve processes and performance across our enterprise, using both internal and external resources. A significant amount of transformational and restructuring activities were related to our anesthesiology medical group, which was divested in May 2020. We believed these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, positioned us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We originally expected these activities to continue through at least 2020. However, as discussed above, beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they are initiatives that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare Reform </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including changes to subsidies, healthcare insurance marketplaces and Medicaid expansion. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA remains subject to continuing legislative and administrative flux and uncertainty. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Congress may again attempt to enact substantial or target changes to the ACA in the future. Additionally, Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the end of 2017, Congress repealed the part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty, known as the individual mandate. In light of these changes, in December 2018, a federal district court in Texas declared that key portions of the ACA were inconsistent with the U.S. Constitution and that the entire ACA is invalid as a result. Several states appealed this decision, and in December 2019, a federal court of appeals upheld the district court&#8217;s conclusion that part of the ACA is unconstitutional but remanded for further evaluation whether in light of this defect the entire ACA must be invalidated. These legal proceedings are likely to continue for several years, and the fate of the ACA will be unresolved and uncertain during this period. Actions by the court of appeals or eventually the Supreme Court of the United States could invalidate portions or all of the ACA. Changes resulting from these proceedings could have a material impact on our business. In the meantime, it also is possible that as a result of these actions, enrollment in healthcare exchanges could decline. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In 2020, there will be federal and state elections that could affect which persons and parties occupy the Office of the President of the United States, control one or both chambers of Congress and many states&#8217; governors and legislatures. Some candidates running for President of the United States are proposing sweeping changes to the U.S. healthcare system, including expanding government-funded healthcare insurance options. Any legislative or administrative change to the current healthcare financing system could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the ACA is repealed or further substantially modified by judicial, legislative or administrative action, or if implementation of certain aspects of the ACA are diluted, delayed or replaced with a &#8220;Medicare for All&#8221; or single payor system, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate or implementation of a single payor system, on us at this time. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the potential impacts to the ACA, there could be changes to other GHC Programs, such as a change to the structure of Medicaid. Congress and the Administration have sought to convert Medicaid into a block grant or to institute &#8220;per capita spending caps&#8221;, among other things. These changes, if implemented, could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment or education activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Medicare Access and CHIP Reauthorization Act </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Medicare Access and CHIP Reauthorization Act (&#8220;MACRA&#8221;) requires physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (&#8220;MIPS&#8221;) or Alternative Payment Models (&#8220;APMs&#8221;). Beginning in 2020, MIPS allows eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in an advanced APM, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians will continue to be eligible to receive bonus payments in 2020 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicaid Expansion </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state&#8217;s historic eligibility levels to 133% of the federal poverty level. To date, 37 states and the District of Columbia have expanded Medicaid eligibility to cover this additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-income</div> patient population, and other states are considering expansion. All of the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Surprise&#8221; Billing Legislation </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">&#8220;Surprise&#8221; medical bills arise when an insured patient receives care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider resulting in costs that were not expected by the patient. The bill is a &#8220;surprise&#8221; either because the patient did not expect to receive care from an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> provider, or because their cost-sharing responsibility is higher than the patient expected. For the past several years, state legislatures have been enacting laws that are intended to address the problems associated with surprise billing or balance billing.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">More recently, Congress and President Trump have proposed bipartisan solutions to address this circumstance, either by working in tandem with, or in the absence of, applicable state laws. Several committees of jurisdiction in the U.S. House of Representatives and in the U.S. Senate have proposed solutions to address surprise medical bills, but it is unclear whether any of the proposed solutions will become law. In addition, state legislatures and regulatory bodies continue to address and modify existing laws on the same issue. Any state or federal legislation on the topic of surprise billing may have an unfavorable impact on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> reimbursement that we receive. In addition, actual or prospective legislative changes in this area may impact, and may have impacted, our ability to contract with private payors at favorable reimbursement rates or remain in contract with such payors.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-network</div></div> revenue is currently not material, we cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that future legislation or regulations will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicare Sequestration </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">across-the-board</div></div> cuts (&#8220;sequestrations&#8221;) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. In connection with the CARES Act, the Medicare sequestrations were suspended beginning on May&#160;1, 2020 and are expected to remain suspended through December&#160;31, 2020. Aside from the suspension, the reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-GAAP</div> Measures </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In our analysis of our results of operations, we use certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> financial measures. We have incurred and anticipate we will continue to incur certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted earnings before interest, taxes and depreciation and amortization (&#8220;EBITDA&#8221;) from continuing operations, defined as income (loss) from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per share (&#8220;Adjusted EPS&#8221;) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income (loss) from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations is being further adjusted to reflect the impacts from discrete tax events.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We believe these measures, in addition to income (loss) from continuing operations, net income (loss) and diluted net income (loss) from continuing operations per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GAAP</div> measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and six months ended June&#160;30, 2020 and 2019, refer to the tables below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">20,047</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(6,149</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42,593</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,265</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">31,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">55,931</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,764</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,486</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,109</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,588</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,393</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,779</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,792</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">27,584</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,537</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">17,866</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,581</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,305</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted EBITDA from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">65,168</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">94,241</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">115,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">165,834</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">83,745</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">83,689</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations and diluted income from continuing operations per share</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.09</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">20,047</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments <div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div>:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $1,731 and $1,655)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,193</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,964</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $1,658 and $2,477)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,973</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7,430</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.09</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses (net of tax of $2,884 and $4,467)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,653</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.11</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,400</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.16</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">171</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,987</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.03</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">26,590</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.32</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">48,828</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.58</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our blended statutory tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June&#160;30, 2020 and 2019. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average diluted shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">83,061</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';;text-align:center;">&#160;</td>
<td colspan="5" style="vertical-align: bottom;;text-align:center;">85,087</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from continuing operations and diluted income from continuing operations per share</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(6,149</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(0.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42,593</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments <div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div>:</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization (net of tax of $3,454 and $3,328)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,363</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,984</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.12</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation (net of tax of $3,579 and $5,214)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.13</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,639</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses (net of tax of $7,645 and $5,076)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">22,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,229</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.18</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net impact from discrete tax events</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,028</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">0.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,601</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted income and diluted EPS from continuing operations</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">42,916</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">81,844</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">0.96</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(2)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our blended statutory tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June&#160;30, 2020 and 2019. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Three Months Ended June&#160;30, 2020 as Compared to Three Months Ended June&#160;30, 2019 </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our net revenue attributable to continuing operations was $509.2&#160;million for the three months ended June&#160;30, 2020, as compared to $561.2&#160;million for the same period in 2019. The decrease in revenue of $52.0&#160;million, or 9.3%, was primarily attributable to the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on same-unit revenue, driven by declines in volume. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $65.3&#160;million, or 11.7%. The decline in same-unit net revenue was comprised of a decrease of $66.2&#160;million, or 11.9%, related to patient service volumes, partially offset by a net increase of $0.9&#160;million, or 0.2%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was related to a decline across all our services, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The net increase in revenue related to net reimbursement-related factors was primarily due to CARES Act relief, modest improvements in managed care contracting and an increase in revenue caused by a decrease in the percentage of our patients enrolled in GHC programs, partially offset by unfavorable net rate impacts from radiology services.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Practice salaries and benefits attributable to continuing operations decreased $11.9&#160;million, or 3.3%, to $349.3&#160;million for the three months ended June&#160;30, 2020, as compared to $361.2&#160;million for the same period in 2019. This decrease was primarily attributable to decreases in salary expense, including salary reductions and cessation of contract labor, related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives. Of the $11.9&#160;million decrease, $24.4&#160;million was related to salaries, partially offset by an increase of $12.5&#160;million for benefits and incentive compensation. Notwithstanding the salary expense decreases related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives, we anticipate that we will experience a higher rate of growth in clinician compensation expense and malpractice expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Practice supplies and other operating expenses attributable to continuing operations decreased $3.4&#160;million, or 13.5%, to $21.4&#160;million for the three months ended June&#160;30, 2020, as compared to $24.8&#160;million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year, primarily related to decreased activity across many expense categories such as travel, office expenses and professional services resulting from impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were $77.7&#160;million for the three months ended June&#160;30, 2020, as compared to $84.2&#160;million for the same period in 2019. The decrease of $6.5&#160;million was primarily related to salary reductions and furloughs resulting from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives, partially offset by increases in other expense categories, primarily legal expenses. General and administrative expenses as a percentage of net revenue was 15.3% for the three months ended June&#160;30, 2020, as compared to 15.0% for the same period in 2019. Certain general and administrative expenses related to corporate overhead represent various support services provided across the company, including costs that are continuing to support the recently divested anesthesiology medical group through a transition services agreement. Because a portion of such expenses were previously allocated to but not specifically identifiable to, the anesthesiology medical group, they are required to be presented as continuing operations. Therefore, general and administrative expenses do not reflect potential general and administrative cost savings that may be achieved in future periods.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Transformational and restructuring related expenses attributable to continuing operations were $11.5&#160;million for the three months ended June&#160;30, 2020, as compared to $17.9&#160;million for the same period in 2019. The expenses were primarily for external consulting costs for various process improvement and restructuring initiatives. Beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives critical to our business operations or those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $14.4&#160;million for the three months ended June&#160;30, 2020, as compared to $13.8&#160;million for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income from operations attributable to continuing operations decreased $24.5&#160;million, or 41.2%, to $34.9&#160;million for the three months ended June&#160;30, 2020, as compared to $59.4&#160;million for the same period in 2019. Our operating margin was 6.9% for the three months ended June&#160;30, 2020, as compared to 10.6% for the same period in 2019. The decrease in our operating margin was primarily due to the decrease in revenue related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> partially offset by lower operating expense growth, including lower transformation and restructuring related expenses, primarily related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives. Excluding transformation and restructuring expenses, our income from operations attributable to continuing operations for the three months ended June&#160;30, 2020 and 2019 was $46.4&#160;million and $77.3&#160;million, respectively, and our operating margin was 9.1% and 13.8%, respectively. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations; however, this comparison is affected by the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $23.9&#160;million for the three months ended June&#160;30, 2020, as compared to $27.9&#160;million for the same period in 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to a decrease in interest expense, primarily due to lower average borrowings under our credit agreement (the &#8220;Credit Agreement&#8221;) and other income related to the transition services being provided to the buyer of the anesthesiology medical group, partially offset by a decrease in equity earnings resulting from the impacts to the underlying joint venture from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our effective income tax rate attributable to continuing operations was 30.7% and 36.4% for the three months ended June&#160;30, 2020 and 2019, respectively. Income taxes for the second quarter of 2020 were calculated by applying the actual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> effective rate to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income. After excluding discrete tax impacts, during the three months ended June&#160;30, 2020 and 2019, our effective income tax rate was 29.2% and 27.0%, respectively. We believe excluding discrete tax impacts on our effective income tax rate provides a more comparable view of our effective income tax rate.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from continuing operations was $7.6&#160;million for the three months ended June&#160;30, 2020, as compared to $20.0&#160;million for the same period in 2019. Adjusted EBITDA from continuing operations was $65.2&#160;million for the three months ended June&#160;30, 2020, as compared to $94.2&#160;million for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted income from continuing operations per common and common equivalent share was $0.09 on weighted average shares outstanding of 83.7&#160;million for the three months ended June&#160;30, 2020, as compared to $0.24 on weighted average shares outstanding of 83.7&#160;million for the same period in 2019. Adjusted EPS from continuing operations was $0.32 for the three months ended June&#160;30, 2020, as compared to $0.58 for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $680.0&#160;million for the three months ended June&#160;30, 2020, as compared to loss of $28.3&#160;million for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $8.12 for the three months ended June&#160;30, 2020, as compared to $0.34 for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $672.4&#160;million for the three months ended June&#160;30, 2020, as compared to $8.2&#160;million for the same period in 2019. Diluted net loss per common and common equivalent share was $8.03 for the three months ended June&#160;30, 2020, as compared to $0.10 for the same period in 2019. </div></div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 20pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Six Months Ended June&#160;30, 2020 as Compared to Six Months Ended June&#160;30, 2019 </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">Our net revenue attributable to continuing operations was $1.07&#160;billion for the six months ended June&#160;30, 2020, as compared to $1.10&#160;billion for the same period in 2019. The decrease in revenue of $33.2&#160;million, or 3.0%, was primarily attributable to the unfavorable impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on same-unit revenue, driven by declines in volume. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue declined by $60.5&#160;million, or 5.5%. The decline in same-unit net revenue was comprised of a decrease of $72.3&#160;million, or 6.6%, related to patient service volumes, partially offset by a net increase of $11.8&#160;million, or 1.1%, from net reimbursement-related factors. The decrease in revenue from patient service volumes was primarily related to a decline across all our services, primarily as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The net increase in revenue related to net reimbursement-related factors was primarily due to CARES Act relief, modest improvements in managed care contracting and an increase in revenue caused by a decrease in the percentage of our patients enrolled in GHC programs, partially offset by unfavorable net rate impacts from radiology services.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">Practice salaries and benefits attributable to continuing operations increased $17.1&#160;million, or 2.3%, to $748.7&#160;million for the six months ended June&#160;30, 2020, as compared to $731.6&#160;million for the same period in 2019. This increase was primarily attributable to growth in benefits related costs at our existing units, partially offset by the decrease in salary expense from salary reductions and cessation of contract labor resulting from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives that took place during the second quarter of 2020. The increase of $17.1&#160;million was comprised of $25.3&#160;million from benefits and incentive compensation, primarily malpractice expense, partially offset by a decrease of $8.2&#160;million from salaries. Notwithstanding the salary expense decreases related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives, we anticipate that we will experience a higher rate of growth in clinician compensation expense and malpractice expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">Practice supplies and other operating expenses attributable to continuing operations decreased $0.3&#160;million, or 0.6%, to $46.8&#160;million for the six months ended June&#160;30, 2020, as compared to $47.1&#160;million for the same period in 2019. The decrease was primarily attributable to decreases in other practice operating expenses as compared to the prior year, primarily related to decreased activity across many expense categories such as travel, office expenses and professional services resulting from impacts of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> primarily during the second quarter of 2020.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically identifiable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> operations of our physician practices and services. General and administrative expenses were $165.2&#160;million for the six months ended June&#160;30, 2020, as compared to $165.8&#160;million for the same period in 2019. The decrease of $0.6&#160;million is primarily related to salary reductions and furloughs resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives, almost entirely offset by increases in other expense categories, primarily legal expenses. General and administrative expenses as a percentage of net revenue was 15.4% for the three months ended June&#160;30, 2020, as compared to 15.0% for the same period in 2019. Certain general and administrative expenses related to corporate overhead represent various support services provided across the company, including costs supporting the recently divested anesthesiology medical group through a transition services agreement. Because a portion of such expenses were previously allocated to but not specifically identifiable to the anesthesiology medical group, they are required to be presented as continuing operations. Therefore, general and administrative expenses do not reflect potential general and administrative cost savings that may be achieved in future periods.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">Transformational and restructuring related expenses attributable to continuing operations were $30.6&#160;million for the six months ended June&#160;30, 2020, as compared to $20.3&#160;million for the same period in 2019. The expenses were primarily for external consulting costs for various process improvement and restructuring initiatives. Beginning in April 2020, we reduced the scope of our transformation and restructuring related initiatives unless they were initiatives critical to our business operations or those that provide essential support for our response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization expense attributable to continuing operations was $28.8&#160;million for the six months ended June&#160;30, 2020, as compared to $27.6&#160;million for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Income from operations attributable to continuing operations decreased $61.0&#160;million, or 54.5%, to $50.9&#160;million for the six months ended June&#160;30, 2020, as compared to $111.9&#160;million for the same period in 2019. Our operating margin was 4.8% for the six months ended June&#160;30, 2020, as compared to 10.1% for the same period in 2019. The decrease in our operating margin was primarily due to the decrease in revenue related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> partially offset by lower operating expense growth, including transformation and restructuring related expenses, primarily related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> mitigation initiatives. Excluding transformation and restructuring expenses, our income from operations attributable to continuing operations for the six months ended June&#160;30, 2020 and 2019 was $81.5&#160;million and $132.2&#160;million, respectively, and our operating margin was 7.6% and 12.0%, respectively. We believe excluding the impacts from the transformational and restructuring related activity provides a more comparable view of our operating income and operating margin from continuing operations; however, this comparison is affected by the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> during 2020.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses attributable to continuing operations were $50.9&#160;million for the six months ended June&#160;30, 2020, as compared to $55.7&#160;million for the same period in 2019. The decrease in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses was primarily related to a decrease in interest expense, primarily due to lower average borrowings under our Credit Agreement, partially offset by a decrease in equity earnings resulting from the impacts to the underlying joint venture from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the settlement of a litigation matter.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our effective income tax rate attributable to continuing operations is not meaningful as calculated for the six months ended June&#160;30, 2020 due to the insignificant level of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income generated due to the impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Income taxes for the six months ended June&#160;30, 2020 were calculated by applying the actual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> effective rate to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> loss. Our effective income tax attributable to continuing operations was 24.2% for the six months ended June&#160;30, 2019. After excluding discrete tax impacts, during the six months ended June&#160;30, 2019, our effective income tax rate was 27.0%. We believe excluding discrete tax impacts on our effective income tax rate provides a more comparable view of our effective income tax rate.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations was $6.1&#160;million for the six months ended June&#160;30, 2020, as compared to income from continuing operations of $42.6&#160;million for the same period in 2019. Adjusted EBITDA from continuing operations was $115.3&#160;million for the six months ended June&#160;30, 2020, as compared to $165.8&#160;million for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted loss from continuing operations per common and common equivalent share was $0.07 on weighted average shares outstanding of 83.1&#160;million for the six months ended June&#160;30, 2020, as compared to diluted income of $0.50 on weighted average shares outstanding of 85.1&#160;million for the same period in 2019. Adjusted EPS from continuing operations was $0.52 for the six months ended June&#160;30, 2020, as compared to $0.96 for the same period in 2019. The decrease of 2.0&#160;million in our weighted average shares outstanding is primarily due to the impact of shares repurchased in 2019 through open market repurchase activity and the exclusion of common stock equivalents from the weighted average shares calculation for the six months ended June&#160;30, 2020 as the effect would have been antidilutive. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations, net of tax, was $685.0&#160;million for the six months ended June&#160;30, 2020, as compared to loss of $293.7&#160;million for the same period in 2019. Diluted loss from discontinued operations per common and common equivalent share was $8.25 for the six months ended June&#160;30, 2020, as compared to $3.45 for the same period in 2019. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss was $691.1&#160;million for the six months ended June&#160;30, 2020, as compared to $251.1&#160;million for the same period in 2019. Diluted net loss per common and common equivalent share was $8.32 for the six months ended June&#160;30, 2020, as compared $2.95 for the same period in 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020, we had $132.2&#160;million of cash and cash equivalents attributable to our continuing operations as compared to $107.9&#160;million at December&#160;31, 2019. Additionally, we had working capital attributable to our continuing operations of $304.4&#160;million at June&#160;30, 2020, an increase of 64.2&#160;million from working capital of $240.2&#160;million at December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows from Continuing Operations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash (used in) provided by operating, investing and financing activities from continuing operations is summarized as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">19,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,031</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(37,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(19,196</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(611</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(40,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the six months ended June&#160;30, 2020, our net cash provided by operating activities for continuing operations was $19.9&#160;million, compared to $7.0&#160;million for the same period in 2019. The net increase in cash provided of $12.9&#160;million was primarily due to an increase in cash flow from accounts receivable and increases in deferred taxes, partially offset by changes in accounts payable and accrued expenses and a decrease in cash flow from lower earnings. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the six months ended June&#160;30, 2020, cash flow from accounts receivable for continuing operations was $44.3&#160;million, as compared to $1.7&#160;million for the same period in 2019. The increase in cash flow from accounts receivable for the six months ended June&#160;30, 2020 was primarily due to decreases in ending accounts receivable balances at existing units due to timing of cash collections. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Days sales outstanding (&#8220;DSO&#8221;) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 52.4 days at June&#160;30, 2020 as compared to 49.9 days at December&#160;31, 2019. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 16pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the six months ended June&#160;30, 2020, our net cash used in investing activities for continuing operations of $37.1&#160;million consisted primarily of capital expenditures of $23.3&#160;million and net purchases of investments of $14.2&#160;million. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 16pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities from Continuing Operations </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the six months ended June&#160;30, 2020, our net cash used in financing activities for continuing operations of $0.6&#160;million consisted of proceeds from the issuance of common stock of $4.4&#160;million, partially offset by the repurchase of $3.0&#160;million of our common stock and contingent consideration payments of $1.2&#160;million. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 16pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;25, 2020, we amended and restated our Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by us from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that we maintain minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict our ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">The Credit Agreement provides for a $1.2&#160;billion unsecured revolving credit facility, subject to the limitations discussed above, and includes a $37.5&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-facility</div> for the issuance of letters of credit. The Credit Agreement matures on March&#160;28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i)&#160;the alternate base rate (defined as the higher of (a)&#160;the prime rate, (b)&#160;the Federal Funds Rate plus 1/2 of 1.00% and (c)&#160;LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii)&#160;the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2020, we had no outstanding principal balance on our Credit Agreement. We had outstanding letters of credit of $0.2&#160;million which reduced the amount available on our Credit Agreement to $899.8&#160;million at June&#160;30, 2020, after giving effect to the temporary reduction of the capacity of our Credit Agreement described above through September&#160;30, 2021. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2020, we had an outstanding principal balance of $750.0&#160;million on our 5.25% senior unsecured notes due 2023 (the &#8220;2023 Notes&#8221;) and an outstanding principal balance of $1.0&#160;billion on our 6.25% senior unsecured notes due 2027 (the &#8220;2027 Notes&#8221;). Our obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25% per annum, or $39.4&#160;million, and is payable semi-annually in arrears on June&#160;1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5&#160;million, and is payable semi-annually in arrears on January&#160;15 and July 15. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The indenture under which the 2023 Notes and the 2027 Notes are issued, among other things, limits our ability to (1)&#160;incur liens and (2)&#160;enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Notes or the 2027 Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Notes and the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes and the 2027 Notes repurchased plus accrued and unpaid interest. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2020, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. We believe we will be in compliance with these covenants throughout 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June&#160;30, 2020 was $318.4&#160;million, of which $57.5&#160;million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $35.4&#160;million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q.</div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Caution Concerning Forward-Looking Statements </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain information included or incorporated by reference in this Quarterly Report may be deemed to be &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as &#8220;believe,&#8221; &#8220;hope,&#8221; &#8220;may,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2019 Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> and this Quarterly Report, including the sections entitled &#8220;Risk Factors.&#8221;</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx919859_9" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At June&#160;30, 2020, we had no outstanding principal balance on our Credit Agreement. </div></div> <div id="tx919859_10" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;4. Controls and Procedures </div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Evaluation of Disclosure Controls and Procedures </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We maintain disclosure controls and procedures (as defined in Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-15(e)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15d-15(e)</div> under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i)&#160;recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in Internal Controls Over Financial Reporting </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No changes in our internal control over financial reporting occurred during the three months ended June&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx919859_11" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II - OTHER INFORMATION </div></div></div> <div id="tx919859_12" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1. Legal Proceedings </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians and other clinicians. We may also become subject to other lawsuits that could involve large claims and significant defense costs. We believe, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable to us. With respect to professional liability risk, we self-insure a significant portion of this risk through our wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. </div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">On July&#160;10, 2018, a securities class action lawsuit was filed against our company and certain of our officers and a director in the U.S. District Court for the Southern District of Florida (Case No. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0:18-cv-61572-WPD)</div></div></div> that purports to state a claim for alleged violations of Sections 10(b) and 20(a) of the Exchange Act, and Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b-5</div> thereunder, based on statements made by the defendants primarily concerning our former anesthesiology business. The complaint was seeking unspecified damages, interest, attorneys&#8217; fees and other costs. We filed a motion to dismiss in April 2019, which was granted in October 2019; however, the plaintiff filed a second amended complaint on October&#160;25, 2019. On November&#160;25, 2019, we filed a motion to dismiss the second amended complaint, and on February&#160;7, 2020 a final order granting our motion to dismiss the second amended complaint with prejudice was issued.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">On March&#160;20, 2019, a separate derivative action was filed by plaintiff Beverly Jackson on behalf of MEDNAX, Inc. against MEDNAX, Inc. and certain of its officers and directors in the Seventeenth Judicial Circuit in and for Broward County, Florida (Case Number <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CACE-19-006253).</div></div> The plaintiff purported to bring suit derivatively on behalf of our company against certain of our officers and directors for breach of fiduciary duties and unjust enrichment. The derivative complaint repeated many of the allegations in the securities class action described above. We filed a motion to dismiss in December 2019, and on March&#160;16, 2020, an order granting our motion to dismiss without prejudice was issued. On April&#160;6, 2020, the plaintiff filed an amended complaint, and on April&#160;30, 2020, we filed a motion to dismiss the amended complaint.</div> <div id="tx919859_13" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 16pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;1A. Risk Factors </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Item 1A. Risk Factors in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> includes a discussion of our risk factors. The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> Except as presented below, there have been no material changes to the risk factors disclosed in our most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div></div> <div style="text-indent: 9%; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our financial condition and results of operations for fiscal year 2020 and beyond may be materially adversely affected by the ongoing coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> outbreak. </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The outbreak of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has evolved into a global pandemic. The coronavirus has spread to many regions of the world, including virtually all of the United States. The full extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak will impact our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and the actions to contain it or treat its impact, such as the potential for further shutdown or stay at home orders, and shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services, including an increase in unemployment and underemployment as well as losses of commercial health insurance.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;">Our anesthesiology medical group, which we divested on May&#160;6, 2020, experienced a significant decline in the number of elective surgeries at a number of the facilities where its affiliated clinicians provide anesthesia services as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> A significant portion of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within our radiology medical group, orders for radiological studies declined by a meaningful amount from historically normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. Additionally, our office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, saw a significant elevation of appointment cancellations compared to historical normal levels as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> To date, we have not experienced, nor do we currently anticipate, any significant impact to our NICU patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> however, there is no assurance that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will not adversely affect our NICU patient volumes or otherwise adversely affect our NICU and related neonatology business. Overall, our operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Across our medical groups, we believe that these patient volume declines primarily reflect a deferral of healthcare services utilization to a later period, rather than a permanent reduction in demand for our services. Given the general necessity of the services our affiliated clinicians provide, we anticipate that this deferral of services may create a backlog of demand in the future, in addition to the resumption of historically normal activity, however, there is no assurance that either will occur. We may also require an increased level of working capital if we experience extended billing and collection cycles as a result of displaced employees, payors, revenue cycle management contractors, or otherwise. The foregoing and other continued disruptions to our business as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could result in a material adverse effect on our business, results of operations, financial condition, prospects and the trading prices of our securities in the near-term and beyond 2020.</div> <div id="tx919859_14" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended June&#160;30, 2020, we repurchased 34,157 shares of our common stock that were withheld to satisfy minimum statutory withholding obligations in connection with the vesting of restricted stock and deferred stock. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; font-family: 'Times New Roman';"></td>
<td style="width: 11%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 11%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 11%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Period</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Number&#160;of<br/> Shares<br/> Repurchased (a)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Price&#160;Paid<br/> per Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total Number of<br/> Shares Purchased as<br/> part of the<br/> Repurchase&#160;Program</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate Dollar<br/> Value of Shares that<br/> May&#160;Yet&#160;Be&#160;Purchased<br/> Under the Repurchase<br/> Programs (a)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;1 &#8211; April&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May&#160;1 &#8211; May&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/> (b)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13.06</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;1 &#8211; June&#160;30, 2020</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,847</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;<br/> (b)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">34,157</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">14.64</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. Our August 2018 repurchase program allows us to repurchase up to an additional $500.0&#160;million of shares of our common stock, of which we repurchased $395.8&#160;million as of June&#160;30, 2020. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents shares withheld to satisfy minimum statutory withholding obligations of an aggregate of $0.5&#160;million in connection with the vesting of restricted stock. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount and timing of any future repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx919859_15" style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;6. Exhibits </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: 'Times New Roman';"></td>
<td style="width: 3%; vertical-align: bottom; font-family: 'Times New Roman';"></td>
<td style="width: 89%; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit No.</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.1</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520140531/d915708dex21.htm">Securities Purchase Agreement, dated as of May&#160;6, 2020, by and between MEDNAX Services, Inc. and NMSC II, LLC (incorporated by reference to Exhibit 2.1 to MEDNAX&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed on May&#160;12, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d919859dex101.htm">Employment Agreement, dated July&#160;12, 2020, by and between MEDNAX Services, Inc. and Mark S. Ordan. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1024.htm">First Amendment to Amended and Restated Employment Agreement, effective April&#160;1, 2020, by and between MEDNAX Services, Inc. and Stephen D. Farber (incorporated by reference to Exhibit 10.24 to MEDNAX&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019 filed on April&#160;28, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1026.htm">First Amendment to Amended and Restated Employment Agreement, effective April&#160;1, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano (incorporated by reference to Exhibit 10.26 to MEDNAX&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019 filed on April&#160;28, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/893949/000119312520123354/d919155dex1028.htm">First Amendment to Employment Agreement, effective April&#160;1, 2020, by and between MEDNAX Services, Inc. and John C. Pepia (incorporated by reference to Exhibit 10.28 to MEDNAX&#8217;s Annual Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</span> for the year ended December&#160;31, 2019 filed on April&#160;28, 2020). </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.1+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d919859dex311.htm">Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">31.2+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d919859dex312.htm">Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13a-14(a),</span> as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">32.1*</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d919859dex321.htm">Certification pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.1+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">Interactive Data File</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Schema Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Calculation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Definition Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Label Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Presentation Linkbase Document.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 6pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104+</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furnished herewith. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx919859_16" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 4%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 3%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 45%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="3" style="vertical-align: top;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MEDNAX, INC.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: July&#160;30, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Mark S. Ordan</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Mark S. Ordan</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Executive Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Executive Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: July&#160;30, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Stephen D. Farber</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Stephen D. Farber</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Financial Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Financial Officer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td>
<td colspan="2" style="height: 12pt; font-family: 'Times New Roman';"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Date: July&#160;30, 2020</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John C. Pepia</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">John C. Pepia</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">Chief Accounting Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman';"></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top;">(Principal Accounting Officer)</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px; background: none;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d919859dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS EMPLOYMENT AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is made and entered into by and between <B>MEDNAX SERVICES, INC.</B>, a
Florida corporation (&#147;<U>Employer</U>&#148;), <B>MARK ORDAN</B> (&#147;<U>Employee</U>&#148;), and solely for purposes of <U>Sections 1.1</U>, <U>2.2</U>, <U>3.4</U>, <U>5.13</U> and <U>8.7</U> hereof, <B>MEDNAX, INC.</B>, a Florida corporation
and the parent corporation of Employer (&#147;<U>MEDNAX</U>&#148;), effective as of July&nbsp;12, 2020 (the &#147;<U>Effective Date</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,
</B>Employer is presently engaged in &#147;<U>Employer&#146;s Business</U>&#148; as defined on Exhibit A hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,&nbsp;&nbsp;&nbsp;&nbsp;Employer desires to employ Employee; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in order to induce Employer to enter into this Agreement on the terms and conditions set forth herein, and disclose its trade
secrets and confidential information in connection with Employee&#146;s employment by Employer and award from time to time equity based compensation, Employee hereby agrees to be bound by the terms of this Agreement, including the arbitration, <FONT
STYLE="white-space:nowrap">non-competition</FONT> and related restrictive covenants set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in
consideration of the premises and mutual covenants set forth herein, the parties agree as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;Employment. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Employment and Term</I>. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer
on the terms and conditions set forth herein for an &#147;<U>Initial Term</U>&#148; commencing on the Effective Date and continuing for a period of five (5)&nbsp;years, unless sooner terminated as hereinafter set forth; provided, however, that the
Initial Term shall automatically renew for two successive one (1)&nbsp;year periods thereafter (each a &#147;<U>Renewal Period</U>,&#148; and any and all Renewal Periods (if any) together with the Initial Term, the &#147;<U>Employment
Period</U>&#148;), unless at least ninety (90)&nbsp;days prior to the end of the Initial Term or the first Renewal Period, one party notifies the other in writing that he/it is exercising the option not to renew the Employment Period.
Employee&#146;s employment shall terminate on the last day of the Employment Period following any such notice of <FONT STYLE="white-space:nowrap">non-renewal</FONT> or the end of the second Renewal Period, in the absence of a mutually agreed
successor employment agreement. While serving in the position of Chief Executive Officer, MEDNAX shall appoint Employee to the Board (as defined below) as of the Effective Date and MEDNAX shall <FONT STYLE="white-space:nowrap">re-nominate</FONT>
Employee for election to the Board upon the end of each term of Employee&#146;s service as a member of the Board during the Employment Period. Employee shall not receive additional compensation for his service as a Board member. As a Board member,
Employee shall be held to, and must abide by, the highest fiduciary duties permitted under applicable state law. Upon the termination of this Agreement or his removal from the position of Chief Executive Officer for any reason, Employee shall be
removed from the Board automatically and without any vote required by the shareholders of MEDNAX or other Board members. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Duties of Employee</I>. As of the Effective Date and
thereafter during the remaining Employment Period, Employee shall serve as Chief Executive Officer of Employer and MEDNAX, and perform such duties as are customary to the position Employee holds or as may be reasonably assigned to Employee by the
Board of Directors of MEDNAX (&#147;<U>Employee&#146;s Supervisor</U>&#148; or the &#147;<U>Board</U>&#148;), including, but not limited to, also serving as an officer and/or director, or equivalent, of subsidiaries and/or affiliates of MEDNAX;
<I>provided, </I>that such duties as assigned shall be customary to Employee&#146;s role as chief executive officer of Employer and MEDNAX. Employee shall report solely and directly to the Board. Employee&#146;s employment shall be full-time and, as
such, Employee agrees to devote substantially all of Employee&#146;s attention and professional time to the business and affairs of Employer and MEDNAX. Employee will devote his reasonable best efforts to the promotion of the goodwill of Employer,
MEDNAX and their affiliates, taken as a whole. During the Employment Period, Employer shall promote the proficiency of Employee by, among other things, providing Employee with Confidential Information, specialized professional development programs,
and information regarding the organization, administration and operation of Employer. During the Employment Period, Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably
withheld), serve as a director on a corporate board of directors or in any other similar capacity for any institution other than Employer and MEDNAX, and their respective subsidiaries and affiliates in accordance with this
<U>Section</U><U></U><U>&nbsp;1.2</U>. Employer agrees that Employee&#146;s serving on the board of directors of the entities disclosed to Employer on or prior to the Effective Date has been consented to by Employer and such service shall not
constitute Employee&#146;s breach of this Agreement. During the Employment Period, it shall not be a violation of this Agreement to (i)&nbsp;serve on civic or charitable boards or committees, (ii)&nbsp;manage personal investments, or
(iii)&nbsp;deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities do not violate any code of conduct or personnel policies and procedures of Employer or MEDNAX and do not interfere with the
performance of Employee&#146;s responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of <U>Section</U><U></U><U>&nbsp;8</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Place of Performance</I>. Employee shall be permitted to work remotely, except for required travel relating to
Employer&#146;s Business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;Compensation and Performance Bonus. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Base Salary</I>. Employee shall be paid an annual base salary as determined by the Compensation Committee
(&#147;<U>Compensation Committee</U>&#148;) of the Board from time to time (the &#147;<U>Base Salary</U>&#148;), payable in installments consistent with Employer&#146;s customary payroll schedule and subject to applicable withholding for taxes and
other Employee directed withholdings. Employee&#146;s initial Base Salary will be set forth on Exhibit B hereto. The Compensation Committee shall review the amount of Employee&#146;s Base Salary, for increase but not decrease, on an annual basis no
later than ninety (90)&nbsp;days after the beginning of Employer&#146;s fiscal year. Any change to Employee&#146;s Base Salary that is approved by the Compensation Committee shall become Employee&#146;s new Base Salary for purposes of this
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Initial Equity Award.</I> On the Effective Date, MEDNAX shall
grant to Employee, pursuant to the terms of the MEDNAX, Inc. Amended and Restated 2008 Incentive Compensation Plan, as amended (the &#147;<U>Plan</U>&#148;) and applicable award agreements, the following equity grants: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock Grant</U>. A grant of 113,314 shares of Restricted Stock (as defined in the Plan), pursuant to the terms
of the Plan and an award agreement in the form attached hereto as Exhibit C, which the Employee must continue to directly own until the fifth (5th) anniversary of the grant date, unless otherwise set forth in the award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Performance-Based Stock Option Grant</U>. A grant of stock options under the Plan exercisable for up to 550,331
shares of common stock of MEDNAX (the &#147;<U>2020 Option</U>&#148;), subject to the terms of the Plan and an award agreement in the form attached hereto as Exhibit D. The 2020 Option shall be a nonqualified stock option and will have an exercise
price per share equal to the Fair Market Value (as defined in the Plan) of one share of common stock of MEDNAX on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.&nbsp;&nbsp;&nbsp;&nbsp;<I>2020 Corporate Strategy.</I> Employer shall pay Employee $250,000 upon delivery of a strategic plan for MEDNAX
to the Strategy Committee of the Board no later than October&nbsp;1, 2020. Such amount shall be subject to applicable taxes and withholdings and shall be paid to the Employee within 90 days of delivering a satisfactory plan as determined reasonably
and in good faith by the Strategy Committee, but in no event later than December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<I>Performance
Bonus</I>. Employee shall be eligible for an annual bonus in accordance with the incentive programs approved from time to time by the Compensation Committee, which programs shall contemplate a target bonus payment of at least the amount set forth on
Exhibit B (the &#147;<U>Performance Bonus</U>&#148;) based upon the fulfillment of reasonable performance objectives set by the Compensation Committee in consultation with Employee. Except in the situations described in <U>Sections</U> <U>5.4</U>
and <U>5.6</U>, the Performance Bonus shall only be payable to Employee if Employee is employed with Employer as of the date that the Performance Bonus is paid by Employer. Each Performance Bonus (except the Performance Bonus for the fiscal year
commencing January&nbsp;1, 2020 (the &#147;<U>2020 Performance Bonus</U>&#148;)) shall be paid in the calendar year immediately following the calendar year in which it is earned, as soon as practicable after the audited financial statements for
Employer for the year for which the bonus is earned have been released, but in no event later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> following the year for which the Performance Bonus is earned. The 2020 Performance
Bonus shall be prorated (on a daily basis relative to 366) based on the Effective Date and payable at 150% of Employee&#146;s Base Salary (as so prorated) and shall be paid in a lump amount on December&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;Benefits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Expense Reimbursement</I>. Employer shall promptly reimburse Employee for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employer&#146;s Business pursuant to the reimbursement standards and guidelines of
Employer in effect from time to time and no less favorable than provided for other senior executive officers of Employer, including reimbursement for appropriate professional organizations. Employee shall account for such expenses and submit
reasonable supporting documentation to Employer in accordance with Employer&#146;s policies in effect from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee shall be permitted to travel first-class and to use Employer&#146;s private aircraft for business travel during the lease period of such aircraft, <U>provided</U> that Employer shall not
be obligated to maintain any such leased aircraft during the Employment Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<I>Employee Benefits</I>.
During the Employment Period, Employee shall be entitled to participate in such health, welfare, disability, retirement savings, perquisites and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs)
as may be provided from time to time to senior executive officers of Employer and to the extent that such plans and programs are applicable to other senior executive officers of Employer. Notwithstanding the foregoing, Employee may choose to waive
participation in Employer&#146;s health and welfare plans pursuant to the standard waiver provisions thereof and remain on Employee&#146;s existing health and welfare plans, in which case Employee shall be reimbursed a monthly amount equal to the
cost of such Employee health and welfare plans, up to the amount of Employer&#146;s monthly COBRA (as defined below) rate, subject to applicable taxes and withholdings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Leave Time</I>. During the Employment Period, Employee shall be entitled to paid vacation and leave days each
calendar year in accordance with the leave policies established by Employer from time to time, but in no event less than 38 days per year. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the
extent permitted by Employer policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<I>Equity Plans. </I>During the Employment Period, it shall be
recommended to the Compensation Committee that Employee shall receive equity compensation grants following the Effective Date, of stock options and restricted stock and other time-based or performance-based stock units, options, or other awards
(each an &#147;<U>Equity Award</U>&#148;) pursuant to the Plan, or any other similar plan adopted by MEDNAX(each an &#147;<U>Equity Plan</U>&#148;), with a guideline grant value that will be at least the amount set forth on <U>Exhibit B</U>, with
the actual grant value and forms of grant determined by the Compensation Committee in the same manner as for other executive officers of Employer. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement and
the terms of the applicable Equity Plan and shall be made subject to an award agreement that is consistent with the foregoing. Employee shall also be eligible to participate in MEDNAX&#146;s <FONT STYLE="white-space:nowrap">non-qualified</FONT>
employee stock purchase plan and any successor plan. Employee acknowledges Employee&#146;s participation in the Equity Plan pursuant to this <U>Section</U><U></U><U>&nbsp;3</U> is sufficient consideration for Employee to enter into this Agreement,
including the restrictive covenants set forth in <U>Section</U><U></U><U>&nbsp;8</U> below<I>. </I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination for Cause</I>. Employer may terminate Employee&#146;s employment under this Agreement for Cause. As
used in this Agreement, the term &#147;<U>Cause</U>&#148; shall mean the occurrence of any of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Employee&#146;s engagement in
(A)&nbsp;willful misconduct resulting in material harm to MEDNAX or Employer, or (B)&nbsp;gross negligence resulting in material harm to MEDNAX or Employer; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Employee&#146;s conviction of, or pleading nolo contendere to, a felony or any other
crime involving fraud, financial misconduct, or misappropriation of Employer&#146;s assets; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Employee&#146;s willful and continual
refusal after written notice from the Board to (A)&nbsp;perform substantially his employment duties consistent with his position and authority, or (B)&nbsp;follow, consistent with Employee&#146;s position, duties, and authorities, the reasonable
written and lawful mandates of the Board; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) Employee&#146;s failure or refusal to comply in a material respect with a reasonable
policy, standard or regulation of Employer in a manner that could reasonably be expected to cause harm to Employer, MEDNAX, or their affiliates taken as a whole, including but not limited to Employer&#146;s sexual harassment, other unlawful
harassment, workplace discrimination or substance abuse policies; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) Employee&#146;s breach of <U>Section</U><U></U><U>&nbsp;8.4</U>
of this Agreement resulting in material harm to MEDNAX or Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No act or omission shall be deemed willful or grossly negligent for purposes of this
definition if taken or omitted to be taken by Employee in a good faith belief that such act or omission to act was in the best interests of Employer or MEDNAX or if done at the express direction of the Board or upon the advice of counsel to
Employer. Employee shall be provided written notice of any action or inaction alleged to constitute Cause and not less than thirty (30)&nbsp;days to cure, to the extent curable. The termination date for a termination of Employee&#146;s employment
under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.1</U> shall be the date specified by Employer in a written notice to Employee of finding of Cause, which may not be retroactive. Upon termination of Employee&#146;s employment
under this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U>, Employee shall be entitled to compensation in accordance with and subject to, the provisions of <U>Section</U><U></U><U>&nbsp;5.1</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Disability</I>. Employer may terminate Employee&#146;s employment under this Agreement upon the Disability (as
defined below) of Employee. Subject to the requirements of applicable law, Employee shall be deemed to have a &#147;<U>Disability</U>&#148; for purposes of this Agreement in the event of both: (i)&nbsp;Employee&#146;s inability to perform
Employee&#146;s duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii)&nbsp;a determination by an independent qualified physician selected by Employer and acceptable to Employee
(which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional one hundred and eighty (180)or more
days. The termination date for a termination of this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U> shall be the date specified by Employer in a notice to Employee, which date shall not be retroactive. Upon any termination of this
Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U>, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of <U>Section</U><U></U><U>&nbsp;5.2</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Death</I>. Employee&#146;s employment under this Agreement shall terminate automatically upon the death of
Employee, without any requirement of notice by Employer to Employee&#146;s estate. The date of Employee&#146;s death shall be the termination date for a termination of Employee&#146;s employment under this Agreement pursuant to this
<U>Section</U><U></U><U>&nbsp;4.3</U>. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.3</U>, Employee shall be entitled to the compensation specified in
<U>Section</U><U></U><U>&nbsp;5.3</U> hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination by Employer Without Cause</I>. Employer may
terminate Employee&#146;s employment without Cause by giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which shall be between thirty (30)&nbsp;and ninety (90)&nbsp;days
from the date of such notice. The <FONT STYLE="white-space:nowrap">non-renewal</FONT> of this Agreement pursuant to <U>Section</U><U></U><U>&nbsp;1.1</U> as of the end of the Initial Term or the end of the first Renewal Period shall be considered a
termination of Employee&#146;s employment by Employer without Cause. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U>, Employee shall be entitled to compensation and/or
benefits in accordance with, and subject to, the provisions of <U>Section</U><U></U><U>&nbsp;5.4</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination by Employee</I>. Employee may terminate Employee&#146;s employment under this Agreement for any
reason whatsoever upon not less than sixty (60)&nbsp;days prior written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of
such sixty (60)&nbsp;day period. The termination date under this <U>Section</U><U></U><U>&nbsp;4.5</U> shall be the date specified by Employer, but in no event more than ninety (90)&nbsp;days after Employer&#146;s receipt of notice from Employee as
contemplated by this Section. Upon any termination of Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.5</U>, Employee shall be entitled to compensation and/or benefits in accordance with, and subject
to, the provisions of <U>Section</U><U></U><U>&nbsp;5.5</U> hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination by Employee with Good
Reason. </I>Employee may terminate Employee&#146;s employment hereunder with Good Reason. For purposes of this Section, &#147;<U>Good Reason</U>&#148; shall mean, without the Employee&#146;s express written consent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &nbsp;&nbsp;&nbsp;&nbsp;a decrease in Employee&#146;s Base Salary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;a decrease in Employee&#146;s Performance Bonus opportunity as set forth on Exhibit B or a failure
of the Compensation Committee to approve an equity grant within the guidelines set forth on <U>Exhibit B</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Employee is assigned any position, duties, responsibilities or compensation that is inconsistent
with the position, duties, or responsibilities of Employee contemplated herein as of the Effective Date or compensation of Employee as of the Effective Date, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in
bad faith and which is remedied by Employer promptly after receipt of written notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Employee
experiences a material diminution in his authorities, duties or responsibilities, excluding for this purpose any isolated and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice,
provided that, if following a Change in Control, neither the common stock of MEDNAX nor the common equity of its successor, parent or subsidiary is listed for trading on a national securities exchange or if Employee is not chief executive officer of
a publicly-traded entity, Employee shall have Good Reason to terminate employment; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Employee is required to report to any person
other than the Board, is not nominated to the Board, or is removed from the Board; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;the
requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employee resides as of the Effective Date, except for travel reasonably required in the performance of Employee&#146;s duties; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;any other action or inaction that constitutes a material breach of this Agreement or any material
compensation agreement by Employer or MEDNAX (including a violation of <U>Section</U><U></U><U>&nbsp;6.1</U>); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Employee desires to terminate
Employee&#146;s employment under this Agreement pursuant to this Section, Employee must, within one hundred eighty (180)&nbsp;days after Employee&#146;s knowledge of the occurrence of events giving rise to the Good Reason, provide Employer with a
written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty (30)&nbsp;days after the date of Employee&#146;s notice, then Employee shall have sixty (60)&nbsp;days following the end of such
cure period to terminate employment with Good Reason. If Employee terminates Employee&#146;s employment under this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;4.6</U>, then Employee shall be entitled to compensation and/or benefits in
accordance with, and subject to, the provisions of <U>Section</U><U></U><U>&nbsp;5.6</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Employee in Connection With Change in Control of Employer. </I>In the event that Employer
terminates Employee&#146;s employment without Cause in accordance with <U>Section</U><U></U><U>&nbsp;4.4</U>, or Employee terminates Employee&#146;s employment with Good Reason in accordance with <U>Section</U><U></U><U>&nbsp;4.6</U>, and in either
case the termination occurs within six (6)&nbsp;months prior to or within 12 months following the effective date of a Change in Control, then in lieu of the compensation and/or benefits that Employee would otherwise be entitled to under
<U>Section</U><U></U><U>&nbsp;5.4</U> or <U>Section</U><U></U><U>&nbsp;5.6</U>, Employee shall be entitled to the compensation and/or benefits in accordance with, and subject to, the provisions of <U>Section</U><U></U><U>&nbsp;5.14</U>. For purposes
of this Agreement, &#147;<U>Change in Control</U>&#148; shall mean (i)&nbsp;the acquisition by a person or an entity or a group of persons and entities, directly or indirectly, of more than fifty (50%) percent of MEDNAX&#146;s common stock in a
single transaction or a series of transactions (hereinafter referred to as a &#147;<U>50% Change in Control</U>&#148;), (ii) a merger or other form of corporate reorganization of MEDNAX resulting in an actual or de facto 50% Change in Control, or
(iii)&nbsp;the failure of Applicable Directors (defined below) to constitute a majority of the Board during any two (2)&nbsp;consecutive year period after the date of this Agreement (the &#147;<U><FONT STYLE="white-space:nowrap">Two-Year</FONT>
Period</U>&#148;). &#147;<U>Applicable Directors</U>&#148; shall mean those individuals who are members of the Board at the inception of a <FONT STYLE="white-space:nowrap">Two-Year</FONT> Period and any new director whose election to the Board or
nomination for election to the Board was approved (prior to any vote thereon by the shareholders) by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> (2/3) of the directors then still in office who either were directors at the
beginning of the <FONT STYLE="white-space:nowrap">Two-Year</FONT> Period at issue or whose election or nomination for election during such <FONT STYLE="white-space:nowrap">Two-Year</FONT> Period was previously approved as provided in this sentence.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;Compensation and Benefits Upon Termination. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Cause</I>. If Employee&#146;s employment is terminated for Cause, Employer shall pay Employee&#146;s Base Salary
through the termination date specified in <U>Section</U><U></U><U>&nbsp;4.1</U> at the rate in effect at the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Disability</I>. In the event of Employee&#146;s Disability, Employee shall continue to receive Employee&#146;s
Base Salary for the first ninety (90)&nbsp;days of Disability plus any amounts as may be due under <U>Sections 5.7</U>, <U>5.10</U> and <U>5.13</U>. Employee shall also receive any earned and unpaid Performance Bonus with respect to the year prior
to the year of termination, which shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U> without regard to its continued employment requirement. Amounts payable under this <U>Section</U><U></U><U>&nbsp;5.2</U> are not intended to be
in lieu of benefits under any long-term disability plan Employer may maintain from time to time, but any benefits and payments under any such plan shall offset the payments to be made in the first sentence of this Section, and Employee&#146;s
entitlement to benefits under such plan, if any, shall be determined solely by the plan&#146;s terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Death</I>. Upon Employee&#146;s death during the Employment Period, Employer shall pay to the person or entity
designated by Employee in a notice filed with Employer or, if no person is designated, to Employee&#146;s estate any unpaid amounts of Base Salary to the date of Employee&#146;s death, plus any amounts as may be due under <U>Sections 5.7</U>,
<U>5.10</U>, and <U>5.13</U> below. Employee&#146;s estate (or the person or entity designated by Employee in a notice filed with Employer) shall also receive any earned and unpaid Performance Bonus with respect to the year prior to the year of
termination, which shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U> without regard to its continued employment requirement. Any payments that Employee&#146;s spouse, beneficiaries or estate may be entitled to receive pursuant
to any pension plan, employee welfare benefit plan, life insurance policy, or similar plan or policy then maintained by Employer shall be determined and paid in accordance with the written instruments governing the respective plans and policies. In
the event of Employee&#146;s death during the Employment Period, Employer shall notify Employee&#146;s designee or estate of the Equity Awards held by Employee and the procedures pursuant to which all vested stock options may be exercised and other
Equity Awards may be realized under the terms applicable to such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination by Employer Without
Cause</I>. If Employer terminates Employee&#146;s employment in accordance with <U>Section</U><U></U><U>&nbsp;4.4</U>, then (i)&nbsp;Employer shall pay Employee&#146;s Base Salary through the termination date specified in
<U>Section</U><U></U><U>&nbsp;4.4</U> at the rate in effect at such termination date, plus any amount due under <U>Section</U><U></U><U>&nbsp;5.7</U> hereof; (ii)&nbsp;Employer shall pay Employee a bonus calculated and paid in accordance with
<U>Section</U><U></U><U>&nbsp;5.10</U> hereof; (iii)&nbsp;Employee shall also receive any earned and unpaid Performance Bonus with respect to the year prior to the year of termination, which shall be paid in accordance with
<U>Section</U><U></U><U>&nbsp;2.4</U> without regard to its continued employment requirement; (iv)&nbsp;within sixty (60)&nbsp;days of the termination date and on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;anniversary
of the termination date, Employer shall pay Employee on each such date a lump sum payment equal to Employee&#146;s annual Base Salary; (v)&nbsp;within sixty (60)&nbsp;days of the termination date and on the first (1<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;anniversary of the termination date, Employer shall pay Employee on each such date an amount equal to the greater of (A)&nbsp;Employee&#146;s Average Annual Performance Bonus (as defined
below) or (B)&nbsp;Employee&#146;s target Performance Bonus amount set forth on Exhibit B; and (v)&nbsp;if applicable, Employee shall vest into the Equity Awards granted to Employee that are outstanding (the &#147;<U>Accelerated Awards</U>&#148;) as
set forth in <U>Section</U><U></U><U>&nbsp;5.13</U> hereof. For purposes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Agreement, &#147;<U>Average Annual Performance Bonus</U>&#148; shall be equal to the average of the percentage of the Performance Bonus target achieved by (or provided to) Employee for
the three (3)&nbsp;calendar years (including the partial 2020 year) prior to the termination date (or such lesser period as Employee may have been employed by Employer), and calculated based on Employee&#146;s Base Salary and target Performance
Bonus in Employee&#146;s current position. <I>For illustration purposes, if Employee earned 40%, 100% and 70% of Employee&#146;s target Performance Bonus in each of the three full calendar years prior to termination, and Employee&#146;s current
target Performance Bonus was 100% of Base Salary, and Base Salary was $1,000,000.00, then Employee&#146;s Average Annual Performance Bonus would equal $700,000.00. ((40%+ 100% + 70%) / 3 x 100% x $1,000,000.00 = $700,000.00).</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination by Employee</I>. If Employee&#146;s employment under this Agreement terminates pursuant to
<U>Section</U><U></U><U>&nbsp;4.5</U> hereof, Employer shall pay to Employee any unpaid amounts of Base Salary to the termination date specified in <U>Section</U><U></U><U>&nbsp;4.5</U>, plus any amounts as may be due under
<U>Section</U><U></U><U>&nbsp;5.7</U> below. In the event that the termination date specified by Employer is less than ninety (90)&nbsp;days after the date of Employer&#146;s receipt of notice as contemplated by Section&nbsp;4.5, then Employer shall
continue Employee&#146;s Base Salary for a period of days equal to ninety (90)&nbsp;minus the number of days from Employee&#146;s notice to the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination with Good Reason.</I><B> </B>If Employee&#146;s employment under this Agreement is terminated
pursuant to <U>Section</U><U></U><U>&nbsp;4.6</U>, then Employer shall pay or provide the same benefits as described in <U>Section</U><U></U><U>&nbsp;5.4 </U>(and any reductions in Base Salary or target Performance Bonus opportunity resulting in
Good Reason shall be disregarded). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7.&nbsp;&nbsp;&nbsp;&nbsp;<I>Expense Reimbursement; Vacation, Benefits Plans. </I>Upon any
termination of employment<I>, </I>Employee shall be entitled to reimbursement for reasonable business expenses incurred prior to the termination date, subject, however to the provisions of <U>Section</U><U></U><U>&nbsp;3.1</U>. Such reimbursement
shall be made at the times and in accordance with Employer&#146;s normal procedures for reimbursements. In addition, Employee shall be paid for accrued vacation pursuant to Employer&#146;s then-current policy and shall be provided his vested and
accrued employee benefits pursuant to the terms of the applicable benefits plans of Employer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8.&nbsp;&nbsp;&nbsp;&nbsp;<I>Continuation
of Benefit Plans</I>. Employee shall be entitled to continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as regular, full-time employees of Employer and their eligible dependents (or the
reimbursement amounts provided in <U>Section</U><U></U><U>&nbsp;3.2</U>) during the period with respect to which Employee is receiving Base Salary payments under <U>Section</U><U></U><U>&nbsp;5</U> of this Agreement (e.g., twenty-four
(24)&nbsp;months of Base Salary severance corresponds to twenty-four (24)&nbsp;months of continued benefits) and, in all cases, as provided by any applicable law. Following such period of continued benefit plan coverage, Employee and each of his
eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to Section&nbsp;601 et. seq. of the Employee Retirement Income Security Act of 1974, 29 USC &#167;1101 (&#147;<U>COBRA</U>&#148;). If the Employee&#146;s
employment under this Agreement terminates pursuant to <U>Sections 4.2</U>, <U>4.3</U>, <U>4.4</U>, <U>4.6</U>, or <U>4.7</U>, Employee may continue on Employer&#146;s group medical plan until he is eligible for Medicare benefits provided that he
timely elects COBRA coverage, such continuation is permitted under the terms of the applicable group health and, except as provided in this <U>Section</U><U></U><U>&nbsp;5.8</U>, Employee pays the full cost (at applicable COBRA rates) of such
benefits continuation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9&nbsp;&nbsp;&nbsp;&nbsp;<I>Period for Exercising Stock Options After Termination.
</I>With respect to stock options granted to the Employee during the Employment Period: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;after termination of
Employee&#146;s employment under this Agreement for any reason other than pursuant to <U>Section</U><U></U><U>&nbsp;4.</U>1, with respect to any stock option that includes a share price condition (a &#147;<U>Share Price Option</U>&#148;) vested as
of Employee &#146;s termination date, Employee shall be allowed a period of twelve (12)&nbsp;months after termination under this Agreement to exercise any such option (subject to earlier termination as set forth below); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;after termination of Employee&#146; s employment under this Agreement pursuant to
<U>Section</U><U></U><U>&nbsp;4.2</U>, <U>4.3</U>, <U>4.4</U>, or <U>4.6</U>, with respect to any Share Price Option that is unvested as of Employee&#146; s termination date, such option shall remain outstanding for twelve (12)&nbsp;months to
determine if the applicable performance vesting condition(s) have been met (subject to earlier termination as set forth below) and shall become exercisable only if the applicable price condition(s) during such continuation period are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing paragraphs (i)&nbsp;and (ii), in no event shall the period during which Employee may exercise any stock option
be extended pursuant to this <U>Section</U><U></U><U>&nbsp;5.9</U> to a date that is later than the earlier of (i)&nbsp;the latest date upon which the stock right could have expired by its original terms under any circumstances or (ii)&nbsp;the
tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the original date of grant of the stock right. In all other respects, the terms of the applicable Equity Plan and award agreement shall control with respect to the
period for exercising stock options after termination of employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10.&nbsp;&nbsp;&nbsp;&nbsp;<I>Performance Bonus.</I> In the
situations described in <U>Sections 5.2</U>, <U>5.3</U>, <U>5.4</U> and <U>5.6</U>, the Employer shall pay Employee, solely in consideration of services rendered by Employee prior to termination, a bonus with respect to Employer&#146;s fiscal year
in which the termination date occurs, equal to Employee&#146;s Performance Bonus amount set forth on Exhibit B determined based on actual performance<B>,</B> multiplied by the number of days in the fiscal year prior to and including the date of
termination and divided by three hundred sixty five (365), which shall be paid in the calendar year immediately following the calendar year in which it is earned, as soon as practicable after the audited financial statements for Employer for the
year for which the bonus is earned have been released, but in no event later than March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> following the year for which the Performance Bonus is earned. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11.&nbsp;&nbsp;&nbsp;&nbsp;<I>Section</I> <I>409A Compliance</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;General.<B> </B>It is the intention of both Employer and Employee that the benefits and rights to
which Employee could be entitled in connection with termination of employment comply with Section&nbsp;409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder
(&#147;<U>Section</U><U></U><U>&nbsp;409A</U>&#148;), and the provisions of this Agreement shall be construed in a manner consistent with that intention. If Employee or Employer believes, at any time, that any such benefit or right does not so
comply, it shall promptly advise the other and shall negotiate reasonably and in good faith to amend the terms of such benefits and rights such that they comply with Section&nbsp;409A of the Code (with the most limited possible economic effect on
Employee and on Employer). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Distributions on Account of Separation from
Service.<B> </B>If and to the extent required to comply with Section&nbsp;409A, no payment or benefit required to be paid under this Agreement on account of termination of Employee&#146;s employment shall be made unless and until Employee incurs a
&#147;separation from service&#148;, within the meaning of Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;6 Month Delay for
Specified Employees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;If Employee is a &#147;specified employee&#148;, then no payment or
benefit that is payable on account of Employee&#146;s &#147;separation from service&#148;, as that term is defined for purposes of Section&nbsp;409A, shall be made before the date that is six months after Employee&#146;s &#147;separation from
service&#148; (or, if earlier, the date of Employee&#146;s death) if and to the extent that such payment or benefit constitutes deferred compensation (or may be nonqualified deferred compensation) under Section&nbsp;409A and such deferral is
required to comply with the requirements of Section&nbsp;409A. Any payment or benefit delayed by reason of the prior sentence shall be paid out or provided in a single lump sum at the end of such required delay period in order to catch up to the
original payment schedule. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this provision, Employee shall be considered to be
a &#147;specified employee&#148; if, at the time of his separation from service, Employee is a &#147;key employee&#148;, within the meaning of Section&nbsp;416(i) of the Code, of Employer (or any person or entity with whom Employer would be
considered a single employer under Section&nbsp;414(b) or Section&nbsp;414(c) of the Code) any stock in which is publicly traded on an established securities market or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;No Acceleration of Payments. Neither Employer nor Employee, individually or in combination, may
accelerate any payment or benefit that is subject to Section&nbsp;409A, except in compliance with Section&nbsp;409A and the provisions of this Agreement, and no amount shall be paid prior to the earliest date on which it may be paid without
violating Section&nbsp;409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Treatment of Each Installment as a Separate Payment. For purposes
of applying the provisions of Section&nbsp;409A to this Agreement, each separately identified amount to which Employee is entitled under this Agreement shall be treated as a separate payment. In addition, to the extent permissible under
Section&nbsp;409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;Reimbursements and <FONT STYLE="white-space:nowrap">In-Kind</FONT> Benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Any reimbursements by Employer to Employee of any eligible expenses pursuant to
<U>Section</U><U></U><U>&nbsp;3.1</U> or <U>5.7</U> of this Agreement, that are not excludible from Employee&#146;s income for Federal income tax purposes (&#147;<U>Taxable </U><U>Reimbursements</U>&#148;) shall be made on or before the last day of
the taxable year of Employee following the year in which the expense was incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The amount of any Taxable Reimbursements, and
the value of any <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided to Employee under this Agreement, during any taxable year of Employee shall not affect the expenses eligible for reimbursement, or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits to be provided, in any other taxable year of Employee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The right to Taxable Reimbursements, or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits,
shall not be subject to liquidation or exchange for another benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12.&nbsp;&nbsp;&nbsp;&nbsp;<I>Release. </I>Employer shall provide
Employee with a general release in the form attached as Exhibit E (subject to such modifications as Employer may reasonably request to comply with applicable law) within seven (7)&nbsp;days after Employee&#146;s termination date.&nbsp;Payments or
benefits to which Employee may be entitled pursuant to this <U>Section</U><U></U><U>&nbsp;5</U> (other than any accrued but unpaid Base Salary, reimbursement of business expenses, accrued vacation pursuant to Employer&#146;s then-current policy and
employee benefits as of the end of the Employment Period) (the &#147;<U>Severance Amounts</U>&#148;) shall be conditioned upon Employee executing the general release within twenty one (21)&nbsp;days after receiving it from Employer and the general
release becoming irrevocable upon the expiration of seven (7)&nbsp;days following Employee&#146;s execution of it. Payment of the Severance Amounts shall be suspended during the period (the &#147;<U>Suspension Period</U>&#148;) that begins on
Employee&#146;s termination date and ends on the date (&#147;<U>Suspension Termination Date</U>&#148;) that is thirty-five (35)&nbsp;days after Employee&#146;s termination date; provided, however, that this suspension shall not apply to, and
Employer shall be required to provide, any continued health insurance coverage that would be required under <U>Section</U><U></U><U>&nbsp;5.8</U> hereof during the Suspension Period. If Employee executes the general release and the general release
becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that follows the Suspension Termination Date, and
any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in <U>Section</U><U></U><U>&nbsp;5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.13.&nbsp;&nbsp;&nbsp;&nbsp;<I>Vesting of Incentive Awards (Accelerated Awards). </I>Notwithstanding any contrary provision in this Agreement
or<B> </B>any Equity Plan then maintained by MEDNAX, and in addition to any other payments or benefits provided in this Agreement, in the event Employee&#146;s employment terminates pursuant to <U>Section</U><U></U><U>&nbsp;4.2</U>, <U>4.3</U>,
<U>4.4</U>, or <U>4.6</U>, all time-based Equity Awards (which for the avoidance of doubt does not include the 2020 Option) granted to Employee by MEDNAX prior to termination of Employee&#146;s employment shall immediately become fully vested, <FONT
STYLE="white-space:nowrap">non-forfeitable,</FONT> and, if applicable, exercisable, and all performance-based shares awards (which for the avoidance of doubt does not include the 2020 Option) shall remain outstanding and shall vest based upon actual
performance determined at the end of the applicable performance period. In the event Employee&#146;s employment is terminated pursuant to <U>Section</U><U></U><U>&nbsp;4.7</U>, all time-based Equity Awards (which for the avoidance of doubt does not
include the 2020 Option) granted to Employee by MEDNAX prior to termination of Employee&#146;s employment shall immediately become fully vested, <FONT STYLE="white-space:nowrap">non-forfeitable,</FONT> and, if applicable, exercisable and, with
respect to performance-based share awards (which for the avoidance of doubt does not include the 2020 Option), if the applicable performance condition has been met at the time of the Change in Control, any such Equity Award that is assumed or
converted shall immediately become fully vested, non-forfeitable and, if applicable, exercisable upon termination of employment except if Employee is terminated for Cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14.&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Employee in Connection With Change in Control
of Employer. </I>If Employee&#146;s employment under this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;4.7</U>, then Employer shall pay Employee&#146;s monthly Base Salary through the termination date specified pursuant
to <U>Section</U><U></U><U>&nbsp;4.7</U> at the rate in effect at such termination date, plus any amounts as may be due under <U>Section</U><U></U><U>&nbsp;5.7</U> hereof. In addition, Employee will receive the following severance payments from the
Employer if he is terminated within six (6)&nbsp;months prior to a Change in Control or within twelve (12)&nbsp;months after a Change in Control that is not a &#147;change in control&#148; for purposes of Section&nbsp;409A of the Code:
(i)&nbsp;within sixty (60)&nbsp;days of the termination date and on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;anniversary of the termination date, on each such date a lump sum payment equal to eighteen
(18)&nbsp;months of Employee&#146;s Base Salary; (ii)&nbsp;a bonus calculated and paid in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> hereof; (iii)&nbsp;any earned and unpaid Performance Bonus with respect to the year prior to the year of
termination, which shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U>; (iv) within sixty (60)&nbsp;days of the termination date and on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>)&nbsp;anniversary of the
termination date, Employer shall pay Employee on each such date an amount equal to the greater of (A)&nbsp;one and one half (1.5) times Employee&#146;s Average Annual Performance Bonus (as defined below) or (B)&nbsp;one and one half (1.5) times
Employee&#146;s target Performance Bonus amount set forth on Exhibit B; and (v)&nbsp;if applicable, Employee shall vest into the Accelerated Awards as set forth in <U>Section</U><U></U><U>&nbsp;5.13</U> hereof. If Employee is terminated on or after
a Change in Control that is a &#147;change in control&#148; for purposes of Section&nbsp;409A of the Code, Employee will receive the following severance payments: (A)&nbsp;(i) a lump sum payment within sixty (60)&nbsp;days of termination equal to <FONT
STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;months of Employee&#146;s Base Salary; (ii)&nbsp;a bonus calculated and paid in accordance with <U>Section</U><U></U><U>&nbsp;5.10</U> hereof; (iii)&nbsp;any earned and unpaid Performance Bonus
with respect to the year prior to the year of termination, which shall be paid in accordance with <U>Section</U><U></U><U>&nbsp;2.4</U>; (iv) a lump sum payment within sixty (60)&nbsp;days of termination of an amount equal to the greater of
(1)&nbsp;three (3) times Employee&#146;s Average Annual Performance Bonus or (2)&nbsp;three (3) times Employee&#146;s target Performance Bonus amount set forth on Exhibit B, and (v)&nbsp;if applicable, Employee shall vest into the Accelerated Awards
as set forth in <U>Section</U><U></U><U>&nbsp;5.13</U> hereof. For the avoidance of doubt, and any reductions in Base Salary or target Performance Bonus opportunity resulting in Good Reason shall be disregarded in calculating severance under this
<U>Section</U><U></U><U>&nbsp;5.14</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.15&nbsp;&nbsp;&nbsp;&nbsp;<I>Termination of Employment Period. </I>For the avoidance of doubt,
termination of Employee&#146;s employment at the end of the second Renewal Period shall not entitle Employee to payment of severance under this <U>Section</U><U></U><U>&nbsp;5</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;Successors; Binding Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>Successors</I>. Employer shall require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) acquiring a majority of Employer&#146;s voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same
manner and to the same extent that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, &#147;Employer&#148; shall mean Employer as previously defined and
any successor to its business and/or assets which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executes and delivers the agreement provided for in this <U>Section</U><U></U><U>&nbsp;6</U> or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of
law. This Section shall not limit Employee&#146;s ability to terminate this Agreement in the circumstances described in <U>Section</U><U></U><U>&nbsp;4.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefit</I>. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and
be enforceable by Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee
under this Agreement if Employee had continued to live, including under Section&nbsp;5 hereof, then such amounts shall be paid to Employee&#146;s devisee, legatee, or other designee or, if there is no such designee, Employee&#146;s estate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Conflicts. </B>Except as otherwise provided in this Agreement, this Agreement constitutes the entire
agreement among the parties pertaining to the subject matter hereof, and supersedes and revokes any and all prior offer letters or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely
determinative of the subject matter hereof. Any conflict between this Agreement and any plan document or award agreement or policy shall be resolved in favor of this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1.&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Competition</I>. Employer and Employee acknowledge and agree that a strong relationship and
connection exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and
agree that the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the
following: (1)&nbsp;the use and disclosure of the Confidential Information as described in <U>Section</U><U></U><U>&nbsp;8.4</U>; (2) the professional development activities described in <U>Section</U><U></U><U>&nbsp;1.2</U>; and (3)&nbsp;the
goodwill of Employer, as promoted by Employee as provided in <U>Section</U><U></U><U>&nbsp;1.2</U>. The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such interests. Employee
acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the goodwill and other
proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, <B>Employee shall
not</B>, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly participate or engage in or own an
interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee,
consultant, independent contractor, stockholder, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lender, , if such entity is engaged in, directly or indirectly, &#147;<U>Employer&#146;s Business</U>&#148;, as defined on Exhibit A hereto. Employee acknowledges that, as of the date hereof,
Employee&#146;s responsibilities will include matters affecting the businesses of Employer listed on Exhibit A. Notwithstanding the foregoing and except as otherwise set forth on Exhibit A, Employee shall not violate this
<U>Section</U><U></U><U>&nbsp;8.1</U> by providing services to an entity which has a unit, division, subsidiary, or affiliate engaged in the Employer&#146;s Business so long as Employee does not directly or indirectly provide services to such unit,
division, subsidiary, or affiliate. For purposes of this <U>Section</U><U></U><U>&nbsp;8</U>, the &#147;<U>Restricted Period</U>&#148; shall mean the Employment Period plus (i)&nbsp;eighteen (18) months in the event this Agreement is terminated
pursuant to <U>Section</U><U></U><U>&nbsp;4.1</U>, and (ii)&nbsp;twenty-four (24)&nbsp;months in the event the Agreement is terminated for any other reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2.&nbsp;&nbsp;&nbsp;&nbsp;<I>No Hire</I>. Employee further agrees that <B>Employee shall not</B>, at any time during the Employment Period
(other than on behalf of Employer or its affiliates) and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership,
corporation or employer, intentionally, knowingly, or willingly employ, or intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to (a)&nbsp;employ or otherwise hire (i)&nbsp;any person
who is a then current employee or exclusive independent contractor of Employer or one of its affiliates , or (ii)&nbsp;any person who was an employee or exclusive independent contractor of Employer or one of its affiliates in the prior six
(6)&nbsp;month period, or (b)&nbsp;take any action that would reasonably be expected to induce an employee or independent contractor of Employer or one of its affiliates to leave his employment or engagement with Employer or one of its affiliates
(including without limitation for or on behalf of a subsequent employer of Employee). Employee shall not violate this <U>Section</U><U></U><U>&nbsp;8.2</U> by (x)&nbsp;soliciting employees or consultants through a general advertisement not directed
specifically at employees or exclusive independent contractors of Employer or one of its affiliates or (y)&nbsp;providing a personal reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <I><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;Non-Solicitation.</FONT> </I>Employee further agrees that <B>Employee shall
not</B>, at any time during the Employment Period (other than on behalf of Employer or its affiliates) and for a period of eighteen (18)&nbsp;months immediately following termination of this Agreement for any reason, for Employee or on behalf of any
other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly solicit or accept business from (but solely in connection with Employer&#146;s Business) or take any action that would reasonably be expected
to materially interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with (i)&nbsp;hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional
services or otherwise have established relationships, (ii)&nbsp;patients, (iii) referral sources, (iv)&nbsp;vendors, (v) any other clients of Employer or its affiliates , or (vi)&nbsp;prospective hospitals, patients, referral sources, vendors or
clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of soliciting at the time of Employee&#146;s termination (including potential acquisition targets<B>)</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.4.&nbsp;&nbsp;&nbsp;&nbsp;<I>Confidential Information</I>. At all times during the term of this Agreement, Employer shall provide Employee
with access to &#147;Confidential Information.&#148; As used in this Agreement, the term &#147;<U>Confidential Information</U>&#148; means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly,
verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Employee, applicable to or in any way related to: (i)&nbsp;patients with whom Employer has a physician/patient relationship; (ii)&nbsp;the present or future business of Employer; or
(iii)&nbsp;the research and development of Employer. Without limiting the generality of the foregoing, Confidential Information includes: (a)&nbsp;the development and operation of Employer&#146;s medical practices, including information relating to
budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically including the procedures and business plans developed by Employer for
use at the hospitals where Employer conducts its business; (b)&nbsp;contractual arrangements between Employer and insurers or managed care associations or other payors; (c)&nbsp;the databases of Employer; (d)&nbsp;the clinical and research protocols
of Employer, including coding guidelines; (e)&nbsp;the referral sources of Employer; (f)&nbsp;other confidential information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an advantage over
competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in Employer&#146;s
business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and projections, and computer programs. The parties agree that, as between
them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employer&#146;s business and its goodwill. Employer acknowledges that the Confidential Information specifically
enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might otherwise obtain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Confidential Information shall not include any information that (i)&nbsp;was known by Employee from a third
party source before disclosure by or on behalf of Employer, (ii)&nbsp;becomes available to Employee from a source other than Employer that is not, to Employee&#146;s knowledge, bound by a duty of confidentiality to Employer, (iii)&nbsp;becomes
generally available or known in the industry other than as a result of its disclosure by Employee, or (iv)&nbsp;has been independently developed by Employee and may be disclosed by Employee without breach of this Agreement, provided, in each case,
that Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Additionally, notwithstanding anything herein to the contrary, nothing in this Agreement or any other agreement between Employer and Employee
shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency having jurisdiction over Employer or its operations, and cooperating in any
investigation by any such federal government agency; provided, however, that to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary
relief or other individual remedies thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except as provided herein, Employee agrees that Employee will not at any time, whether
during or subsequent to the term of Employee&#146;s employment with Employer, in any fashion, form or manner, unless specifically consented to in writing by Employer (or as reasonably appropriate in connection with Employee&#146;s performance of his
duties), either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whatsoever, any Confidential Information of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this
<U>Section</U><U></U><U>&nbsp;8.4</U> resulting in material harm to MEDNAX or Employer is a material breach of this Agreement and shall constitute &#147;Cause&#148; for the termination of Employee&#146;s employment hereunder pursuant to
<U>Section</U><U></U><U>&nbsp;4.1</U> hereof. In the event that Employee is ordered to disclose any Confidential Information, whether in a legal or a regulatory proceeding or otherwise, to the extent legally permitted, Employee shall provide
Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to
the extent practicable, compliance with the provisions of this Agreement. In the case of any disclosure required by law, Employee shall disclose only that portion of the Confidential Information that Employee is ordered to disclose in a legally
binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding. Employee may also disclose Confidential Information as reasonably appropriate pursuant to any litigation or arbitration between Employee and Employer or
any of its affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books,
correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or
control shall be and remain Employer&#146;s sole property (collectively &#147;<U>Employer Property</U>&#148;). Upon termination or expiration of this Agreement, or earlier upon Employer&#146;s request, Employee shall promptly deliver to Employer all
Employer Property, retaining none other than Employee&#146;s contacts, calendar and personal correspondence and any of Employee&#146;s compensation-related information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.5.&nbsp;&nbsp;&nbsp;&nbsp;<I>Ownership of Work Product.</I> Employee agrees and acknowledges that (i)&nbsp;all copyrights, patents, trade
secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course of performing
work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employer&#146;s Business (collectively, the &#147;<U>Work
Product</U>&#148;), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered a work made
for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration. Upon request of Employer
(and at Employer&#146;s cost), Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of
all right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or
modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employer&#146;s successors and assigns, as fully and as entirely as
the same might be held by Employee had this assignment not been made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.6.&nbsp;&nbsp;&nbsp;&nbsp;<I>Clearance Procedure for Proprietary Rights Not Claimed by
Employer.</I> In the event that Employee wishes to create or develop, <I>other than</I> on Employer&#146;s time or using Employer&#146;s resources, anything that may be considered Work Product but to which Employee believes Employee should be
entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently
detailed written description of the work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with
respect to such request or description. Employer will determine in its sole discretion, within thirty (30)&nbsp;days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer. If Employer
determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If Employer fails to so
notify Employee within such thirty (30)&nbsp;day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any significant
improvement, modification, or adaptation that could reasonably be related to Employer&#146;s Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer. Clearance under
this procedure does not relieve Employee of the restrictive covenants set forth in this <U>Section</U><U></U><U>&nbsp;8</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.7.&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Disparagement.</FONT></I> For a period of ten (10)&nbsp;years after
termination of Employee&#146;s employment , Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, intentionally, knowingly, or willingly make any comment that would
reasonably be expected to be materially disparaging or negative to any other person or entity regarding Employer or MEDNAX or any of its affiliates, employees, officers and directors, Employee&#146;s work conditions or circumstances surrounding
Employee&#146;s separation from Employer or otherwise impugn or criticize the name or reputation of Employer or MEDNAX, its affiliates, employees, officers or directors, orally or in writing. For a period of ten (10)&nbsp;years after termination of
Employee&#146;s employment, Employer and MEDNAX will not, directly or indirectly, intentionally, knowingly, or willingly make any comment that would reasonably be expected to be materially disparaging or negative to Employee, Employee&#146;s work
performance or circumstances surrounding Employee&#146;s separation from Employer or otherwise impugn or criticize the name or reputation of Employee. This <U>Section</U><U></U><U>&nbsp;8.7</U> shall not be violated by truthful testimony or
statements made in the normal course of Employee&#146;s employment or permitted competitive activities or by Employer or Employee in enforcing the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.8.&nbsp;&nbsp;&nbsp;&nbsp;<I>Review by Employee.</I> <B>Employee has carefully read and considered the terms and provisions of this
</B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;8</U></B><B>, and having done so, agrees that the restrictions set forth in this </B><B><U>Section</U></B><B><U></U></B><B><U>&nbsp;8</U></B><B> are fair and reasonably required for the protection
of the interests of Employer.</B> In the event that any term or provision set forth in this <U>Section</U><U></U><U>&nbsp;8</U> shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such
invalid or unenforceable term(s) or provision(s) may be severed from this Agreement without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive or
other equitable relief will be available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to enforce the covenants set forth in this Section, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the covenants set
forth in this Section shall be held to be invalid, overbroad, or unenforceable by an arbitration panel or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or
severed from this Agreement without, in any manner, affecting the remaining portions of this <U>Section</U><U></U><U>&nbsp;8</U> (all of which shall remain in full force and effect). In the event that any provision of this
<U>Section</U><U></U><U>&nbsp;8</U> related to time period or areas of restriction shall be declared by an arbitration panel or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitration panel or court
deems reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.9.&nbsp;&nbsp;&nbsp;&nbsp;<I>Survival; Notice of Breach and Right to Cure.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If Employer reasonably believes that Employee has breached a provision of this <U>Section</U><U></U><U>&nbsp;8</U>, Employer shall provide
prompt written notice thereof to Employee that explains such reasonably believed breach (the &#147;<U>Alleged Breach</U>&#148;). Employer agrees to work in good faith with Employee to provide Employee a reasonable opportunity to promptly cure such
Alleged Breach. In the event that Employee, acting in good faith, promptly takes actions that would reasonably be expected to cure the Alleged Breach, including, with respect to a comment made by Employee that Employer reasonably believes is in
breach of <U>Section</U><U></U><U>&nbsp;8.7</U>, by Employee retracting such comment, then Employee shall be deemed not to be in breach of this <U>Section</U><U></U><U>&nbsp;8</U> with respect to the Alleged Breach. Employer and Employee further
agree that Employee shall not be deemed to be in breach of any term of <U>Section</U><U></U><U>&nbsp;8.4</U> or <U>Section</U><U></U><U>&nbsp;8.7</U> unless such breach results in material harm to MEDNAX or Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> shall survive the termination of this Agreement and Employee&#146;s employment with
Employer. In the event of a breach of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof, Employer retains the right to terminate any continuing payments to Employee
provided for in <U>Section</U><U></U><U>&nbsp;5</U> of this Agreement. In the event of a breach of any provisions of this <U>Section</U><U></U><U>&nbsp;8</U> by Employee, as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof,
the period for which those provisions would remain in effect shall be extended for a period of time equal to that period beginning when such breach commenced and ending when the activities constituting such breach shall have been finally terminated
(unless Employer was aware of such breach and did not commence actions to cause Employee to cease his actions), in each case as finally determined pursuant to <U>Section</U><U></U><U>&nbsp;11</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The provisions of this <U>Section</U><U></U><U>&nbsp;8</U> are expressly intended to benefit and be enforceable by other affiliated entities
of Employer, who are express third party beneficiaries hereof. Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Section 280G. </B>Notwithstanding any other provision of this Agreement or any other plan, arrangement or
agreement to the contrary, if any of the payments or benefits provided or to be provided by Employer or its affiliates to Employee or for Employee&#146;s benefit pursuant to the terms of this Agreement or otherwise (the &#147;<U>Covered
Payments</U>&#148;) constitute parachute payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(the &#147;<U>Parachute Payments</U>&#148;) within the meaning of Section&nbsp;280G of the Code and, but for this <U>Section</U><U></U><U>&nbsp;9</U>, would be subject to the excise tax imposed
under Section&nbsp;4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the &#147;<U>Excise Tax</U>&#148;), then prior to making
the Covered Payments, a calculation shall be made comparing (i)&nbsp;the Net Benefit (as defined below) to Employee of the Covered Payments after payment of the Excise Tax to (ii)&nbsp;the Net Benefit to Employee if the Covered Payments are limited
to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i)&nbsp;above is less than the amount under (ii)&nbsp;above will the Covered Payments be reduced to the minimum extent necessary to ensure that no
portion of the Covered Payments is subject to the Excise Tax (that amount, the &#147;<U>Reduced Amount</U>&#148;). &#147;<U>Net Benefit</U>&#148; shall mean the present value of the Covered Payments net of all federal, state, local, foreign income,
employment and excise taxes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Any such reduction shall be made in accordance with
Section&nbsp;409A and the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Covered Payments consisting of cash severance benefits
that do not constitute nonqualified deferred compensation subject to Section&nbsp;409A shall be reduced first, in reverse chronological order; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;all other Covered Payments consisting of cash payments, and Covered Payments consisting of
accelerated vesting of equity based awards to which Treas. Reg. &#167; <FONT STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> does not apply, and that in either case do not constitute nonqualified deferred
compensation subject to Section&nbsp;409A, shall be reduced second, in reverse chronological order; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;all Covered Payments consisting of cash payments that constitute nonqualified deferred
compensation subject to Section&nbsp;409A shall be reduced third, in reverse chronological order; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;all Covered Payments consisting of accelerated vesting of equity-based awards to which Treas. Reg.
&#167; <FONT STYLE="white-space:nowrap">1.280G-1</FONT> <FONT STYLE="white-space:nowrap">Q/A-24(c)</FONT> applies shall be the last Covered Payments to be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any determination required under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made in writing in good faith by
an independent accounting firm selected by Employee, subject to the approval of Employer which shall not be unreasonably withheld (the &#147;<U>Accountants</U>&#148;). Employer and Employee shall provide the Accountants with such information and
documents as the Accountants may reasonably request in order to make a determination under this <U>Section</U><U></U><U>&nbsp;9</U>. For purposes of making the calculations and determinations required by this <U>Section</U><U></U><U>&nbsp;9</U>, the
Accountants may rely on reasonable, good-faith assumptions and approximations concerning the application of Section&nbsp;280G and Section&nbsp;4999 of the Code. The Accountants&#146; determinations shall be final and binding on Employer and
Employee, absent manifest error. Employer shall be responsible for all fees and expenses incurred by the Accountants in connection with the calculations required by this <U>Section</U><U></U><U>&nbsp;9</U>. The Accountants shall Employee with its
analysis as soon as practicable following Employee&#146;s request and prior to the occurrence of any transaction which would result in the possibility of Covered Payments being made. Employer shall cooperate with the Employee in good faith in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valuing, and the Accountants shall take into account the value of, services to be provided by the Employee (including the Employee agreeing to refrain from performing services pursuant to a
covenant not to compete) before, on or after the date of the transaction which causes the application of Section&nbsp;280G of the Code such that payments in respect of such services may be considered to be &#147;reasonable compensation&#148; within
the meaning of <FONT STYLE="white-space:nowrap">Q&amp;A-9</FONT> and <FONT STYLE="white-space:nowrap">Q&amp;A-40</FONT> to <FONT STYLE="white-space:nowrap">Q&amp;A-44</FONT> of the final regulations under Section&nbsp;280G of the Code and/or exempt
from the definition of the term &#147;parachute payment&#148; within the meaning of <FONT STYLE="white-space:nowrap">Q&amp;A-2(a)</FONT> of such final regulations in accordance with <FONT STYLE="white-space:nowrap">Q&amp;A-5(a)</FONT> of such final
regulations </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;It is possible that after the determinations and selections made pursuant to this
<U>Section</U><U></U><U>&nbsp;9</U>, Employee will receive Covered Payments that are in the aggregate more than the amount intended or required to be provided after application of this <U>Section</U><U></U><U>&nbsp;9</U>
(&#147;<U>Overpayment</U>&#148;) or less than the amount intended or required to be provided after application of this <U>Section</U><U></U><U>&nbsp;9</U> (&#147;<U>Underpayment</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;In the event that: (A)&nbsp;the Accountants determine, based upon the assertion of a deficiency by
the Internal Revenue Service against either Employer or Employee that the Accountants believe has a high probability of success, that an Overpayment has been made or (B)&nbsp;it is established pursuant to a final determination of a court or an
Internal Revenue Service proceeding that has been finally and conclusively resolved that an Overpayment has been made, then Employee shall pay any such Overpayment to Employer together with interest at the applicable federal rate (as defined in
Section&nbsp;7872(f)(2)(A) of the Code) from the date of Employee&#146;s receipt of the Overpayment until the date of repayment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event that: (A)&nbsp;the Accountants, based upon controlling precedent or substantial
authority, determine that an Underpayment has occurred or (B)&nbsp;a court of competent jurisdiction determines that an Underpayment has occurred, any such Underpayment will be paid promptly by Employer to or for the benefit of Employee together
with interest at the applicable federal rate (as defined in Section&nbsp;7872(f)(2)(A) of the Code) from the date the amount should have otherwise been paid to Employee until the payment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Arbitration. </B>Any controversy or claim arising out of or relating to this Agreement, or any alleged
breach hereof shall be finally determined by a single arbitrator, jointly selected by Employee and Employer, provided that if Employee and Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an
impartial arbitrator selected by the American Arbitration Association. Each party hereto shall share equally the costs of the arbitrator, and the parties agree that the costs of arbitration shall not be subject to reapportionment by the arbitrator;
<I>provided, however</I>, that if following a termination of Employee&#146;s employment that follows or is within six (6)&nbsp;months prior to a Change in Control, Employee seeks arbitration to enforce the terms of this Agreement, Employer shall
bear all costs associated with such arbitration, including but not limited to all costs of the arbitrator, and shall reimburse Employee on a monthly basis for his reasonable legal and other expenses, including all fees, incurred in connection with
any such arbitration. The arbitration proceedings shall be held in Broward County, Florida, unless otherwise mutually agreed by the parties, and shall be conducted in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect. Judgment on the award rendered by the arbitration panel may be
entered and enforced by any court having jurisdiction thereof. Any such arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the
arbitrators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the
party shall be entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable
service of process. Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i)&nbsp;they are not subject to the jurisdiction of such courts, (ii)&nbsp;they are immune from any
legal process issued by such courts and (iii)&nbsp;any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. In the event that either party hereto brings suit seeking injunctive relief, the party found to be at
fault shall pay all reasonable court costs and attorneys&#146; fees of the other, whether such costs and fees are incurred in a court of original jurisdiction or one or more courts of appellate jurisdiction. Notwithstanding the foregoing, in the
event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all of Employee&#146;s reasonable legal and other expenses, including all fees, incurred by Employee in connection with such action, provided,
however, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer all such advanced legal fees and other expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law.</B> This Agreement shall be governed by and construed in accordance with the laws of the
State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices.</B> Any notice required or permitted to be given under this Agreement shall be in writing and
shall be deemed to have been given when delivered by hand or when deposited in the United States mail by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Employer:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">If to Employee:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mednax Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1301 Concord Terrace</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Last known address on</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sunrise, FL 33323</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employer&#146;s records.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention: General Counsel</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Benefits: Binding Effect.</B> This Agreement shall be for the benefit of and binding upon the
parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable in connection with corporate acquisition transactions, assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer, other than in connection with Employee&#146;s death. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability. </B>The invalidity of any one or more of the words, phrases, sentences, clauses or sections
contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event that any one or more of the
words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or clauses, or section or
sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Waivers. </B>The waiver by either party hereto of a breach or violation of any term or provision of this
Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Damages. </B>Nothing contained herein shall be construed to prevent Employer or Employee from seeking and
recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Third Party Beneficiary. </B>Except as provided in <U>Section</U><U></U><U>&nbsp;8.9</U>, nothing
expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employee&#146;s heirs, personal representative(s) and/or legal representative)
any rights or remedies under or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or
representations are not set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment.</B> Upon notice to Employee, this Agreement may be assigned by Employer to an affiliate of
Employer (with a sufficient net worth to perform the obligations hereunder) in connection with a corporate reorganization, restructuring, or similar corporate transaction, or to a successor to Employer in connection with a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20</B>. <B>Legal Fees</B>. Employer shall reimburse Employee for his reasonable legal fees incurred in connection with the negotiation of
this Agreement and the ancillary agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The remainder of this page has been left blank intentionally. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Agreement this 12th day of
July, 2020, effective as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>EMPLOYER:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>MEDNAX SERVICES, INC</B>.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic J. Andreano</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark S. Ordan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dominic J. Andreano</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EVP, General Counsel and Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>MEDNAX, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic J. Andreano</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dominic J. Andreano</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EVP, General Counsel and Secretary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Employment Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BUSINESS OF EMPLOYER </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively
referred to herein as &#147;<U>Employer&#146;s Business</U>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Neonatology, including hospital well baby care; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Maternal-Fetal Medicine, including general obstetrics services; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) Pediatric Cardiology; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pediatric Intensive Care,
including Pediatric Hospitalist Care; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Newborn hearing screening services; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) Pediatric Surgery; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(7) Pediatric Emergency Medicine; and
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(8) Radiology and Teleradiology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to Employer&#146;s Business in this Agreement shall include such other medical service lines, practice management services and
other businesses in which Employer is engaged during the Employment Period; <I>provided,</I> that to be considered a part of Employer&#146;s Business, Employer must have engaged in such other service line, practice management service or other
business at least six (6)&nbsp;months prior to the termination of Employee&#146;s employment. For purposes of this Exhibit A, businesses of Employer shall include the businesses conducted by Employer&#146;s subsidiaries, entities under common
control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for financial reporting
purposes, provided that for purposes of Section&nbsp;8.2 and 8.3 of the Agreement, the term &#147;affiliates&#148; shall only mean the foregoing affiliates and subsidiaries. As used in the Agreement, the term &#147;affiliate&#148; shall exclude
unrelated entities owned by an acquirer of Employer or MEDNAX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Employer acknowledges and agrees to the
following exceptions and clarifications regarding the scope of Employer&#146;s Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;<I>Hospital Services.
</I>Employer and Employee acknowledge that, as of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as
Employer&#146;s Business where such hospitals, hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employer&#146;s Business. Therefore, the parties desire to clarify their
intent with respect to the limitations on Employee&#146;s ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period.
<U>Section</U><U></U><U>&nbsp;8.1</U> shall not be deemed to restrict Employee&#146;s ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included
in Employer&#146;s Business. Furthermore, even if a hospital, hospital system or university provides medical services that are included in Employer&#146;s Business, Employee may work for such hospital,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hospital system or university if Employee has no direct supervisory responsibility for or involvement in the hospital&#146;s, hospital system&#146;s or university&#146;s provision of medical
services that are Employer&#146;s Business. For the avoidance of doubt, Employer and Employee agree that if Employee becomes the Chief Executive Officer of, or a member of the board of directors of, a university, a hospital system or health system,
or other executive officer of similar level to the foregoing, that Employee shall not be in breach of the provisions of this Agreement. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the
medical services of a hospital, hospital system or university that are included in Employer&#146;s Business so long as such hospital, hospital system or university is located at least ten (10)&nbsp;miles from a medical practice owned or operated by
Employer or its affiliate. Subject to paragraph B below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;<I>De Minimus Exception. </I>Employer agrees that a medical service line (other than those listed in items
(1)&nbsp;through (8) above), practice management service or other business in which Employer is engaged shall not be considered to be a part of Employer&#146;s Business if such medical service line, practice management service or other business
constitutes less than three percent (3%) of Employer&#146;s annual revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;<I>Divested Lines of Service.
</I>Employer agrees that any medical service line (including those listed in items (1)&nbsp;through (8) above), practice management or other business in which Employer is engaged that is divested pursuant to a disposition, sale of assets or equity,
or otherwise after the Effective Date shall not be considered to be a part of Employer&#146;s Business effective as of the effective date of such divestiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>D.</I>&nbsp;&nbsp;&nbsp;&nbsp;<I>Certain Ownership Interests. </I><B></B>It shall not be deemed to be a violation of
<U>Section</U><U></U><U>&nbsp;8.1</U> for Employee to: (i)&nbsp;own, directly or indirectly, one percent (1%) or less of a publicly-traded entity that has a market capitalization of $1&nbsp;billion or more; (ii)&nbsp;own, directly or indirectly,
five percent (5%) or less of a publicly-traded entity that has a market capitalization of less than $1&nbsp;billion; or (iii)&nbsp;own, directly or indirectly, less than ten percent (10%) of a privately-held business or company, if Employee is at
all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company.<I> </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Base Salary: </B>One
Million US Dollars ($1,000,000). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Performance Bonus:</B> Target of One Hundred and Fifty Percent (150%) of Employee&#146;s Base Salary with a Maximum
Bonus potential of Two Hundred Percent (200%) of Employee&#146;s Base Salary, and opportunity for threshold bonus. Employee&#146;s 2020 performance bonus shall be prorated (on a daily basis relative to 366) based on the Effective Date and payable at
150% of Employee&#146;s Base Salary (as so prorated). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation: </B>Employee&#146;s initial 2020 equity compensation grant fair value
amount shall be at least $5&nbsp;million, consisting of $2&nbsp;million in Restricted Stock and $3&nbsp;million in performance stock options, and Employee&#146;s equity compensation grant fair value amount for 2021 shall be at least
$3.5&nbsp;million and thereafter shall be an annual fair value amount of at least $3.5&nbsp;million, subject to the approval of the Compensation Committee. The terms of the equity grants and the breakdown of performance and time-based awards shall
be no less favorable than that provided for other senior executive officers of Employer, and shall be agreed upon by Employee and the Compensation Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTRICTED
STOCK AGREEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mark Ordan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(the
&#147;<B>Recipient</B>&#148;) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Grant of Restricted Stock</U>. The Compensation Committee (the &#147;Committee&#148;) of the Board of
Directors of MEDNAX, Inc. (the &#147;Company&#148;) has granted on July&nbsp;12, 2020, the &#147;<B>Date of Grant</B>&#148;), to the Recipient, 113,314 shares of restricted common stock, par value $.01 per share, of the Company (collectively the
&#147;<B>Restricted Stock</B>&#148;). The Restricted Stock shall be subject to the terms, conditions and restrictions set forth in this Agreement. The Restricted Stock was issued pursuant to the Company&#146;s Amended and Restated 2008 Incentive
Compensation Plan (the &#147;<B>Plan</B>&#148;), which is incorporated herein for all purposes. The Recipient hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all of the terms and conditions hereof and thereof and all
applicable laws and regulations. Unless otherwise provided herein, terms used herein that are defined in the Plan and not defined herein shall have the meanings attributed thereto in the Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Vesting of Restricted Stock</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The shares of Restricted Stock shall be fully vested on the Date of Grant. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delivery of Restricted Stock</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Restricted Stock shall be issued in the name of the Recipient and held in electronic book entry format by
the Company&#146;s transfer agent until the date (the &#147;<B>Applicable Date</B>&#148;) on which the shares (or a portion thereof) subject to this Restricted Stock award become transferable or otherwise subject to disposition. All such Restricted
Stock held by the Company&#146;s transfer agent shall be deemed restricted and may not be sold, transferred, or disposed of until the earlier of (A)&nbsp;the fifth (5th) anniversary of the grant date (the &#147;<B>Anniversary Date</B>&#148;), (B) a
Change in Control (as defined in Recipient&#146;s employment agreement dated July&nbsp;12, 2020 (the &#147;<B>Employment Agreement</B>&#148;), (C) Recipient&#146;s termination of employment pursuant to Sections 4.2, 4.3, 4.4, or 4.6 of the
Employment Agreement, or (D)&nbsp;Recipient&#146;s termination of employment pursuant to Sections 4.1 or 4.5 of the Employment Agreement, in which case of this subsection (D)&nbsp;Recipient must own 100% of such shares until the earlier of
(i)&nbsp;the twelve (12)&nbsp;month anniversary of Recipient&#146;s termination, (ii)&nbsp;the Anniversary Date, or (iii)&nbsp;a Change in Control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until such shares become transferable or otherwise subject to disposition, the Recipient hereby irrevocably
appoints the Secretary of the Company as his/her <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> with full power of appointment and substitution, to effectuate the transfer of the Restricted Stock
(or assignment of distributions thereon) on the books and records of the Company in accordance with and as required to adhere to the restrictions set forth in this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or after each Applicable Date and subject to compliance with Section&nbsp;7 below, upon written request to
the Company by the Recipient, the Company shall promptly cause a certificate or certificates to be issued for and with respect to all shares, which certificate(s) shall be delivered to the Recipient as soon as administratively practicable after the
date of receipt by the Company of the Recipient&#146;s written request. The certificate(s) shall bear those legends and endorsements that the Company shall deem necessary or appropriate (including those relating to restrictions on transferability
and/or obligations and restrictions under the Securities Laws). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rights with Respect to Restricted Stock</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in this Agreement, the Recipient shall have, with respect to all of the shares of
Restricted Stock, all of the rights of a holder of shares of common stock of the Company, including without limitation (i)&nbsp;the right to vote such Restricted Stock, (ii)&nbsp;the right to receive dividends, if any, as may be declared on the
Restricted Stock from time to time, and (iii)&nbsp;the rights available to all holders of shares of common stock of the Company upon any merger, consolidation, reorganization, liquidation or dissolution, stock
<FONT STYLE="white-space:nowrap">split-up,</FONT> stock dividend or recapitalization undertaken by the Company; <U>provided</U>, <U>however</U>, that all of such rights shall be subject to the terms, provisions, conditions and restrictions set forth
in this Agreement. Any shares of Stock issued to the Recipient as a dividend with respect to shares of Restricted Stock shall have the same status and bear the same legend as the shares of Restricted Stock and shall be held by the Company, if the
shares of Restricted Stock that such dividend is attributed to is being so held, unless otherwise determined by the Committee. In addition, notwithstanding any provision to the contrary herein, any cash dividends declared with respect to shares of
Restricted Stock subject to this Agreement shall be paid to the Recipient. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If at any time while this Agreement is in effect, there shall be any increase or decrease in the number of
issued and outstanding shares of Stock of the Company through the declaration of a stock dividend or through any recapitalization, combination or exchange of such shares, then and in that event, the Board or the Committee shall make any adjustments
it deems in good faith fair and appropriate, in view of such change, in the number of shares of Restricted Stock then subject to this Agreement, to preserve the intended economics of the Restricted Stock. If any such adjustment shall result in a
fractional share, such fraction shall be disregarded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any term or provision of this Agreement to the contrary, the existence of this Agreement, or of
any outstanding Restricted Stock awarded hereunder, shall not affect in any manner the right, power or authority of the Company to make, authorize or consummate: (i)&nbsp;any or all adjustments, recapitalizations, reorganizations or other changes in
the Company&#146;s capital structure or its business; (ii)&nbsp;any merger, consolidation or similar transaction by or of the Company; (iii)&nbsp;any offer, issue or sale by the Company of any capital stock of the Company, including any equity or
debt securities, or preferred or preference stock that would rank prior to or on parity with the Restricted Stock and/or that would include, have or possess other rights, benefits and/or preferences superior to those that the Restricted Stock
includes, has or possesses, or any warrants, options or rights with respect to any of the foregoing; (iv)&nbsp;the dissolution or liquidation of the Company; (v)&nbsp;any sale, transfer or assignment of all or any part of the stock, assets or
business of the Company; or (vi)&nbsp;any other corporate transaction, act or proceeding (whether of a similar character or otherwise). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Shares</U>. A Beneficiary or other person
claiming any rights under the Plan or this Agreement from or through the Recipient shall be subject to all of the terms and conditions of the Plan and this Agreement, except as otherwise determined by the Committee, and to any additional terms and
conditions deemed necessary or appropriate by the Committee. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Tax Matters</U>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall withhold such number of shares of Restricted Stock on the Grant Date having a fair market
value (as determined by the Company) equal to the amount necessary to satisfy the Recipient&#146;s federal, state or local taxes of any kind required by law (the &#147;<B>Tax Obligations</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tax consequences on the Recipient (including without limitation federal, state, local and foreign income tax
consequences) with respect to the Restricted Stock (including without limitation the grant and the Tax Obligations) are the sole responsibility of the Recipient. The Recipient shall consult with his or her own personal accountant(s) and/or tax
advisor(s) regarding these matters including the payment (or tax liability) obligations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment, Modification</U><U></U><U>&nbsp;&amp; Assignment;
<FONT STYLE="white-space:nowrap">Non-Transferability</FONT></U>. This Agreement may only be modified or amended in a written document signed by the parties hereto. No promises, assurances, commitments, agreements, undertakings or representations,
whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have been made by either party which are not set forth expressly in this Agreement. The rights and obligations created
hereunder shall be binding on the Recipient and his heirs and legal representatives and on the successors and assigns of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Complete Agreement</U>. This Agreement (together with those agreements and documents expressly referred to
herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties with respect to the subject matter hereof, and supersede any and all prior promises, assurances, commitments, agreements,
undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Miscellaneous</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Right to (Continued) Employment or Service</U>. This Agreement and the grant of Restricted Stock
hereunder shall not confer, or be construed to confer, upon the Recipient any right to employment or service, or continued employment or service, with the Company or any Related Entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Limit on Other Compensation Arrangements</U>. Nothing contained in this Agreement shall preclude the
Company or any Related Entity from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific
cases or to specific persons. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. If any term or provision of this Agreement is or becomes or is deemed to be invalid,
illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended
without materially altering the purpose or intent of this Agreement and the grant of Restricted Stock hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in
full force and effect). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Trust or Fund Created</U>. Neither this Agreement nor the grant of Restricted Stock hereunder shall
create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Related Entity and the Recipient or any other person. To the extent that the Recipient or any other person acquires a right
to receive payments from the Company or any Related Entity pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Law Governing</U>. This Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of Florida (without reference to the conflict of laws rules or principles thereof). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Interpretation</U>. This Agreement is subject to all of the terms, conditions and provisions of the Plan,
including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that the Agreement
conflicts or is inconsistent with the terms, conditions and provisions of the Plan, this Agreement shall control. The Recipient accepts the Restricted Stock subject to all of the terms, provisions and restrictions of this Agreement and the Plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings</U>. Section, paragraph and other headings and captions are provided solely as a convenience to
facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. Any notice under this Agreement shall be in writing and shall be deemed to have been duly given
when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company&#146;s General Counsel at 1301 Concord Terrace, Sunrise, FL 33323 or if the Company should
move its principal office, to such principal office, and, in the case of the Recipient, to the Recipient&#146;s last permanent address as shown on the Company&#146;s records, subject to the right of the Company to designate some other address at any
time hereafter in a notice satisfying the requirements of this Section. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U><FONT STYLE="white-space:nowrap">Non-Waiver</FONT> of Breach</U>. The waiver by any party hereto of the
other party&#146;s prompt and complete performance, or breach or violation, of any term or provision of this Agreement shall be effected solely in writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent
breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or
remedy by such party, upon the occurrence of any subsequent breach or violation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Agreement may be executed in two or more separate counterparts, each of which shall
be an original, and all of which together shall constitute one and the same agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Return of Value of Shares</U><B>.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Recipient is a party to an Employment Agreement with the Company or any Related Entity and the Recipient
violates in any material respect any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> or confidentiality agreement contained therein (and such violation is not cured within 30 days
following written notice from the Company), then, in addition to any other remedy the Company may have, the Company may, in the sole discretion of the Committee, require the Recipient to pay to the Company, upon written demand, (i)&nbsp;if the
Recipient is employed by the Company at the time of such violation, an amount equal to the aggregate Fair Market Value of the Shares of Restricted Stock that have vested during the period beginning on the date twelve months before such violation and
ending on the date on which senior management of the Company acquires actual knowledge of such violation or (ii)&nbsp;if the Recipient is not employed by the Company at the time of such violation, an amount equal to the aggregate Fair Market Value
of the Shares of Restricted Stock that have vested during the twelve months preceding the date on which the Recipient&#146;s employment with the Company was terminated. The aggregate Fair Market Value of such Shares of Restricted Stock shall be
determined with respect to each Share on the applicable vesting date for that Share pursuant to Section&nbsp;2 hereof, without regard to any changes in the Fair Market Value that occurred after the vesting date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Regardless of whether the Recipient is a party to an Employment Agreement with the Company or any Related
Entity, in addition to any other remedy the Company may have, the Shares of Restricted Stock subject of this Agreement shall be subject to recoupment by the Company if the Recipient is subject to any recoupment or clawback policy of the Company in
effect on or after the date hereof (a &#147;<B>Clawback Policy</B>&#148;) or any law, rule or regulation which imposes mandatory recoupment. Recipient acknowledges that, as of the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
date hereof, the Company has adopted the Clawback Policy set forth on Appendix A attached hereto and agrees to comply therewith and with any proper demand of the Company, the Board or Committee
made pursuant thereto to enforce or otherwise comply with such Clawback Policy. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">To enforce the provisions of Section&nbsp;11
the Company may (i)&nbsp;cause the cancellation of Restricted Stock, (ii)&nbsp;require Recipient to return to the Company the Shares of Restricted Stock, (iii)&nbsp;require reimbursement of any benefit under the Restricted Stock granted to the
Recipient, (iv)&nbsp;require the Recipient to pay to the Company the value realized by the Recipient from the sale or other disposition of the Shares of Restricted Stock and (v)&nbsp;effect any other right of recoupment or legal remedy with respect
to equity or other compensation provided under the Plan or otherwise, in all cases, in accordance with and to the extent required by any Clawback Policy applicable to the Recipient. Additionally, the Company may require that, and the Recipient
shall, repay to the Company certain previously paid compensation, either provided under the Plan or an award agreement or otherwise, in accordance with any Clawback Policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">By accepting the Restricted Stock granted hereunder, the Recipient agrees to be bound by any existing or future Clawback Policy adopted by the
Board or the Committee, or any amendments to any Clawback Policy that may from time to time be made by the Board or the Committee in their discretion or as any law, rule or regulation which imposes recoupment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">C-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have executed this Agreement as of
the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dominic J. Andreano</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EVP, General Counsel and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreed and Accepted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Recipient:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Mark S. Ordan</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clawback Policy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following policy is
excerpted from the MEDNAX, Inc. Corporate Governance Principles: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Recoupment of Incentive Compensation</U></B><B>. </B>In the event of a restatement
of the Company&#146;s financial statements due to the material noncompliance of the Company with any financial reporting requirement under applicable securities laws as a result of misconduct, the result of which is that any incentive compensation
(as defined below) that was based on such noncompliant financial statements and received during the three year period preceding the date on which the Board of Directors or a duly authorized committee thereof determines that the Company is required
to prepare such restatement would have been a lower amount had it been based on such restated financial statements, a committee consisting of <FONT STYLE="white-space:nowrap">non-management</FONT> members of the Board of Directors established by the
Board of Directors in its discretion in light of the circumstances, which may be the Audit Committee of the Board of Directors (any such committee, the &#147;Independent Director Committee&#148;), shall review such incentive compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Independent Director Committee determines that the amount of any such incentive compensation actually paid or awarded to an executive officer (the
&#147;Awarded Compensation&#148;) would have been a lower amount had it been calculated based on such restated financial statements (the &#147;Actual Compensation&#148;) and such executive officer engaged in Improper Conduct (as defined below) that
materially contributed to the need for such restatement, then the Independent Director Committee shall, except as provided below, seek to recover for the benefit of the Company the <FONT STYLE="white-space:nowrap">after-tax</FONT> portion of the
difference between the Awarded Compensation and the Actual Compensation (such difference, the &#147;Excess Compensation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the <FONT
STYLE="white-space:nowrap">after-tax</FONT> portion of the Excess Compensation, the Independent Director Committee shall take into account its good faith estimate of the value of any tax deduction available to the executive officer in respect of
such repayment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Independent Director Committee may determine not to seek recovery to the extent it finds (i)&nbsp;that to do so would be
inappropriate or unreasonable or (ii)&nbsp;that it would be better for the Company not to do so. In making such determination, the Independent Director Committee shall take into account such considerations as it deems appropriate, including, without
limitation, (A)&nbsp;the position held by the executive officer at the time of the material <FONT STYLE="white-space:nowrap">non-compliance,</FONT> (B)&nbsp;the conduct of the executive officer with respect to any such material <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> (C)&nbsp;the likelihood of success under governing law versus the cost and effort involved, (D)&nbsp;whether the assertion of a claim may prejudice the interests of the Company, including in any
related proceeding or investigation, (E)&nbsp;the passage of time since the occurrence of the act in respect of the material <FONT STYLE="white-space:nowrap">non-compliance,</FONT> (F)&nbsp;any pending legal proceeding relating to the applicable <FONT
STYLE="white-space:nowrap">non-compliance</FONT> and (G)&nbsp;whether the executive officer&#146;s employment with the Company has terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before the
Independent Director Committee determines to seek recovery pursuant to this policy, it shall provide to the applicable executive officer written notice and the opportunity to be heard, at a meeting of the Independent Director Committee (which may be
<FONT STYLE="white-space:nowrap">in-person</FONT> or telephonic, as determined by the Independent Director Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Independent Director
Committee determines to seek a recovery pursuant to this policy, it shall make a written demand for repayment from the executive officer and, if the executive officer does not within a reasonable period tender repayment in response to such demand,
and the Independent Director Committee determines that he or she is unlikely to do so, the Independent Director Committee may seek a court order against the executive officer for such repayment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this policy, (i)&nbsp;the term &#147;executive officer&#148; has the meaning given to that term in the Securities Exchange Act of 1934, as
amended; (ii)&nbsp;the term &#147;incentive compensation&#148; means all bonuses, other incentive compensation and equity compensation awarded to each of the Company&#146;s executive officers, the amount, payment and/or vesting of which was
calculated based wholly or in part on the application of objective financial performance criteria measured during any part of the period covered by </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the restatement and set forth in or reflected in the Company&#146;s financial statements subject to the restatement; and (iii) &#147;Improper Conduct&#148; shall mean willful commission of an act
of fraud, dishonesty or recklessness in the performance of a person&#146;s duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This policy shall apply to incentive compensation awards granted on or
after January&nbsp;1, 2014. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT D </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NONQUALIFIED STOCK OPTION AGREEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mark Ordan </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(the &#147;Optionee&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Grant of Option</U>. The Compensation Committee (the &#147;<B>Committee</B>&#148;) of the Board of Directors (the
&#147;<B>Board</B>&#148;) of MEDNAX, Inc. (the &#147;<B>Company</B>&#148;) has granted on July&nbsp;12, 2020 (&#147;<B>Date of Grant</B>&#148;), to the Optionee an option (the &#147;<B>Option</B>&#148;) to purchase up to 550,331 shares of the
Company&#146;s Common Stock, $.01 par value per share (the &#147;<B>Shares</B>&#148;), at an exercise price per share equal to $17.65 (the &#147;<B>Exercise Price</B>&#148;). The Option shall be subject to the terms and conditions set forth in this
Agreement. The Option was issued pursuant to the Company&#146;s Amended and Restated 2008 Incentive Compensation Plan, as may be amended from time to time (the &#147;<B>Plan</B>&#148;), which is incorporated herein for all purposes. The Option is a
Nonqualified Stock Option, and not an Incentive Stock Option. The Optionee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all of the terms and conditions hereof and thereof and all applicable laws and regulations. Unless
otherwise provided herein, terms used herein that are defined in the Plan and not defined herein shall have the meanings attributed thereto in the Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Vesting and Exercisability; Expiration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided herein with respect to an earlier expiration date, the Option will expire and be of no further effect on the
ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day (the &#147;<B>Expiration Date</B>&#148;) after the third anniversary of the Date of Grant (the &#147;<B>Performance End Date</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Option shall become vested on the first anniversary of the Date of Grant so long as the Optionee remains in Continuous Service from the
Date of Grant through such first anniversary (such service vesting requirement referred to herein as the &#147;<B>Service Vesting Requirement</B>&#148;), except as otherwise provided herein. The Option may only be exercised, however, after the
Optionee has satisfied the Service Vesting Requirement and only if and to the extent the Option has become exercisable due to satisfaction of the stock price hurdle requirements (&#147;<B>Price Hurdle Requirement</B>&#148;) during the
Optionee&#146;s Continuous Service as follows, except as otherwise provided herein: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Option shall be exercisable with respect to
175,747 Shares if and when the Company stock price on the NYSE closes at $22 per Share (or above) for any 40 consecutive trading days before the Performance End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Option shall be exercisable with respect to 181,160 Shares if and when the Company stock price on the NYSE closes at $25 per Share (or
above) for any 40 consecutive trading days before the Performance End Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Option shall be exercisable with respect to 193,424
Shares if and when the Company stock price on the NYSE closes at $29 per Share (or above) for any 40 consecutive trading days before the Performance End Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Share price targets shall be subject to adjustment by the Committee due to changes in capitalization or other transactions as described in
Section&nbsp;10(c) of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Change in Control occurs, then the 40 consecutive trading days requirement of the foregoing Price
Hurdle Requirements is waived but the stock price still must be achieved for the applicable portion of the Option to become exercisable as of immediately before and contingent upon the Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Price Hurdle Requirement for any <FONT STYLE="white-space:nowrap">one-third</FONT> tranche is not achieved by the Performance End Date,
then such applicable portion of the Option is cancelled for no consideration. Notwithstanding the foregoing, the Committee shall have discretion to determine a performance tranche achieved if the specific requirements above have not been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Optionee&#146;s Continuous Service terminates due to death, Disability, termination by the Company without Cause or by the Optionee
with Good Reason (as those terms are defined in the Optionee&#146;s employment agreement with the Company), then the vested and exercisable portion of the Option as of the Optionee&#146;s termination date will remain exercisable until the earlier of
the one year anniversary of such termination or the Expiration Date.<B> </B>Additional portions of the Option may become vested and exercisable as provided below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Optionee&#146;s Continuous Service terminates due to voluntary termination by the Optionee without Good Reason, then the vested and
exercisable portion of the Option as of the Optionee&#146;s termination date will remain exercisable until the earlier of the thirtieth (30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after such termination or the Expiration Date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Optionee&#146;s Continuous Service terminates due to death, Disability, termination by the Company without Cause or by the
Optionee with Good Reason before a Change in Control and before either the Service Vesting Requirement or all of the Price Hurdle Requirements are achieved, then the Option will remain outstanding with respect to the portions thereof for which the
Price Hurdle Requirement has not been achieved until the earlier of the one year anniversary of such termination date or the Expiration Date but will become exercisable if and to the extent any of such Price Hurdle Requirements are achieved before
such expiration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided herein, upon the termination of the Optionee&#146;s Continuous
Service, any portion of the Option which is not yet vested and/or exercisable shall automatically and without notice terminate and be null and void. Upon termination of the Optionee&#146;s Continuous Service by the Company for Cause, the Option
shall immediately terminate for no consideration, whether vested or exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, upon a Change in Control, the Service Vesting
Requirement has not been achieved but the Price Hurdle Requirement has been achieved with respect to all or a portion of the Option, and the Optionee continues in employment with a successor company that is publicly-listed and the Option is
converted into a successor option, then the Service Vesting Requirement will be deemed achieved upon termination of the Optionee&#146;s Continuous Service by the Company or successor without Cause or by the Optionee for Good Reason. If a successor
is privately held, and the Price Hurdle Requirement has been achieved with respect to all or a portion of the Option, then the Service Vesting Requirement will be deemed achieved immediately before and contingent upon the Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Expiration Date shall be tolled while the Optionee cannot exercise the Option because such an exercise would violate an applicable
Federal, state, local, or foreign law, provided that the period during which the Option may be exercised is not extended more than 30 days after the exercise of the Option first would no longer violate an applicable Federal, state, local, or foreign
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Method of Exercise</U>. The vested and exercisable portion of this Option shall be exercisable in whole
or in part in accordance with Section&nbsp;2 hereof by written notice, in a form approved by the Company, which notice shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such
other representations and agreements as to the holder&#146;s investment intent with respect to such Shares as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be signed by the Optionee and shall be
delivered in person or by certified mail or facsimile to the Secretary of the Company. The written notice shall be accompanied by payment of the Exercise Price or arrangements in place, which are satisfactory to the Company, for such payment, which
are set forth in paragraph 4 below.<B> </B>This Option shall be deemed to be exercised after both (a)&nbsp;receipt by the Company of such written notice accompanied by the Exercise Price or satisfactory arrangements in place for payment of the
Exercise Price and (b)&nbsp;arrangements that are satisfactory to the Company in its sole discretion have been made for Optionee&#146;s payment to the Company of the amount, if any, that is necessary to be withheld in accordance with applicable
Federal or state withholding requirements. No Shares will be issued pursuant to the Option unless and until such issuance and such exercise shall comply with all relevant provisions of applicable law, including the requirements of any stock exchange
upon which the Shares then may be traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Method of Payment</U>. Payment of the Exercise Price shall be by
any of the following, or a combination thereof, at the election of the Optionee: (a)&nbsp;cash; (b) check; (c)&nbsp;pursuant to a &#147;cashless exercise&#148; procedure, by delivery of a properly executed exercise notice together with such other
documentation, and subject to such guidelines, as the Committee shall require to effect an exercise of the Option and delivery to the Company by a licensed broker acceptable to the Company of proceeds from the sale of Shares sufficient to pay the
Exercise Price and any applicable income or employment taxes; or (d)&nbsp;such other consideration or in such other manner as may be determined by the Committee in its absolute discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT></U>. The Option shall not be pledged, hypothecated or
otherwise encumbered or subject to any lien, obligation or liability of the Optionee to any party (other than the Company or any Related Entity), or assigned or transferred by the Optionee otherwise than by will or the laws of descent and
distribution or to a Beneficiary upon the death of the Optionee, and during the lifetime of the Optionee, the Option only may be exercisable by the Optionee or his or her guardian or legal representative; except that the Option may be transferred to
one or more Beneficiaries or other transferees during the lifetime of the Optionee, and may be exercised by such transferees in accordance with the terms of this Agreement, but only if and to the extent such transfers are permitted by the Committee
(and subject to any terms and conditions which the Committee may impose thereon). A Beneficiary or other person claiming any rights under the Plan or this Agreement from or through the Optionee shall be subject to all of the terms and conditions of
the Plan and this Agreement, except as otherwise determined by the Committee, and to any additional terms and conditions deemed necessary or appropriate by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>No Rights of Stockholders</U>. Neither the Optionee nor any personal representative (or beneficiary) shall be, or
shall have any of the rights and privileges of, a stockholder of the Company with respect to any Shares purchasable or issuable upon the exercise of the Option, in whole or in part, prior to the date of exercise of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment, Modification</U><U></U><U>&nbsp;&amp; Binding Effect</U>. This Agreement may only be modified or
amended in a written document signed by the parties hereto. No promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, with respect to the
subject matter hereof, have been made by either party which are not set forth expressly in this Agreement. The rights and obligations created hereunder shall be binding on the Optionee and his heirs and legal representatives and on the successors
and assigns of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete Agreement</U>. This Agreement (together with those
agreements and documents expressly referred to herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties with respect to the subject matter hereof, and supersede any and all prior
promises, assurances, commitments, agreements, undertakings or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject matter hereof in any way. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Right to (Continued) Employment or Service</U>. This Agreement and the grant of the Option hereunder shall not
confer, or be construed to confer, upon the Optionee any right to employment or service, or continued employment or service with the Company or any Related Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Limit on Other Compensation Arrangements</U>. Nothing contained in this Agreement shall preclude the Company
or any Related Entity from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such plans, agreements and arrangements may be either generally applicable or applicable only in specific cases
or to specific persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any term or provision of this Agreement is or becomes or is
deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or
deemed amended without materially altering the purpose or intent of this Agreement and the grant of the Option hereunder, such provision shall be stricken as to such jurisdiction and the remainder of this Agreement and the award hereunder shall
remain in full force and effect). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Trust or Fund Created</U>. Neither this Agreement nor the grant of the
Option hereunder shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Related Entity and the Optionee or any other person. To the extent that the Optionee or any other
person acquires a right to receive payments from the Company or any Related Entity pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Law Governing</U>. This Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of Florida (without reference to the conflict of laws, rules or principles thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Interpretation</U>. This Agreement is subject to all of the terms, conditions and provisions of the Plan,
including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that this Agreement
conflicts or is inconsistent with the terms, conditions and provisions of the Plan, this Agreement shall control. The Optionee accepts the Option subject to all of the terms and provisions of the Plan and this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. Section, paragraph and other headings and captions are provided solely as a convenience to
facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of this Agreement or any term or provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. Any notice under this Agreement shall be in writing and shall be deemed to have been duly given
when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company&#146;s General Counsel at the Company&#146;s principal office, and, in the case of the
Optionee, to the Optionee&#146;s last permanent address as shown on the Company&#146;s records, subject to the right of the Company to designate some other address at any time hereafter in a notice satisfying the requirements of this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Waiver</FONT> of Breach</U>. The waiver by any party hereto of the other
party&#146;s prompt and complete performance, or breach or violation, of any term or provision of this Agreement shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach
or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy
by such party, upon the occurrence of any subsequent breach or violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement
may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Return of Option Gains</U>. In consideration for the
Company&#146;s grant of this Option to the Optionee, and for the valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Optionee agrees to the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Optionee is a party to an Employment Agreement with the Company or any Related Entity and the Optionee
violates in any material respect any <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> or confidentiality agreement contained therein (and such violation is not cured within 30 days
following written notice from the Company), then, in addition to any other remedy the Company or the Related Entity may have, the Company may, in the sole discretion of the Committee, require the Optionee to pay to the Company, upon written demand,
(i)&nbsp;if the Optionee is employed by the Company at the time of such violation, an amount equal to Optionee&#146;s aggregate Option Gains during the period beginning on the date twelve months before such violation and ending on the date on which
senior management of the Company acquires actual knowledge of such violation or (ii)&nbsp;if the Optionee is not employed by the Company at the time of such violation, an amount equal to the Optionee&#146;s aggregate Option Gains during the twelve
months preceding the date on which the Optionee&#146;s employment with the Company was terminated. For the purposes of this Agreement, &#147;<B>Option Gains</B>&#148; shall mean (i)&nbsp;the Fair Market Value of a Share on the date of exercise
during the relevant period less the Exercise Price, multiplied by (ii)&nbsp;the number of Shares that the Optionee purchased as a result of the exercise of the Option. No regard shall be given to any changes in the Fair Market Value of a Share that
occurred after the date of exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto, intending to be legally bound, have executed this
Agreement effective as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDNAX, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dominic J. Andreano</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">EVP, General Counsel and Secretary</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreed and Accepted: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Optionee:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark S. Ordan</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT E </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>GENERAL RELEASE OF CLAIMS </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;Mark Ordan (&#147;<U>Employee</U>&#148;), for himself and his family, heirs, executors, administrators, legal
representatives and their respective successors and assigns, in exchange for the consideration received pursuant to <U>Section</U><U></U><U>&nbsp;5.[ ]</U> of that certain Employment Agreement, dated as of July&nbsp;12, 2020, by and between Employee
and Employer, to which this release is attached as Exhibit E (the &#147;<U>Employment Agreement</U>&#148;), does hereby release and forever discharge
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&#147;<U>Employer</U>&#148;), its subsidiaries, affiliated companies, successors and assigns, and its current or former
directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the &#147;<U>Released Parties</U>&#148;) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or
by reason of any matter, cause or thing whatsoever, whether known or unknown arising as a result of events occurring through the date hereof, including, but not limited to, all claims under any laws applicable to Employee&#146;s employment, whether
for discrimination, harassment, retaliation, claims relating to or in connection with Employee&#146;s employment or termination thereof, claims for tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of
emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Employee acknowledges that Employer encouraged him to consult with an attorney of his choosing, and through this General Release of
Claims encourages Employee to consult with his attorney with respect to possible claims under the Age Discrimination in Employment Act (&#147;<U>ADEA</U>&#148;) and that he understands that the ADEA is a Federal statute that, among other things,
prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that he may have as of the
date hereof. Employee further understands that by signing this General Release of Claims he is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have
existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i)&nbsp;any actions to enforce rights to receive any payments or benefits which may be due
Employee pursuant to <U>Section</U><U></U><U>&nbsp;5.[</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>]</U> of the Employment Agreement, or under any of Employer&#146;s employee benefit or incentive compensation plans, (ii)&nbsp;any rights or claims that may
arise as a result of events occurring after the date this General Release of Claims is executed, (iii)&nbsp;any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies,
(iv)&nbsp;any claims for benefits under any directors&#146; and officers&#146; liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, and (v)&nbsp;any rights as a holder of
equity securities or equity awards of Employer or MEDNAX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Employee represents that he has not filed against the
Released Parties any complaints, charges, or lawsuits arising out of his employment, or any other matter arising on or prior to the date of this General Release of Claims , and covenants and agrees that he will never individually or with any person
file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a
&#147;<U>Proceeding</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary,
nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to Employer, with any federal government agency
having jurisdiction over Employer or its operations, and cooperating in any investigation by any such federal government agency; However, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made relating
to claims that would otherwise be released pursuant to paragraph 1 above, Employee shall not be entitled to recover any individual monetary relief or other individual remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;Employee hereby acknowledges that Employer has informed him that he has up to
<FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to sign this General Release of Claims and he may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this General
Release of Claims earlier. Employee also understands that he shall have seven (7)&nbsp;days following the date on which he signs this General Release of Claims within which to revoke it by providing a written notice of his revocation to Employer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in
accordance with the internal laws of the State of Florida applicable to contracts made and to be performed entirely within such State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;Employee acknowledges that he has read this General Release of Claims, that he has been advised that he should
consult with an attorney before he executes this general release of claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;This General Release of Claims shall take effect on the eighth day following Employee&#146;s execution of this
General Release of Claims unless Employee&#146;s written revocation is delivered to Employer within seven (7)&nbsp;days after such execution. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">E-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>d919859dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Mark S. Ordan, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;30, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Mark S. Ordan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>d919859dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Stephen D. Farber, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MEDNAX, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;30, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>d919859dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification Pursuant to 18 U.S.C Section&nbsp;1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Adopted by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of MEDNAX, Inc. on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
June&nbsp;30, 2020 (the &#147;Report&#148;), each of the undersigned hereby certifies, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that (i)&nbsp;the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of
the Securities Exchange Act of 1934 and (ii)&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A signed original of this written statement required by Section&nbsp;906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX,
Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;30, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark S. Ordan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark S. Ordan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/<B> </B>Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(Principal Financial Officer)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>md-20200630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-July-2020 [01:00:25] {PM}-->
<schema targetNamespace="http://www.mednax.com/20200630" elementFormDefault="qualified" xmlns:md="http://www.mednax.com/20200630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.mednax.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" id="ConsolidatedBalanceSheetsUnaudited">
<link:definition>1002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" id="ConsolidatedBalanceSheetsUnauditedParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" id="ConsolidatedStatementsOfIncome">
<link:definition>1004 - Statement - Consolidated Statements of Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" id="ConsolidatedStatementsOfEquity">
<link:definition>1005 - Statement - Consolidated Statements of Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" id="BasisOfPresentationAndNewAccountingPronouncements">
<link:definition>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" id="CoronavirusPandemicCovid19">
<link:definition>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" id="CashEquivalentsAndInvestments">
<link:definition>1009 - Disclosure - Cash Equivalents and Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1010 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" id="AccountsReceivableAndNetRevenue">
<link:definition>1011 - Disclosure - Accounts Receivable and Net Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
<link:definition>1012 - Disclosure - Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
<link:definition>1013 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" id="CommonAndCommonEquivalentShares">
<link:definition>1014 - Disclosure - Common and Common Equivalent Shares</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" id="StockIncentivePlansAndStockPurchasePlans">
<link:definition>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" id="CommonStockRepurchasePrograms">
<link:definition>1016 - Disclosure - Common Stock Repurchase Programs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" id="BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<link:definition>1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" id="CashEquivalentsAndInvestmentsTables">
<link:definition>1019 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1020 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" id="AccountsReceivableAndNetRevenueTables">
<link:definition>1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
<link:definition>1022 - Disclosure - Discontinued Operations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
<link:definition>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" id="CommonAndCommonEquivalentSharesTables">
<link:definition>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" id="BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<link:definition>1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" id="CoronavirusPandemicCovid19AdditionalInformationDetail">
<link:definition>1026 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" id="CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<link:definition>1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" id="CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<link:definition>1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<link:definition>1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" id="FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<link:definition>1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" id="AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<link:definition>1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<link:definition>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" id="AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<link:definition>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" id="DiscontinuedOperationsAdditionalInformationDetail">
<link:definition>1034 - Disclosure - 	 Discontinued Operations -  Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" id="DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<link:definition>1035 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" id="AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<link:definition>1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" id="AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<link:definition>1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" id="CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<link:definition>1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" id="StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" id="CommonStockRepurchaseProgramsAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="md-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
<element name="AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PracticeSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PracticeSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PracticeSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesStockSwaps" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodSharesStockSwaps" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueStockSwaps" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_StockIssuedDuringPeriodValueStockSwaps" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExtraordinaryItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAbstract" substitutionGroup="xbrli:item" />
<element name="CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableAndNetRevenueDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_AccountsReceivableAndNetRevenueDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockRepurchasesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_CommonStockRepurchasesTextBlock" substitutionGroup="xbrli:item" />
<element name="FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndNewAccountingPronouncementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationAndNewAccountingPronouncementsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="UnnamedCorporateJointVentureOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureOneMember" substitutionGroup="xbrli:item" />
<element name="UnnamedCorporateJointVentureTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_UnnamedCorporateJointVentureTwoMember" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_BasisOfPresentationLineItems" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondAndThirdQuartersOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondAndThirdQuartersOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFourthQuarterOf2020Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFourthQuarterOf2020Member" substitutionGroup="xbrli:item" />
<element name="ForecastForFirstQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForFirstQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="ForecastForSecondQuarterOf2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ForecastForSecondQuarterOf2021Member" substitutionGroup="xbrli:item" />
<element name="CreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="ExtraordinaryItemsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ExtraordinaryItemsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ExtraordinaryItemsDomain" substitutionGroup="xbrli:item" />
<element name="CovidNinenteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CovidNinenteenMember" substitutionGroup="xbrli:item" />
<element name="ContributionsInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ContributionsInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromContributionInAidOfReimbursementOfLostRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfDeferredPaymentOfSocialSecurityTaxes" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" substitutionGroup="xbrli:item" />
<element name="PercentageIncreaseDecreaseInSalaryAndWage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageIncreaseDecreaseInSalaryAndWage" substitutionGroup="xbrli:item" />
<element name="SupplementaryLeverageRatioRequired" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_SupplementaryLeverageRatioRequired" substitutionGroup="xbrli:item" />
<element name="EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2023Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2023Member" substitutionGroup="xbrli:item" />
<element name="Seniorunsecurdnotes2027Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_Seniorunsecurdnotes2027Member" substitutionGroup="xbrli:item" />
<element name="RuralAreaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_RuralAreaMember" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsAndInvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CashEquivalentsAndInvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CashEquivalentsAndInvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MoneyMarketFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MutualFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MutualFundsFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TwoThousandTwentyThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentyThreeMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentySevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandTwentySevenMember" substitutionGroup="xbrli:item" />
<element name="HospitalsContractsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_HospitalsContractsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFinancingReceivablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ScheduleOfFinancingReceivablesLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetPatientServiceRevenueByTypeOfPayor" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" substitutionGroup="xbrli:item" />
<element name="ContractedManagedCareMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_ContractedManagedCareMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="DeferredTaxAssetsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DeferredTaxAssetsDomain" substitutionGroup="xbrli:item" />
<element name="NorthAmericanPartnersInAnesthesiaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NorthAmericanPartnersInAnesthesiaMember" substitutionGroup="xbrli:item" />
<element name="DivestitureOfMeddataMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DivestitureOfMeddataMember" substitutionGroup="xbrli:item" />
<element name="MaximumConsiderationReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_MaximumConsiderationReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountsReceivableRetained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccountsReceivableRetained" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CapitalLossCarryForward" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_CapitalLossCarryForward" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxYearTwoThousandAndTwentyFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TaxYearTwoThousandAndTwentyFiveMember" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedPayrollTaxesAndBenefitsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="md_AccruedPayrollTaxesAndBenefitsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInAccruedSalariesAndBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="md_IncreaseDecreaseInAccruedSalariesAndBonuses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmendedAndRestatedTwoThousandEightPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_AmendedAndRestatedTwoThousandEightPlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenNonQualifiedStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommonStockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="md_CommonStockLineItems" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>md-20200630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-July-2020 [01:00:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_MD_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_MD_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_IncomeTaxesReceivable" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" use="optional" order="32" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeNet" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_MD_PracticeSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSalariesAndBenefits" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_MD_PracticeSuppliesAndOtherOperatingExpenses" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_RestructuringCharges" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="36" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_MD_AccruedPayrollTaxesAndBenefitsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_MD_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_MD_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" use="optional" order="10" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>md-20200630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-July-2020 [01:00:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsTables" roleURI="http://www.mednax.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StatementTable_99" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_RetainedEarningsMember_102" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_670768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_670768" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_StatementTable_686004" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_720100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_us-gaap_LetterOfCreditMember_720100" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_720098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCredit_720098" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_StatementTable_670784" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_670798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_670798" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" xlink:to="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_StatementTable_670805" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_StatementTable_468356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_720124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_DivestitureOfMeddataMember_720124" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_718609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_718609" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_718611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MaximumMember_718611" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_718612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MinimumMember_718612" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_720107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_720107" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_720108" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_718608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_718608" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_718614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_AccountsReceivableRetained_718614" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward_720105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_CapitalLossCarryForward_720105" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_720115" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_720112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_StatementTable_720112" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_720113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_720113" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_720116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_720116" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_us-gaap_StatementTable_393218" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_md_CommonStockTable_637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="18" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>md-20200630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-July-2020 [01:00:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentQuarterlyReport" xml:lang="en-US">Document Quarterly Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xml:lang="en-US">Assets held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred income tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US">Deferred income tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:to="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xml:lang="en-US">Accounts payable and accrued liabilities excluding accrued income taxes current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Current portion of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long-term debt and finance lease liabilities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:to="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xml:lang="en-US">Long term debt and capital lease obligations excluding long term line of credit.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock; $.01 par value; 200,000 shares authorized; 85,536 and 84,248 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained (deficit) earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xml:lang="en-US">Liabilities held for sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, aggregate shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xml:lang="en-US">Weighted average common shares:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common and common equivalent shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (loss) from continuing operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Equity in earnings of unconsolidated affiliates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment Income, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNet" xml:lang="en-US">Investment and other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total non-operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSalariesAndBenefits" xlink:to="lab_md_PracticeSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSalariesAndBenefits" xml:lang="en-US">Practice salaries and benefits.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice Supplies And Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Practice supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PracticeSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_PracticeSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PracticeSuppliesAndOtherOperatingExpenses" xml:lang="en-US">The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (loss) from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Loss from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net incremental loss on the sale of MedData</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (loss) from continuing operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:to="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xml:lang="en-US">It represents Income (Loss) from continuing operations, per basic and diluted share</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xml:lang="en-US">Loss from discontinued operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Forfeitures of restricted stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock swaps, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodSharesStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodSharesStockSwaps" xml:lang="en-US">Stock issued during period shares stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xml:lang="en-US">Forfeitures of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of restricted stock and conversion of restricted stock units to common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock Issued During Period Value Stock Swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock swaps</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_StockIssuedDuringPeriodValueStockSwaps" xlink:to="lab_md_StockIssuedDuringPeriodValueStockSwaps" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_StockIssuedDuringPeriodValueStockSwaps" xml:lang="en-US">Stock issued during period value stock swaps.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Repurchased common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Stock Repurchased During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xml:lang="en-US">Repurchased common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized holding gain (loss) on investments, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in financing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xml:lang="en-US">Payments of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Repurchases of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments for credit facility amendment and financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xml:lang="en-US">Proceeds from issuance of senior notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Borrowings on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Payments on credit agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Payments on finance lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash used in financing activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash used in financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition payments, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Other Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from maturities or sales of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from Sales of Business, Affiliate and Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xml:lang="en-US">Proceeds from sale of business, net of cash sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by (used in) investing activities&#8212;discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of premiums, discounts and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable / receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xml:lang="en-US">Long-term professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xml:lang="en-US">Payments of contingent consideration liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xml:lang="en-US">Net cash provided by operating activities - discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by operating activities &#8211; continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAbstract" xlink:to="lab_md_ExtraordinaryItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAbstract" xml:lang="en-US">Extraordinary Items [Abstract]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic ("COVID-19")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:to="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xml:lang="en-US">Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xml:lang="en-US">Cash Equivalents and Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TextBlockAbstract" xml:lang="en-US">Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable And Net Revenue Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts Receivable and Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:to="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xml:lang="en-US">Accounts receivable and net revenue disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Common and Common Equivalent Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Incentive Plans and Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Common Stock Repurchase Programs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockRepurchasesTextBlock" xlink:to="lab_md_CommonStockRepurchasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockRepurchasesTextBlock" xml:lang="en-US">Entire disclosure of common stock repurchases.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Schedule of Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Financial Instruments Measured At Carrying Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:to="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xml:lang="en-US">Tabular disclosure of financial instruments measured at carrying amount.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedule of Percentage of Net Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xml:lang="en-US">Basis of Presentation and New Accounting Pronouncements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:to="lab_md_BasisOfPresentationAndNewAccountingPronouncementsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureOneMember" xlink:to="lab_md_UnnamedCorporateJointVentureOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_UnnamedCorporateJointVentureOneMember" xml:lang="en-US">Unnamed Corporate Joint Venture [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_UnnamedCorporateJointVentureTwoMember" xml:lang="en-US">Unnamed Corporate Joint Venture Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_UnnamedCorporateJointVentureTwoMember" xlink:to="lab_md_UnnamedCorporateJointVentureTwoMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BasisOfPresentationLineItems" xml:lang="en-US">Basis Of Presentation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BasisOfPresentationLineItems" xlink:to="lab_md_BasisOfPresentationLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method ownership percentage in joint venture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:to="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondAndThirdQuartersOf2020Member" xml:lang="en-US">Forecast For Second And Third Quarters Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFourthQuarterOf2020Member" xlink:to="lab_md_ForecastForFourthQuarterOf2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFourthQuarterOf2020Member" xml:lang="en-US">Forecast For Fourth Quarter Of 2020 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForFirstQuarterOf2021Member" xlink:to="lab_md_ForecastForFirstQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForFirstQuarterOf2021Member" xml:lang="en-US">Forecast For First Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ForecastForSecondQuarterOf2021Member" xlink:to="lab_md_ForecastForSecondQuarterOf2021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ForecastForSecondQuarterOf2021Member" xml:lang="en-US">Forecast For Second Quarter Of 2021 [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CreditAgreementMember" xlink:to="lab_md_CreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CreditAgreementMember" xml:lang="en-US">Credit Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letters of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsAxis" xlink:to="lab_md_ExtraordinaryItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsAxis" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ExtraordinaryItemsDomain" xlink:to="lab_md_ExtraordinaryItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ExtraordinaryItemsDomain" xml:lang="en-US">Extraordinary Items [Axis]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">COVID-19 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CovidNinenteenMember" xlink:to="lab_md_CovidNinenteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CovidNinenteenMember" xml:lang="en-US">Covid Ninenteen [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ExecutiveOfficerMember" xml:lang="en-US">Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContributionsInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Contributions In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:to="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xml:lang="en-US">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Deferred Payment Of Social Security Taxes | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:to="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xml:lang="en-US">Percentage Of Deferred Payment Of Social Security Taxes.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Decrease In Salary | %</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:to="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageIncreaseDecreaseInSalaryAndWage" xml:lang="en-US">Percentage Increase Decrease In Salary And Wage.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Credit Facility Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Leverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_SupplementaryLeverageRatioRequired" xlink:to="lab_md_SupplementaryLeverageRatioRequired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_SupplementaryLeverageRatioRequired" xml:lang="en-US">Supplementary Leverage Ratio Required.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated EBITDA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xml:lang="en-US">Estimated Earnings Before Interest Taxes Depreciation And Amortization</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Line of credit outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xml:lang="en-US">Line of credit remaining borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">SeniorUnsecurdNotes2023 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2023Member" xml:lang="en-US">Senior Unsecurd Notes 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2023Member" xlink:to="lab_md_Seniorunsecurdnotes2023Member" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">SeniorUnsecurdNotes2027 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_Seniorunsecurdnotes2027Member" xml:lang="en-US">Senior Unsecurd Notes 2027 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_Seniorunsecurdnotes2027Member" xlink:to="lab_md_Seniorunsecurdnotes2027Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionAxis" xml:lang="en-US">Geographic Distribution [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionAxis" xlink:to="lab_us-gaap_GeographicDistributionAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicDistributionDomain" xml:lang="en-US">Geographic Distribution [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionDomain" xlink:to="lab_us-gaap_GeographicDistributionDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_RuralAreaMember" xlink:to="lab_md_RuralAreaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_RuralAreaMember" xml:lang="en-US">Rural Area [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsTable" xml:lang="en-US">Cash Equivalents and Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable" xlink:to="lab_md_CashEquivalentsAndInvestmentsTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CashEquivalentsAndInvestmentsLineItems" xml:lang="en-US">Cash Equivalents And Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems" xlink:to="lab_md_CashEquivalentsAndInvestmentsLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xml:lang="en-US">Municipal Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xml:lang="en-US">Federal Home Loan Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xml:lang="en-US">Certificates of Deposit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Other Corporate Bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllOtherCorporateBondsMember" xml:lang="en-US">Corporate Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherCorporateBondsMember" xlink:to="lab_us-gaap_AllOtherCorporateBondsMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Available-for-sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xml:lang="en-US">Available-for-sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money Market Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MoneyMarketFundsFairValueDisclosure" xlink:to="lab_md_MoneyMarketFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MoneyMarketFundsFairValueDisclosure" xml:lang="en-US">Fair value of money market funds.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MutualFundsFairValueDisclosure" xlink:to="lab_md_MutualFundsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MutualFundsFairValueDisclosure" xml:lang="en-US">Mutual funds fair value disclosure.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Business Combination Contingent Consideration Liability Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xml:lang="en-US">Fair value Of contingent consideration liability.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xml:lang="en-US">Notes Payable Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">Two Thousand Twenty Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentyThreeMember" xml:lang="en-US">2023 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentyThreeMember" xlink:to="lab_md_TwoThousandTwentyThreeMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">Two Thousand Twenty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandTwentySevenMember" xml:lang="en-US">2027 Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandTwentySevenMember" xlink:to="lab_md_TwoThousandTwentySevenMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesAbstract" xml:lang="en-US">Receivables [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Gross accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for contractual adjustments and uncollectibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Health Care, Patient Service [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xml:lang="en-US">Net patient service revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospital contract administrative fees [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_HospitalsContractsMember" xlink:to="lab_md_HospitalsContractsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_HospitalsContractsMember" xml:lang="en-US">Hospitals Contracts [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Product and Service, Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xml:lang="en-US">Other revenue [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule Of Financing Receivables [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems" xlink:to="lab_md_ScheduleOfFinancingReceivablesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ScheduleOfFinancingReceivablesLineItems" xml:lang="en-US">Schedule of financing receivables.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xml:lang="en-US">Disaggregation of Revenue [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xml:lang="en-US">Health Care Organization Revenue and Expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xml:lang="en-US">Health Care Organization, Receivable and Revenue Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:to="lab_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage Of Net Patient Service Revenue By Type Of Payor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:to="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xml:lang="en-US">Percentage of net patient service revenue by type payor.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_ContractedManagedCareMember" xlink:to="lab_md_ContractedManagedCareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_ContractedManagedCareMember" xml:lang="en-US">Contracted Managed Care [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GovernmentMember" xml:lang="en-US">Government [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentMember" xlink:to="lab_us-gaap_GovernmentMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Self-Pay [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SelfPayMember" xml:lang="en-US">Private-Pay Patients [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Third-Party Payor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xml:lang="en-US">Other Third-Parties [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsAxis" xml:lang="en-US">Deferred Tax Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsAxis" xlink:to="lab_md_DeferredTaxAssetsAxis" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DeferredTaxAssetsDomain" xml:lang="en-US">Deferred Tax Assets [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DeferredTaxAssetsDomain" xlink:to="lab_md_DeferredTaxAssetsDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US">Disposal Group Classification [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US">Disposal Group Classification [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NorthAmericanPartnersInAnesthesiaMember" xlink:to="lab_md_NorthAmericanPartnersInAnesthesiaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NorthAmericanPartnersInAnesthesiaMember" xml:lang="en-US">North American Partners In Anesthesia [member].</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture of MedData [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DivestitureOfMeddataMember" xlink:to="lab_md_DivestitureOfMeddataMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DivestitureOfMeddataMember" xml:lang="en-US">Divestiture of MedData.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xml:lang="en-US">Preliminary and incremental gain loss on sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum Consideration Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_MaximumConsiderationReceivable" xlink:to="lab_md_MaximumConsiderationReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_MaximumConsiderationReceivable" xml:lang="en-US">Maximum consideration receivable.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts Receivable Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccountsReceivableRetained" xlink:to="lab_md_AccountsReceivableRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccountsReceivableRetained" xml:lang="en-US">Accounts receivable retained.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital Loss Carry Forward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital loss carry forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CapitalLossCarryForward" xlink:to="lab_md_CapitalLossCarryForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CapitalLossCarryForward" xml:lang="en-US">Capital loss carry forward.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Increase decrease in valuation allowance deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax Year Two Thousand and Twenty Five [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax Year Two Thousand and Twenty Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TaxYearTwoThousandAndTwentyFiveMember" xlink:to="lab_md_TaxYearTwoThousandAndTwentyFiveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TaxYearTwoThousandAndTwentyFiveMember" xml:lang="en-US">Tax year two thousand and twenty five [Member].</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xml:lang="en-US">Represents disposal group, including discontinued operation, operating expenses</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">(Loss) income from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Disposal Group Including Discontinued Operation Cost of Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Cost of service salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Disposal Group Including Discontinued Operation Cost of Service Supplies and Other Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Cost of service supplies and other operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Disposal Group Including Discontinued Operation Gain or Loss on Assets Held for Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Loss on sale, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Disposal Group Including Discontinued Operation Other Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Non-operating (expense) income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xml:lang="en-US">Disposal group including discontinued operation other income (expense).</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">(Loss) income before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Income tax benefit (provision)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Disposal Group Including Discontinued Operation Transformational and Restructuring Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Transformational and restructuring related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:to="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xml:lang="en-US">Disposal group including discontinued operation transformational and restructuring expenses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses, total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued Payroll Taxes And Benefits Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:to="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AccruedPayrollTaxesAndBenefitsCurrent" xml:lang="en-US">Accrued payroll taxes and benefits current.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Malpractice Loss Contingency, Accrual, Undiscounted, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xml:lang="en-US">Accrued professional liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:to="lab_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase Decrease In Accrued Salaries And Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Net decrease in accrued salaries and bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:to="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_IncreaseDecreaseInAccruedSalariesAndBonuses" xml:lang="en-US">Increase decrease in accrued salaries and bonuses.</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities not included in the diluted net income per common share calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xml:lang="en-US">Weighted average number of dilutive common share equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated Two Thousand Eight Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and Restated 2008 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:to="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_AmendedAndRestatedTwoThousandEightPlanMember" xml:lang="en-US">Amended and restated two thousand eight plan.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xml:lang="en-US">1996 non-qualified employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">2015 Non-Qualified Stock Purchase Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:to="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xml:lang="en-US">Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock, reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Vesting period of options, maximum years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for future grants and awards under Stock Incentive Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Percentage of market value of common stock at which employees are permitted to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Aggregate number Shares issued under Stock Purchase Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockTable" xlink:to="lab_md_CommonStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockTable" xml:lang="en-US">Common Stock [Table]</label>
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_md_CommonStockLineItems" xlink:to="lab_md_CommonStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_md_CommonStockLineItems" xml:lang="en-US">Common Stock [Line Items]</label>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Amount withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Shares Paid for Tax Withholding for Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US">Number of shares withheld to satisfy minimum statutory tax withholding obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Common stock authorized for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xml:lang="en-US">Company's Common stock repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>md-20200630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-July-2020 [01:00:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoverPage" roleURI="http://www.mednax.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfIncome" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfIncome" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfEquity" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfEquity" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncements" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoronavirusPandemicCovid19" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestments" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestments" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurements" roleURI="http://www.mednax.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenue" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenue" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperations" roleURI="http://www.mednax.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentShares" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentShares" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#StockIncentivePlansAndStockPurchasePlans" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonStockRepurchasePrograms" roleURI="http://www.mednax.com/role/CommonStockRepurchasePrograms" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommitmentsAndContingencies" roleURI="http://www.mednax.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncementsPolicies" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsTables" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsTables" roleURI="http://www.mednax.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueTables" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsTables" roleURI="http://www.mednax.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesTables" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentSharesTables" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CoronavirusPandemicCovid19AdditionalInformationDetail" roleURI="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" roleURI="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" roleURI="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" roleURI="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" roleURI="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#AccountsPayableAndAccruedExpensesAdditionalInformationDetail" roleURI="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" roleURI="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" roleURI="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="md-20200630.xsd#CommonStockRepurchaseProgramsAdditionalInformationDetail" roleURI="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_187927" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_494056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentType_494056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_494062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentQuarterlyReport_494062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_494063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentTransitionReport_494063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_500141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_AmendmentFlag_500141" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_494057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentPeriodEndDate_494057" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_500152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalYearFocus_500152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_500153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_DocumentFiscalPeriodFocus_500153" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_494058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityRegistrantName_494058" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_500154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCentralIndexKey_500154" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_500155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CurrentFiscalYearEndDate_500155" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_494068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCurrentReportingStatus_494068" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_494069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityInteractiveDataCurrent_494069" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_494079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_494079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_494064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_Security12bTitle_494064" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_494065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_TradingSymbol_494065" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_494066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_SecurityExchangeName_494066" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_494070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFileNumber_494070" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_494071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityIncorporationStateCountryCode_494071" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_494072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityTaxIdentificationNumber_494072" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_494073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressAddressLine1_494073" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_494076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressCityOrTown_494076" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_494075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressStateOrProvince_494075" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_494078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityAddressPostalZipCode_494078" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_494077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_CityAreaCode_494077" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_494074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_LocalPhoneNumber_494074" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_494059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityFilerCategory_494059" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_494061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntitySmallBusiness_494061" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_494060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityEmergingGrowthCompany_494060" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_494067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_187927" xlink:to="loc_dei_EntityShellCompany_494067" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_AssetsAbstract_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_AssetsCurrentAbstract_25" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_36" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_38" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_40" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_684080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_IncomeTaxesReceivable_684080" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_OtherAssetsCurrent_41" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_395184" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_25" xlink:to="loc_us-gaap_AssetsCurrent_42" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_31" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Goodwill_32" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_33" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_505340" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_34" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_409691" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24" xlink:to="loc_us-gaap_Assets_35" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent" xlink:label="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent_51" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_393136" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_393137" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_53" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_395187" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27" xlink:to="loc_us-gaap_LiabilitiesCurrent_54" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit" xlink:label="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit_44" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_393146" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent_45" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_46" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_409692" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquityAbstract_28" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_PreferredStockValue_55" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_CommonStockValue_56" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_57" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_28" xlink:to="loc_us-gaap_StockholdersEquity_59" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_50" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_62" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_63" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_PreferredStockSharesIssued_64" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_66" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesIssued_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfIncome">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_70" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingExpensesAbstract_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSalariesAndBenefits" xlink:label="loc_md_PracticeSalariesAndBenefits_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSalariesAndBenefits_89" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PracticeSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_md_PracticeSuppliesAndOtherOperatingExpenses_90" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_91" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_393211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_RestructuringCharges_393211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_500469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_73" xlink:to="loc_us-gaap_OperatingExpenses_500469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_OperatingIncomeLoss_78" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InvestmentIncomeNet_79" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_InterestExpense_80" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_81" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_395226" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395229" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_395230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_NetIncomeLoss_395230" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract" xlink:label="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_395236" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract_395235" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_395237" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_395239" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract_395238" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_395240" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareAbstract_71" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareBasic_74" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_71" xlink:to="loc_us-gaap_EarningsPerShareDiluted_75" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_70" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_72" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_95" xlink:to="loc_us-gaap_StatementTable_99" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_97" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_97" xlink:to="loc_us-gaap_EquityComponentDomain_96" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_CommonStockMember_100" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96" xlink:to="loc_us-gaap_RetainedEarningsMember_102" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99" xlink:to="loc_us-gaap_StatementLineItems_98" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_105" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_NetIncomeLoss_106" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_393245" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_107" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_108" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_109" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_113" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodValueStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodValueStockSwaps_114" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_StockIssuedDuringPeriodSharesStockSwaps" xlink:label="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_md_StockIssuedDuringPeriodSharesStockSwaps_115" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_116" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_117" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_118" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_119" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_121" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_SharesIssued_122" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_124" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_ProfitLoss_166" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_409658" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_132" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_ShareBasedCompensation_134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_135" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_125" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_140" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_141" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_142" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_143" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_144" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_145" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve_146" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_127" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_147" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_500479" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_395242" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_130" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_395244" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_159" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_160" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_161" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment_162" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_165" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_395245" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_129" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_395246" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_148" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_149" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_150" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_151" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_152" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_153" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_155" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_157" use="optional" order="39" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_158" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_395250" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_128" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_395251" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_168" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations_169" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393388" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393388" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_393389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_685995" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock" xlink:label="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_685995" xlink:to="loc_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock_685996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393394" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_393395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393301" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_393302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393301" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_393302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_727" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsReceivableAndNetRevenueDisclosureTextBlock" xlink:label="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_727" xlink:to="loc_md_AccountsReceivableAndNetRevenueDisclosureTextBlock_728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395107" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_395108" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_751" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_751" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_752" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentShares">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_781" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_781" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_787" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchasePrograms">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_794" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockRepurchasesTextBlock" xlink:label="loc_md_CommonStockRepurchasesTextBlock_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_794" xlink:to="loc_md_CommonStockRepurchasesTextBlock_795" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_800" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_801" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393384" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393384" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_393386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393404" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_393406" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_393304" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_393310" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock" xlink:label="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_393304" xlink:to="loc_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock_393311" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="loc_us-gaap_TextBlockAbstract_730" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_731" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_730" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_733" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395110" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395110" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_395111" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_754" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_754" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_755" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_784" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_784" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_393368" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationAndNewAccountingPronouncementsTable" xlink:label="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_393368" xlink:to="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_393376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_393375" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_393376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureOneMember" xlink:label="loc_md_UnnamedCorporateJointVentureOneMember_393377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureOneMember_393377" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_UnnamedCorporateJointVentureTwoMember" xlink:label="loc_md_UnnamedCorporateJointVentureTwoMember_670768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_393376" xlink:to="loc_md_UnnamedCorporateJointVentureTwoMember_670768" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BasisOfPresentationLineItems" xlink:label="loc_md_BasisOfPresentationLineItems_393378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationAndNewAccountingPronouncementsTable_393374" xlink:to="loc_md_BasisOfPresentationLineItems_393378" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_BasisOfPresentationLineItems_393378" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_393379" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAbstract" xlink:label="loc_md_ExtraordinaryItemsAbstract_686001" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAbstract_686001" xlink:to="loc_us-gaap_StatementTable_686004" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_686005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementClassOfStockAxis_686005" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_686006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_686005" xlink:to="loc_us-gaap_ClassOfStockDomain_686006" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsAxis" xlink:label="loc_md_ExtraordinaryItemsAxis_686017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_md_ExtraordinaryItemsAxis_686017" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ExtraordinaryItemsDomain" xlink:label="loc_md_ExtraordinaryItemsDomain_686018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsAxis_686017" xlink:to="loc_md_ExtraordinaryItemsDomain_686018" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CovidNinenteenMember" xlink:label="loc_md_CovidNinenteenMember_686019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ExtraordinaryItemsDomain_686018" xlink:to="loc_md_CovidNinenteenMember_686019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_686021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_TitleOfIndividualAxis_686021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_686021" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="loc_srt_ExecutiveOfficerMember_686023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_686022" xlink:to="loc_srt_ExecutiveOfficerMember_686023" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_686024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_StatementScenarioAxis_686024" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_686025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_686024" xlink:to="loc_srt_ScenarioUnspecifiedDomain_686025" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondAndThirdQuartersOf2020Member" xlink:label="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondAndThirdQuartersOf2020Member_686026" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFourthQuarterOf2020Member" xlink:label="loc_md_ForecastForFourthQuarterOf2020Member_686027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFourthQuarterOf2020Member_686027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForFirstQuarterOf2021Member" xlink:label="loc_md_ForecastForFirstQuarterOf2021Member_686028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForFirstQuarterOf2021Member_686028" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ForecastForSecondQuarterOf2021Member" xlink:label="loc_md_ForecastForSecondQuarterOf2021Member_686029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_686025" xlink:to="loc_md_ForecastForSecondQuarterOf2021Member_686029" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_686030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_CreditFacilityAxis_686030" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_686031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_686030" xlink:to="loc_us-gaap_CreditFacilityDomain_686031" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CreditAgreementMember" xlink:label="loc_md_CreditAgreementMember_686032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_md_CreditAgreementMember_686032" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_720100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_686031" xlink:to="loc_us-gaap_LetterOfCreditMember_720100" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_686033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_srt_RangeAxis_686033" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_686034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_686033" xlink:to="loc_srt_RangeMember_686034" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_686035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MaximumMember_686035" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_686037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_686034" xlink:to="loc_srt_MinimumMember_686037" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaap_GeographicDistributionAxis_686038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_GeographicDistributionAxis_686038" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaap_GeographicDistributionDomain_686039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionAxis_686038" xlink:to="loc_us-gaap_GeographicDistributionDomain_686039" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_RuralAreaMember" xlink:label="loc_md_RuralAreaMember_686041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicDistributionDomain_686039" xlink:to="loc_md_RuralAreaMember_686041" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_689758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_DebtInstrumentAxis_689758" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_689759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_689758" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_689759" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2023Member" xlink:label="loc_md_Seniorunsecurdnotes2023Member_689760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2023Member_689760" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_Seniorunsecurdnotes2027Member" xlink:label="loc_md_Seniorunsecurdnotes2027Member_689762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_689759" xlink:to="loc_md_Seniorunsecurdnotes2027Member_689762" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_686007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_686004" xlink:to="loc_us-gaap_StatementLineItems_686007" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageIncreaseDecreaseInSalaryAndWage" xlink:label="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageIncreaseDecreaseInSalaryAndWage_686008" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:label="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization_689397" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_SupplementaryLeverageRatioRequired" xlink:label="loc_md_SupplementaryLeverageRatioRequired_686070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_SupplementaryLeverageRatioRequired_686070" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686012" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContributionsInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ContributionsInAidOfReimbursementOfLostRevenue_686014" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue" xlink:label="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue_686015" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfDeferredPaymentOfSocialSecurityTaxes" xlink:label="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes_686016" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_689754" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_720098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCredit_720098" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_686007" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_720099" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsTable" xlink:label="loc_md_CashEquivalentsAndInvestmentsTable_393444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393443" xlink:to="loc_md_CashEquivalentsAndInvestmentsTable_393444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_393445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_393445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_393445" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_393447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_393446" xlink:to="loc_us-gaap_CashEquivalentsMember_393447" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_393448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_srt_RangeAxis_393448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_393449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_393448" xlink:to="loc_srt_RangeMember_393449" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CashEquivalentsAndInvestmentsLineItems" xlink:label="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsTable_393444" xlink:to="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CashEquivalentsAndInvestmentsLineItems_393452" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_393453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_393412" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_393416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_InvestmentTypeAxis_393416" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_393417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_393416" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_393417" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllOtherCorporateBondsMember" xlink:label="loc_us-gaap_AllOtherCorporateBondsMember_494118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_AllOtherCorporateBondsMember_494118" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_393418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_393420" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_393421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_393417" xlink:to="loc_us-gaap_CertificatesOfDepositMember_393421" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_393415" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_670778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_393439" xlink:to="loc_us-gaap_AvailableForSaleSecurities_670778" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670782" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670782" xlink:to="loc_us-gaap_StatementTable_670784" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670785" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670785" xlink:to="loc_us-gaap_ClassOfStockDomain_670786" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_670794" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_670796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_670796" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_670797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_670797" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_670798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_670795" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_670798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_670799" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_670800" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_670801" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670784" xlink:to="loc_us-gaap_StatementLineItems_670787" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MoneyMarketFundsFairValueDisclosure" xlink:label="loc_md_MoneyMarketFundsFairValueDisclosure_670789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MoneyMarketFundsFairValueDisclosure_670789" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_670790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_670790" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MutualFundsFairValueDisclosure" xlink:label="loc_md_MutualFundsFairValueDisclosure_670791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_670788" xlink:to="loc_md_MutualFundsFairValueDisclosure_670791" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670787" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:label="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670792" xlink:to="loc_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_670793" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_670803" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_670805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_670803" xlink:to="loc_us-gaap_StatementTable_670805" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_670806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementClassOfStockAxis_670806" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_670807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_670806" xlink:to="loc_us-gaap_ClassOfStockDomain_670807" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_670813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_DebtInstrumentAxis_670813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_670814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_670813" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_670814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentyThreeMember" xlink:label="loc_md_TwoThousandTwentyThreeMember_670815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentyThreeMember_670815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandTwentySevenMember" xlink:label="loc_md_TwoThousandTwentySevenMember_670816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_670814" xlink:to="loc_md_TwoThousandTwentySevenMember_670816" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_670805" xlink:to="loc_us-gaap_StatementLineItems_670808" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_670809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesAbstract_670809" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_670810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_670809" xlink:to="loc_us-gaap_NotesPayable_670810" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670808" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_670812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_670811" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_670812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_249" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_250" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_251" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_249" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_252" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract_254" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_srt_ProductOrServiceAxis_256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_256" xlink:to="loc_srt_ProductsAndServicesDomain_257" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCarePatientServiceMember" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_HospitalsContractsMember" xlink:label="loc_md_HospitalsContractsMember_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_md_HospitalsContractsMember_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_395272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_257" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_395272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ScheduleOfFinancingReceivablesLineItems" xlink:label="loc_md_ScheduleOfFinancingReceivablesLineItems_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_258" xlink:to="loc_md_ScheduleOfFinancingReceivablesLineItems_259" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_ScheduleOfFinancingReceivablesLineItems_259" xlink:to="loc_us-gaap_DisaggregationOfRevenueAbstract_255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_255" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract_265" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_267" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_ContractedManagedCareMember" xlink:label="loc_md_ContractedManagedCareMember_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_md_ContractedManagedCareMember_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GovernmentMember" xlink:label="loc_us-gaap_GovernmentMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_GovernmentMember_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="loc_us-gaap_ThirdPartyPayorMember_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_ThirdPartyPayorMember_273" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelfPayMember" xlink:label="loc_us-gaap_SelfPayMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_268" xlink:to="loc_us-gaap_SelfPayMember_274" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems" xlink:label="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_269" xlink:to="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_PercentageOfNetPatientServiceRevenueByTypeOfPayor" xlink:label="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems_266" xlink:to="loc_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor_270" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_468356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395169" xlink:to="loc_us-gaap_StatementTable_468356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsAxis" xlink:label="loc_md_DeferredTaxAssetsAxis_468387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_md_DeferredTaxAssetsAxis_468387" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DeferredTaxAssetsDomain" xlink:label="loc_md_DeferredTaxAssetsDomain_468388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DeferredTaxAssetsAxis_468387" xlink:to="loc_md_DeferredTaxAssetsDomain_468388" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_670845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_670845" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_670846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_670845" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_670846" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NorthAmericanPartnersInAnesthesiaMember" xlink:label="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_NorthAmericanPartnersInAnesthesiaMember_718617" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DivestitureOfMeddataMember" xlink:label="loc_md_DivestitureOfMeddataMember_720124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_670846" xlink:to="loc_md_DivestitureOfMeddataMember_720124" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_718609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_srt_RangeAxis_718609" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_718610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_718609" xlink:to="loc_srt_RangeMember_718610" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_718611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MaximumMember_718611" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_718612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_718610" xlink:to="loc_srt_MinimumMember_718612" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_720107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_TaxPeriodAxis_720107" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_720108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_720107" xlink:to="loc_us-gaap_TaxPeriodDomain_720108" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TaxYearTwoThousandAndTwentyFiveMember" xlink:label="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_720108" xlink:to="loc_md_TaxYearTwoThousandAndTwentyFiveMember_720109" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_468359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_468356" xlink:to="loc_us-gaap_StatementLineItems_468359" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_574667" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CapitalLossCarryForward" xlink:label="loc_md_CapitalLossCarryForward_720105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_CapitalLossCarryForward_720105" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_720106" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_718517" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_718607" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_MaximumConsiderationReceivable" xlink:label="loc_md_MaximumConsiderationReceivable_718608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_MaximumConsiderationReceivable_718608" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccountsReceivableRetained" xlink:label="loc_md_AccountsReceivableRetained_718614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_468359" xlink:to="loc_md_AccountsReceivableRetained_718614" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395132" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_720112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_395132" xlink:to="loc_us-gaap_StatementTable_720112" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_720113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_720113" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_720114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_720113" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_720114" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_720116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_720114" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_720116" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_720115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_720112" xlink:to="loc_us-gaap_StatementLineItems_720115" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_395133" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_720115" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits_395135" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses_395136" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_395138" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_395139" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses_720104" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale_395142" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_395143" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_395144" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense" xlink:label="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense_395145" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_395146" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_395147" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_395134" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_395148" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_364" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableCurrent_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccruedSalariesCurrent_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AccruedPayrollTaxesAndBenefitsCurrent" xlink:label="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_md_AccruedPayrollTaxesAndBenefitsCurrent_367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent" xlink:label="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent_368" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_InterestPayableCurrent_370" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_371" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_364" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_372" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_393216" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_393216" xlink:to="loc_us-gaap_StatementTable_393218" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_393219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementClassOfStockAxis_393219" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_393220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_393219" xlink:to="loc_us-gaap_ClassOfStockDomain_393220" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_393221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393218" xlink:to="loc_us-gaap_StatementLineItems_393221" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_IncreaseDecreaseInAccruedSalariesAndBonuses" xlink:label="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_393221" xlink:to="loc_md_IncreaseDecreaseInAccruedSalariesAndBonuses_671366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_568" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_569" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_570" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_571" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_568" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_572" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_574" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_PlanNameAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_576" xlink:to="loc_us-gaap_PlanNameDomain_577" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember_583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember_584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_AmendedAndRestatedTwoThousandEightPlanMember" xlink:label="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_AmendedAndRestatedTwoThousandEightPlanMember_585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember" xlink:label="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_577" xlink:to="loc_md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember_586" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_AwardTypeAxis_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_575" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_582" xlink:to="loc_us-gaap_RestrictedStockMember_604" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_srt_RangeAxis_578" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_578" xlink:to="loc_srt_RangeMember_579" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_579" xlink:to="loc_srt_MaximumMember_587" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_580" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_588" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_589" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_590" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_591" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_592" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_593" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_594" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_595" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_581" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_393080" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_634" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockTable" xlink:label="loc_md_CommonStockTable_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_634" xlink:to="loc_md_CommonStockTable_637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_640" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_640" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_641" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_635" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" xlink:to="loc_us-gaap_RestrictedStockMember_650" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_642" xlink:to="loc_us-gaap_EquityComponentDomain_638" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_412583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_412583" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_412584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_412583" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_412584" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="md-20200630.xsd#md_CommonStockLineItems" xlink:label="loc_md_CommonStockLineItems_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockTable_637" xlink:to="loc_md_CommonStockLineItems_636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_643" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_554331" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_md_CommonStockLineItems_636" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_648" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d919859d10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:md="http://www.mednax.com/20200630"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="md-20200630.xsd" xlink:type="simple"/>
    <context id="P01_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_24_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-07-24</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">md:UnnamedCorporateJointVentureTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">md:TaxYearTwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AllOtherCorporateBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:TwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">md:HospitalsContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:TwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">md:ContractedManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:GovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">md:AmendedAndRestatedTwoThousandEightPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">md:Seniorunsecurdnotes2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:DivestitureOfMeddataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-25</instant>
        </period>
    </context>
    <context id="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">md:RuralAreaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="md:ExtraordinaryItemsAxis">md:CovidNinenteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForSecondAndThirdQuartersOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFourthQuarterOf2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">md:ForecastForFirstQuarterOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">md:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-25</startDate>
            <endDate>2020-03-25</endDate>
        </period>
    </context>
    <context id="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">md:NorthAmericanPartnersInAnesthesiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-06</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2020To06_30_2020" id="hidden13911539">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      id="hidden13950822"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      id="hidden13950823"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2020To06_30_2020" id="hidden13911545">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2020To06_30_2020" id="hidden13911547">0000893949</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2020To06_30_2020" id="hidden13911549">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntitySmallBusiness contextRef="P01_01_2020To06_30_2020" id="hidden13913753">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2020To06_30_2020" id="hidden13913752">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentType contextRef="P01_01_2020To06_30_2020">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="P01_01_2020To06_30_2020">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2020To06_30_2020">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2020To06_30_2020">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2020To06_30_2020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2020To06_30_2020">001-12111</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2020To06_30_2020">MEDNAX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2020To06_30_2020">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2020To06_30_2020">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2020To06_30_2020">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2020To06_30_2020">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2020To06_30_2020">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2020To06_30_2020">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2020To06_30_2020">954</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2020To06_30_2020">384-0175</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2020To06_30_2020">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2020To06_30_2020">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2020To06_30_2020">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2020To06_30_2020">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2020To06_30_2020">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2020To06_30_2020">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityShellCompany contextRef="P01_01_2020To06_30_2020">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn07_24_2020"
      decimals="INF"
      unitRef="Unit_shares">85461731</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">132151000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">90642000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">345682000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">498869000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">14343000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21826000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">64428000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">41083000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16864000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11569000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">688329000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">731508000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">98469000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">91881000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2165020000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2165020000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">200408000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">209564000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">75817000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">71421000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">61227000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">104827000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">97942000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">89368000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">682312000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3387212000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:Assets>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">360909000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">453110000</md:AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1426000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">130000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">21598000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">20485000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">6039000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">62055000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">383933000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">541819000</us-gaap:LiabilitiesCurrent>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1737176000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1730295000</md:LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">56936000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56582000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">260936000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">226892000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">68681000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">56468000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">52980000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">22899000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11950000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2560642000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2646905000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">85536000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2020"
      decimals="INF"
      unitRef="Unit_shares">85536000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2019"
      decimals="INF"
      unitRef="Unit_shares">84248000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">855000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1004786000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-179071000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">826570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3387212000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4145901000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">509203000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">561237000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1071054000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1104249000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <md:PracticeSalariesAndBenefits
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">349258000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">361203000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">748715000</md:PracticeSalariesAndBenefits>
    <md:PracticeSalariesAndBenefits
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">731571000</md:PracticeSalariesAndBenefits>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">21433000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">24783000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">46839000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <md:PracticeSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">47107000</md:PracticeSuppliesAndOtherOperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">77674000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">84219000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">165232000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">165790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">14393000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">13779000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">28792000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">27584000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">11537000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">17866000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">30581000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">20305000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">474295000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">501850000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1020159000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">992357000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">34908000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">59387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">50895000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">111892000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3851000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1219000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3172000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2866000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">28265000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">31063000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">55931000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">61764000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">479000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1990000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1824000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">3187000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-23935000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-27854000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-50935000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-55711000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">10973000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">31533000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">56181000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3373000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">11486000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">6109000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">13588000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7600000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">20047000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-6149000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">42593000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-680036000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-28292000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-684999000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-293710000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-691148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-251117000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.50</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.24</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.50</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.34</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.47</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.34</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.25</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.45</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83490000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83234000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83061000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">84623000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83689000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83061000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">85087000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84248000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">842000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">987942000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">510212000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1498996000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-18712000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_13911053"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      id="Fact_13911054"
      unitRef="Unit_USD">-213000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">78000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1831000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">968000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-19000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">125000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2541000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2020To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2542000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85150000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">852000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">995257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">491287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1487396000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-672436000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2078000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2078000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">277000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2541000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2544000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-57000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">34000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">501000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">85536000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">855000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1004786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-179071000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">826570000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">87820000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">992647000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2094359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">3087884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-242872000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="Fact_13911059"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      id="Fact_13911060"
      unitRef="Unit_USD">-194000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">140000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3541000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3542000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">978000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-6000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <md:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-20000</md:StockIssuedDuringPeriodSharesStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <md:StockIssuedDuringPeriodValueStockSwaps
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-666000</md:StockIssuedDuringPeriodValueStockSwaps>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">11100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2525000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">28740000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50217000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P01_01_2019To03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">78982000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">86387000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">864000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">977872000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1801076000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2779812000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8245000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">232000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">232000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">155000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3673000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">3675000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">123000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-61000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">15080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">2508000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">29196000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">36306000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">65527000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesIssued
      contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">84096000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">967429000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1756757000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2725027000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-691148000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-251117000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-684999000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-293710000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">28792000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">27584000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2785000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">2934000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">13819000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">20853000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">55812000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-12378000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2092000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8284000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-44296000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-1703000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">16281000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-3715000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-5560000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-14233000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-86609000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-52307000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-49757000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-40181000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">102000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">418000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2931000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">4628000</us-gaap:IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">26888000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-14212000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">19893000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">7031000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">26658000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">56184000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">46551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">63215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">75000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">11450000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">32335000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">18135000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">8180000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">23326000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">15926000</us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">476000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-37125000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-19196000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">15466000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-8438000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-21659000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-27634000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">898500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">527500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1286500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1248000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">5171000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">186000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">98000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">4376000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">6551000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3043000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">144509000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-611000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-40421000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-611000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-40421000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">24281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">-4840000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">107870000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">40774000</us-gaap:CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">132151000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">35934000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation and New Accounting Pronouncements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#x201c;MDX&#x201d;) together with the accounts of MDX&#x2019;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#x201c;affiliated professional contractors&#x201d;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#x201c;MEDNAX&#x201d; and the &#x201c;Company&#x201d; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is a party to a joint venture in which it owns a 37.5% economic interest and a second joint venture in which it owns a 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#x2019;s most recent Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; (the &#x201c;Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&#x201d;).&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. See Note 6 &#x2013; Assets Held for Sale and Discontinued Operations for additional information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020, the Company divested its anesthesiology medical group. The operating results of the Company&#x2019;s anesthesiology medical group are reported as discontinued operations in the Company&#x2019;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#x2013; Assets Held for Sale and Discontinued Operations for additional information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2020, the Company announced the initiation of a process to divest its radiology services medical group when market conditions are appropriate in order to refocus the business as a dedicated pediatrics and obstetrics organization. However, there can be no assurance that this process will result in a transaction. The Company&#x2019;s radiology services medical group is reported within continuing operations for all periods presented as the accounting criterion for assets held for sale was not met as of June&#160;30, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.375</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn06_30_2020_UnnamedCorporateJointVentureTwoMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.490</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;step-up&lt;/div&gt; in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;year-to-date&lt;/div&gt;&lt;/div&gt; loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Coronavirus Pandemic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;COVID-19&#x201d;):&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and related &#x201c;stay at home&#x201d; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#x2019;s affiliated clinicians. Beginning in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#x2019;s affiliated clinicians provided anesthesiology services. See Note 6 &#x2013; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#x2019;s anesthesiology medical group on May&#160;6, 2020. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; procedures and the prohibition of such procedures by several states. Within the Company&#x2019;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-urgent&lt;/div&gt; studies. The Company&#x2019;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; Overall, the Company&#x2019;s operating results since &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-March&lt;/div&gt; 2020 have been significantly impacted by the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; These steps included a suspension of most activities related to the Company&#x2019;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#x2019;s response to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-clinical&lt;/div&gt; employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also divested its anesthesiology medical group in May 2020, where operating results were significantly impacted by COVID-19. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;In response to the anticipated impact of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; on the Company&#x2019;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#x2019;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At June&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June&#160;30, 2020, the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.2&#160;million which reduced the amount available on its Credit Agreement to $899.8&#160;million at June&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CARES Act &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19.&lt;/div&gt; The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#x201c;HHS&#x201d;) is administering this program and began disbursing funds in April 2020, of which the Company&#x2019;s affiliated physician practices received an aggregate of approximately $12&#160;million during the second quarter of 2020.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company currently expects that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock>
    <md:PercentageIncreaseDecreaseInSalaryAndWage
      contextRef="P01_01_2020To06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_ExecutiveOfficerMembersrtTitleOfIndividualAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageIncreaseDecreaseInSalaryAndWage>
    <md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">139200000</md:EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MinimumMembersrtRangeAxis">4.50:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondAndThirdQuartersOf2020MembersrtStatementScenarioAxis_MaximumMembersrtRangeAxis">5.00:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFourthQuarterOf2020MembersrtStatementScenarioAxis">4.75:1:00</md:SupplementaryLeverageRatioRequired>
    <md:SupplementaryLeverageRatioRequired contextRef="P03_25_2020To03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForFirstQuarterOf2021MembersrtStatementScenarioAxis">2020</md:SupplementaryLeverageRatioRequired>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_25_2020_CreditAgreementMemberusgaapCreditFacilityAxis_ForecastForSecondQuarterOf2021MembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">300000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To06_30_2020_Seniorunsecurdnotes2023MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0525</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2020To06_30_2020_Seniorunsecurdnotes2027MemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCredit
      contextRef="PAsOn06_30_2020_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="PAsOn06_30_2020"
      decimals="-5"
      unitRef="Unit_USD">899800000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-6"
      unitRef="Unit_USD">100000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ContributionsInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis_RuralAreaMemberusgaapGeographicDistributionAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</md:ContributionsInAidOfReimbursementOfLostRevenue>
    <md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue
      contextRef="PAsOn06_30_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</md:ProceedsFromContributionInAidOfReimbursementOfLostRevenue>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <md:PercentageOfDeferredPaymentOfSocialSecurityTaxes
      contextRef="P03_27_2020To03_27_2020_CovidNinenteenMemberMDExtraordinaryItemsAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</md:PercentageOfDeferredPaymentOfSocialSecurityTaxes>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash Equivalents and Investments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#x2019;s cash equivalents consisted entirely of money market funds totaling $1.7&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at June&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; padding: 0px;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="PAsOn12_31_2019_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis"
      decimals="-5"
      unitRef="Unit_USD">16800000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held at June&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; padding: 0px;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom; padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;
&lt;td style="padding: 0px;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Corporate securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;55,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,962&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Municipal debt securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;29,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal home loan securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,537&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certificates of deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;4,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn06_30_2020_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">55677000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_AllOtherCorporateBondsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">32962000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn06_30_2020_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">20831000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USStatesAndPoliticalSubdivisionsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">29066000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn06_30_2020_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8537000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_USGovernmentSponsoredEnterprisesDebtSecuritiesMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8013000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn06_30_2020_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">5597000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019_CertificatesOfDepositMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4469000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">90642000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2013; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2013; inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,549&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments were measured at carrying value as of December&#160;31, 2019. See table below. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;744,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#x2019;s line of credit approximates fair value. If the Company&#x2019;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are accounted for at fair value on a recurring basis at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;br/&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,775&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;74,510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mutual Funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,549&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;14,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;Level&#160;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1676000</md:MoneyMarketFundsFairValueDisclosure>
    <md:MoneyMarketFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16775000</md:MoneyMarketFundsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">90642000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">74510000</us-gaap:InvestmentsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">13549000</md:MutualFundsFairValueDisclosure>
    <md:MutualFundsFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">14264000</md:MutualFundsFairValueDisclosure>
    <md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure
      contextRef="PAsOn12_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">2696000</md:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s financial instruments that are not carried at fair value at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023 Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;744,375&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;766,875&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2027 Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,025,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock>
    <us-gaap:NotesPayable
      contextRef="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">744375000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">750000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">766875000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn06_30_2020_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1000000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="PAsOn12_31_2019_TwoThousandTwentySevenMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1025600000</us-gaap:NotesPayableFairValueDisclosure>
    <md:AccountsReceivableAndNetRevenueDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Receivable and Net Revenue: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,386,562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,943,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,040,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,444,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;345,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;498,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patient service revenue is recognized at the time services are provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#x2019;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#x201c;GHC Programs&#x201d;) and third-party insurance payors. Payments for services rendered to the Company&#x2019;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#x201c;DSO&#x201d;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs&lt;br/&gt;within&#160;30&#160;to&#160;60&#160;days of billing. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the Company&#x2019;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;428,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;486,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;919,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;956,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;129,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;136,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;509,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;561,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,071,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,104,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</md:AccountsReceivableAndNetRevenueDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross accounts receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,386,562&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,943,664&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allowance for contractual adjustments and uncollectibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,040,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1,444,795&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;345,682&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;498,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1386562000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1943664000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1040880000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1444795000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">345682000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">498869000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the Company&#x2019;s net revenue by category (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net patient service revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;428,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;486,368&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;919,431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;956,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hospital contract administrative fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65,138&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;69,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;129,698&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;136,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,925&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;11,442&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;509,203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;561,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,071,054&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,104,249&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">428473000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">486368000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">919431000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To06_30_2019_HealthCarePatientServiceMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">956799000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">65138000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">69619000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To06_30_2020_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">129698000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To06_30_2019_HospitalsContractsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">136008000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">15592000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">5250000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To06_30_2020_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">21925000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To06_30_2019_ProductAndServiceOtherMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">11442000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">509203000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">561237000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1071054000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_USD">1104249000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The approximate percentage of net patient service revenue by type of payor was as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contracted managed care&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other third-parties&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Private-pay&lt;/div&gt; patients&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.67</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.66</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To06_30_2020_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.66</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To06_30_2019_ContractedManagedCareMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.65</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To06_30_2020_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To06_30_2019_GovernmentMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.26</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To06_30_2020_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.06</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To06_30_2019_ThirdPartyPayorMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To06_30_2020_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To06_30_2019_SelfPayMemberusgaapHealthCareOrganizationRevenueSourcesAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P04_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <md:PercentageOfNetPatientServiceRevenueByTypeOfPayor
      contextRef="P01_01_2019To06_30_2019"
      decimals="2"
      unitRef="Unit_pure">1</md:PercentageOfNetPatientServiceRevenueByTypeOfPayor>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discontinued Operations: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; background: none;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of Anesthesiology Medical Group &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#x201c;NAPA&#x201d;) to divest&#160;the Company&#x2019;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#x2019;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $250&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated $110.0&#160;million at March&#160;31, 2020. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The operating results of the anesthesiology medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preliminary loss on sale recorded during the three months ended June&#160;30, 2020 was&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$644.2&#160;million. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon completion of a valuation for the contingent economic interest and working capital true-up, final net proceeds will be determined, and the Company will adjust the loss on sale at that time. As a result of the sale, the Company currently estimates that it will generate an approximately $1.68&#160;billion capital loss carryforward which expires in 2025. Based on management&#x2019;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $419.0&#160;million valuation allowance against this deferred tax asset in its financial results for the three months ended June&#160;30, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the anesthesiology medical group for the three and six months ended June&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;307,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;374,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;615,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;95,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;247,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;348,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;498,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,721&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on sale, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;644,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;640,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;773,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;285,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,059,938&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;568,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(682,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; (expense) income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(682,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (provision)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(677,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(679,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;34,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;  &lt;div style="text-align: center;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Divestiture of MedData &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and six&lt;/div&gt; months ended June&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $3.0&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and &lt;/div&gt;$5.6&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, respectively, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#x2019;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P05_06_2020To05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000.0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MinimumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">0</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_MaximumMembersrtRangeAxis_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:MaximumConsiderationReceivable
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-6"
      unitRef="Unit_USD">250000000</md:MaximumConsiderationReceivable>
    <md:AccountsReceivableRetained
      contextRef="PAsOn05_06_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">110000000.0</md:AccountsReceivableRetained>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">644200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <md:CapitalLossCarryForward
      contextRef="PAsOn06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis_TaxYearTwoThousandAndTwentyFiveMemberusgaapTaxPeriodAxis"
      decimals="-7"
      unitRef="Unit_USD">1680000000</md:CapitalLossCarryForward>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">419000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the results of discontinued operations related to the anesthesiology medical group for the three and six months ended June&#160;30, 2020 and 2019 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;;width:;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;90,894&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;307,072&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;374,961&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;615,243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service salaries and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;95,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;247,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;348,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;498,930&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cost of service supplies and other operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,216&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;19,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;30,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,571&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;2,034&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,030&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;6,308&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;12,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transformational and restructuring related expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,771&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,616&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;28,634&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,721&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss on sale, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;644,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;640,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;773,002&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;285,959&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,059,938&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;568,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(682,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,977&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-operating&lt;/div&gt; (expense) income, net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(682,115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,099&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(684,926&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;47,066&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit (provision)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(5,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;5,561&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(12,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net (loss) income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(677,004&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;15,469&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(679,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;34,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 63%;"/&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 2%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; </us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">90894000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">307072000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">374961000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">615243000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">95398000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">247759000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">348662000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">498930000</md:DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1350000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">3233000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">5216000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6700000</md:DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">13287000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">19321000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">30964000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">39571000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">2034000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6030000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">6308000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">12258000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">16771000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">9616000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">28634000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">10721000</md:DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-644162000</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">0</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-640154000</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">0</md:DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">773002000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">285959000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">1059938000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">568180000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-682108000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">21113000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-684977000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">47063000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-7000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-14000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">51000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</md:DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-682115000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">21099000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-684926000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">47066000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-5111000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">5630000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-5561000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">12490000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-677004000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">15469000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">-679365000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2019To06_30_2019_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis"
      decimals="-3"
      unitRef="Unit_USD">34576000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P01_01_2020To06_30_2020_DivestitureOfMeddataMemberusgaapDisposalGroupClassificationAxis"
      decimals="-5"
      unitRef="Unit_USD">5600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="text-align: center; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts Payable and Accrued Expenses:&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;131,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;223,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;61,130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,466&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;360,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;453,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net decrease in accrued salaries and bonuses of $92.1&#160;million, from December&#160;31, 2019 to June&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#x2019;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June&#160;30, 2020. A majority of the Company&#x2019;s payments for performance-based incentive compensation is paid annually during the first quarter. &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="P01_01_2020To06_30_2020">&lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable and accrued expenses consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;48,982&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;38,598&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued salaries and bonuses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;131,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;223,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued payroll taxes and benefits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;43,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;61,130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;57,466&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;44,869&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,679&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;32,910&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;46,956&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;51,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;360,909&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;453,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">48982000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">38598000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">131739000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">223815000</us-gaap:AccruedSalariesCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">43087000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <md:AccruedPayrollTaxesAndBenefitsCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">61130000</md:AccruedPayrollTaxesAndBenefitsCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">57466000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">44869000</us-gaap:MalpracticeLossContingencyAccrualUndiscountedCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">32679000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">32910000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">46956000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">51788000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">360909000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">453110000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <md:IncreaseDecreaseInAccruedSalariesAndBonuses
      contextRef="P01_01_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_USD">92100000</md:IncreaseDecreaseInAccruedSalariesAndBonuses>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common and Common Equivalent Shares: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June&#160;30, 2020 and 2019 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common equivalent&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;shares outstanding (a)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;85,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted net income per&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;common share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;713&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the six months ended June&#160;30, 2020, no incremental shares are included because the effect would be antidilutive. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="P01_01_2020To06_30_2020">The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June&#160;30, 2020 and 2019 is as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Six Months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;84,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of dilutive common share equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;455&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of common and common equivalent&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;shares outstanding (a)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;83,061&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;85,087&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Antidilutive securities not included in the diluted net income per&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;common share calculation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,335&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,092&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;713&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"/&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: 'Times New Roman';"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;(a)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to a loss from continuing operations for the six months ended June&#160;30, 2020, no incremental shares are included because the effect would be antidilutive. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; </us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83490000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">83234000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">83061000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">84623000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">255000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">455000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">464000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      id="Fact_13911218"
      unitRef="Unit_shares">83745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      id="Fact_13911219"
      unitRef="Unit_shares">83689000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      id="Fact_13911225"
      unitRef="Unit_shares">83061000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      id="Fact_13911226"
      unitRef="Unit_shares">85087000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">1335000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P04_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">923000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_shares">1092000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To06_30_2019"
      decimals="-3"
      unitRef="Unit_shares">713000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive Plans and Stock Purchase Plans: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-align: center;"&gt; &lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Amended and Restated 2008 Incentive Compensation Plan (the &#x201c;A&amp;amp;R 2008 Incentive Plan&#x201d;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;Under the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&amp;amp;R&lt;/div&gt; 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the six months ended June&#160;30, 2020, the Company granted 1.1&#160;million shares of restricted stock to its employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; directors under the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&amp;amp;R&lt;/div&gt; 2008 Incentive Plan. At June&#160;30, 2020, the Company had 6.3&#160;million shares available for future grants and awards under the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&amp;amp;R&lt;/div&gt; 2008 Incentive Plan.&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;Under the Company&#x2019;s 1996 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Employee Stock Purchase Plan, as amended (the &#x201c;ESPP&#x201d;), employees are permitted to purchase the Company&#x2019;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#x2019;s 2015 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-Qualified&lt;/div&gt; Stock Purchase Plan (the &#x201c;SPP&#x201d;), certain eligible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers are permitted to purchase the Company&#x2019;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#x2019;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; service providers. During the six months ended June&#160;30, 2020, approximately 0.4&#160;million shares in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;aggregate were issued under the ESPP and SPP. At June&#160;30, 2020, the Company had approximately 0.7&#160;million shares in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;aggregate reserved for issuance under the ESPP and SPP.&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three and six months ended June&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $6.6&#160;million and $14.3&#160;million, and $9.9&#160;million and $20.9&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2020To06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn06_30_2020_AmendedAndRestatedTwoThousandEightPlanMemberusgaapPlanNameAxis_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">6300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To06_30_2020_TwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">2600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2020To06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">400000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2020_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_USD">6600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_USD">14300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To06_30_2019"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To06_30_2019"
      decimals="-5"
      unitRef="Unit_USD">20900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <md:CommonStockRepurchasesTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common Stock Repurchase Programs: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2013, the Company&#x2019;s Board of Directors authorized the repurchase of shares of the Company&#x2019;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#x2019;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;time-to-time&lt;/div&gt;&lt;/div&gt; based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#x2019;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#x2019;s acquisition program. No shares were purchased under this program during the six months ended June&#160;30, 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#x2019;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the six months ended June&#160;30, 2020, the Company withheld approximately 159,000 shares of its common stock to satisfy minimum statutory withholding obligations of $3.0&#160;million in connection with the vesting of restricted stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</md:CommonStockRepurchasesTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn08_31_2018"
      decimals="-5"
      unitRef="Unit_USD">500000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">107200000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">159000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="P01_01_2020To06_30_2020_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2020To06_30_2020">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px; background: none;"/&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#x2019;s affiliated physicians. The Company&#x2019;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#x2019;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#x2019;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations, cash flows and the trading price of its securities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_13911053"
          xlink:label="Fact_13911053"
          xlink:type="locator"/>
        <link:footnote id="FN_52647" xlink:label="FN_52647" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911053"
          xlink:to="FN_52647"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911054"
          xlink:label="Fact_13911054"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911054"
          xlink:to="FN_52647"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911059"
          xlink:label="Fact_13911059"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911059"
          xlink:to="FN_52647"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911060"
          xlink:label="Fact_13911060"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911060"
          xlink:to="FN_52647"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911218"
          xlink:label="Fact_13911218"
          xlink:type="locator"/>
        <link:footnote id="FN_52648" xlink:label="FN_52648" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Due to a loss from continuing operations for the six months ended June 30, 2020, no incremental shares are included because the effect would be antidilutive. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911218"
          xlink:to="FN_52648"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911219"
          xlink:label="Fact_13911219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911219"
          xlink:to="FN_52648"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911225"
          xlink:label="Fact_13911225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911225"
          xlink:to="FN_52648"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_13911226"
          xlink:label="Fact_13911226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_13911226"
          xlink:to="FN_52648"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264261592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jul. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDNAX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,461,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623336470728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 132,151<span></span>
</td>
<td class="nump">$ 107,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">90,642<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">345,682<span></span>
</td>
<td class="nump">498,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">14,343<span></span>
</td>
<td class="nump">21,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">64,428<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">41,083<span></span>
</td>
<td class="nump">16,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">688,329<span></span>
</td>
<td class="nump">731,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">98,469<span></span>
</td>
<td class="nump">91,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,165,020<span></span>
</td>
<td class="nump">2,165,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">200,408<span></span>
</td>
<td class="nump">209,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use&#160;assets</a></td>
<td class="nump">75,817<span></span>
</td>
<td class="nump">71,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">61,227<span></span>
</td>
<td class="nump">104,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">97,942<span></span>
</td>
<td class="nump">89,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">682,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,387,212<span></span>
</td>
<td class="nump">4,145,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">360,909<span></span>
</td>
<td class="nump">453,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">21,598<span></span>
</td>
<td class="nump">20,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">383,933<span></span>
</td>
<td class="nump">541,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit', window );">Long-term debt and finance lease liabilities, net</a></td>
<td class="nump">1,737,176<span></span>
</td>
<td class="nump">1,730,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">56,936<span></span>
</td>
<td class="nump">56,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent', window );">Long-term professional liabilities</a></td>
<td class="nump">260,936<span></span>
</td>
<td class="nump">226,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">68,681<span></span>
</td>
<td class="nump">56,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">52,980<span></span>
</td>
<td class="nump">22,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,560,642<span></span>
</td>
<td class="nump">2,646,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $.01 par value; 1,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $.01 par value; 200,000 shares authorized; 85,536 and 84,248 shares issued and outstanding, respectively</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,004,786<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained (deficit) earnings</a></td>
<td class="num">(179,071)<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">826,570<span></span>
</td>
<td class="nump">1,498,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 3,387,212<span></span>
</td>
<td class="nump">$ 4,145,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts payable and accrued liabilities excluding accrued income taxes current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt and capital lease obligations excluding long term line of credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623337133944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,536,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,536,000<span></span>
</td>
<td class="nump">84,248,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264421368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 509,203<span></span>
</td>
<td class="nump">$ 561,237<span></span>
</td>
<td class="nump">$ 1,071,054<span></span>
</td>
<td class="nump">$ 1,104,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSalariesAndBenefits', window );">Practice salaries and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">349,258<span></span>
</td>
<td class="nump">361,203<span></span>
</td>
<td class="nump">748,715<span></span>
</td>
<td class="nump">731,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PracticeSuppliesAndOtherOperatingExpenses', window );">Practice supplies and other operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,433<span></span>
</td>
<td class="nump">24,783<span></span>
</td>
<td class="nump">46,839<span></span>
</td>
<td class="nump">47,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,674<span></span>
</td>
<td class="nump">84,219<span></span>
</td>
<td class="nump">165,232<span></span>
</td>
<td class="nump">165,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,393<span></span>
</td>
<td class="nump">13,779<span></span>
</td>
<td class="nump">28,792<span></span>
</td>
<td class="nump">27,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Transformational and restructuring related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,537<span></span>
</td>
<td class="nump">17,866<span></span>
</td>
<td class="nump">30,581<span></span>
</td>
<td class="nump">20,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">474,295<span></span>
</td>
<td class="nump">501,850<span></span>
</td>
<td class="nump">1,020,159<span></span>
</td>
<td class="nump">992,357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,908<span></span>
</td>
<td class="nump">59,387<span></span>
</td>
<td class="nump">50,895<span></span>
</td>
<td class="nump">111,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,851<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">3,172<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,265)<span></span>
</td>
<td class="num">(31,063)<span></span>
</td>
<td class="num">(55,931)<span></span>
</td>
<td class="num">(61,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings of unconsolidated affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">3,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,935)<span></span>
</td>
<td class="num">(27,854)<span></span>
</td>
<td class="num">(50,935)<span></span>
</td>
<td class="num">(55,711)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,973<span></span>
</td>
<td class="nump">31,533<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">56,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,373)<span></span>
</td>
<td class="num">(11,486)<span></span>
</td>
<td class="num">(6,109)<span></span>
</td>
<td class="num">(13,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (loss) from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
<td class="num">(6,149)<span></span>
</td>
<td class="nump">42,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(680,036)<span></span>
</td>
<td class="num">(28,292)<span></span>
</td>
<td class="num">(684,999)<span></span>
</td>
<td class="num">(293,710)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (672,436)<span></span>
</td>
<td class="num">$ (8,245)<span></span>
</td>
<td class="num">$ (691,148)<span></span>
</td>
<td class="num">$ (251,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract', window );"><strong>Income (loss) from continuing operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract', window );"><strong>Loss from discontinued operations:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8.14)<span></span>
</td>
<td class="num">(0.34)<span></span>
</td>
<td class="num">(8.25)<span></span>
</td>
<td class="num">(3.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8.12)<span></span>
</td>
<td class="num">(0.34)<span></span>
</td>
<td class="num">(8.25)<span></span>
</td>
<td class="num">(3.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8.05)<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(8.32)<span></span>
</td>
<td class="num">(2.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8.03)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (8.32)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average common shares:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,490<span></span>
</td>
<td class="nump">83,234<span></span>
</td>
<td class="nump">83,061<span></span>
</td>
<td class="nump">84,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83,745<span></span>
</td>
<td class="nump">83,689<span></span>
</td>
<td class="nump">83,061<span></span>
</td>
<td class="nump">85,087<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the six months ended June 30, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents Income (Loss) from continuing operations, per basic and diluted share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Practice salaries and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PracticeSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PracticeSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264272504">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">$ 992,647<span></span>
</td>
<td class="nump">$ 2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(242,872)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(242,872)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodValueStockSwaps', window );">Stock swaps</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(78,982)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">(28,740)<span></span>
</td>
<td class="num">(50,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,779,812<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">977,872<span></span>
</td>
<td class="nump">1,801,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,087,884<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">992,647<span></span>
</td>
<td class="nump">2,094,359<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(251,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,725,027<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">967,429<span></span>
</td>
<td class="nump">1,756,757<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,779,812<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
<td class="nump">977,872<span></span>
</td>
<td class="nump">1,801,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,245)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(65,527)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">(29,196)<span></span>
</td>
<td class="num">(36,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,725,027<span></span>
</td>
<td class="nump">$ 841<span></span>
</td>
<td class="nump">967,429<span></span>
</td>
<td class="nump">1,756,757<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,487,396<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">995,257<span></span>
</td>
<td class="nump">491,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,498,996<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">987,942<span></span>
</td>
<td class="nump">510,212<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(691,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">826,570<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">1,004,786<span></span>
</td>
<td class="num">(179,071)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,487,396<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">995,257<span></span>
</td>
<td class="nump">491,287<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(672,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) on investments, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Issuance of restricted stock and conversion of restricted stock units to common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Forfeitures of restricted stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeitures of restricted stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchased common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(501)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchased common stock, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 826,570<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 1,004,786<span></span>
</td>
<td class="num">$ (179,071)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Presented within retained earnings on the consolidated balance sheet as the balance is immaterial.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_StockIssuedDuringPeriodValueStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_StockIssuedDuringPeriodValueStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264421096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (691,148)<span></span>
</td>
<td class="num">$ (251,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="nump">684,999<span></span>
</td>
<td class="nump">293,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28,792<span></span>
</td>
<td class="nump">27,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of premiums, discounts and issuance costs</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">13,819<span></span>
</td>
<td class="nump">20,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">55,812<span></span>
</td>
<td class="num">(12,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(2,092)<span></span>
</td>
<td class="nump">8,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">44,296<span></span>
</td>
<td class="nump">1,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(16,281)<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="nump">5,560<span></span>
</td>
<td class="nump">14,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(86,609)<span></span>
</td>
<td class="num">(52,307)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable / receivable</a></td>
<td class="num">(49,757)<span></span>
</td>
<td class="num">(40,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve', window );">Long-term professional liabilities</a></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">26,888<span></span>
</td>
<td class="num">(14,212)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities &#8211; continuing operations</a></td>
<td class="nump">19,893<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities - discontinued operations</a></td>
<td class="nump">26,658<span></span>
</td>
<td class="nump">56,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">46,551<span></span>
</td>
<td class="nump">63,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition payments, net of cash acquired</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(11,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(32,335)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities or sales of investments</a></td>
<td class="nump">18,135<span></span>
</td>
<td class="nump">8,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(23,326)<span></span>
</td>
<td class="num">(15,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Proceeds from sale of business, net of cash sold</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities &#8211; continuing operations</a></td>
<td class="num">(37,125)<span></span>
</td>
<td class="num">(19,196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) investing activities&#8212;discontinued operations</a></td>
<td class="nump">15,466<span></span>
</td>
<td class="num">(8,438)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(21,659)<span></span>
</td>
<td class="num">(27,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on credit agreement</a></td>
<td class="nump">527,500<span></span>
</td>
<td class="nump">898,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payments on credit agreement</a></td>
<td class="num">(527,500)<span></span>
</td>
<td class="num">(1,286,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments for credit facility amendment and financing costs</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of contingent consideration liabilities</a></td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(5,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on finance lease obligations</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,376<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(3,043)<span></span>
</td>
<td class="num">(144,509)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash used in financing activities &#8211; continuing operations</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(40,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash used in financing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(40,421)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">24,281<span></span>
</td>
<td class="num">(4,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">107,870<span></span>
</td>
<td class="nump">40,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 132,151<span></span>
</td>
<td class="nump">$ 35,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623261911496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation and New Accounting Pronouncements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation and New Accounting Pronouncements: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited Consolidated Financial Statements of the Company and the notes thereto presented in this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results of the interim periods presented. The financial statements include all the accounts of MEDNAX, Inc. and its consolidated subsidiaries (collectively, &#8220;MDX&#8221;) together with the accounts of MDX&#8217;s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (the &#8220;affiliated professional contractors&#8221;). Certain subsidiaries of MDX have contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms &#8220;MEDNAX&#8221; and the &#8220;Company&#8221; refer collectively to MEDNAX, Inc., its subsidiaries and the affiliated professional contractors. </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is a party to a joint venture in which it owns a 37.5% economic interest and a second joint venture in which it owns a 49.0% economic interest. The Company accounts for these joint ventures under the equity method of accounting because the Company exercises significant influence over, but does not control, these entities. </div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company&#8217;s most recent Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (the &#8220;Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K&#8221;).</div> </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2019, the Company divested its management services organization, which operated as MedData, to allow the Company to focus on its core physician services business. The operating results of MedData are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, the Company divested its anesthesiology medical group. The operating results of the Company&#8217;s anesthesiology medical group are reported as discontinued operations in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. Reclassifications have been made to certain prior period financial statements and footnote disclosures to reflect the impact of discontinued operations. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for additional information. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2020, the Company announced the initiation of a process to divest its radiology services medical group when market conditions are appropriate in order to refocus the business as a dedicated pediatrics and obstetrics organization. However, there can be no assurance that this process will result in a transaction. The Company&#8217;s radiology services medical group is reported within continuing operations for all periods presented as the accounting criterion for assets held for sale was not met as of June&#160;30, 2020. </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New Accounting Pronouncements</div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623261946376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAbstract', window );"><strong>Extraordinary Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock', window );">Coronavirus Pandemic ("COVID-19")</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Coronavirus Pandemic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;):</div> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and related &#8220;stay at home&#8221; and social distancing measures implemented across the country have significantly impacted demand for medical services provided by the Company&#8217;s affiliated clinicians. Beginning in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020, the Company experienced a significant decline in the number of elective surgeries at the facilities where&#160;the Company&#8217;s affiliated clinicians provided anesthesiology services. See Note 6 &#8211; Assets Held for Sale and Discontinued Operations for information regarding the divestment of the Company&#8217;s anesthesiology medical group on May&#160;6, 2020. Much of this decline was due to the closure of operating suites or facilities following federal advisories to cancel <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> procedures and the prohibition of such procedures by several states. Within the Company&#8217;s radiology services medical group, orders for radiological studies declined by a meaningful amount from historically normal levels, with much of this reduction focused in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-urgent</div> studies. The Company&#8217;s affiliated office-based practices, which specialize in maternal-fetal medicine, pediatric cardiology, and numerous pediatric subspecialties, have seen a significant elevation of appointment cancellations compared to historical normal levels. At this time, the Company has not experienced, nor does it currently anticipate, any significant impact to neonatal intensive care unit (NICU) patient volumes as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Overall, the Company&#8217;s operating results since <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-March</div> 2020 have been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, but volumes did begin to normalize in May 2020 and substantially recovered during the month of June 2020. </div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">The Company implemented a number of actions to preserve financial flexibility and partially mitigate the significant anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> These steps included a suspension of most activities related to the Company&#8217;s transformational and restructuring programs, limiting these expenditures to those that provide essential support for the Company&#8217;s response to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> In addition, (i)&#160;the Company temporarily reduced executive and key management base salaries, including 50% reductions in salaries for its named executive officers through June&#160;30, 2020; (ii) the Board of Directors agreed to forego their annual cash retainer and cash meeting payments, also through June&#160;30, 2020; (iii) the Company enacted a combination of salary reductions and furloughs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> employees; and (iv)&#160;the Company enacted significant operational and practice-specific expense reduction plans across its clinical operations.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company also divested its anesthesiology medical group in May 2020, where operating results were significantly impacted by COVID-19. </div></div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In response to the anticipated impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the Company&#8217;s results of operations, on March&#160;25, 2020, the Company amended and restated its Credit Agreement to, among other things, (i)&#160;establish a deemed Consolidated EBITDA of $139.2&#160;million for the second and third quarters of 2020, reflecting average Adjusted EBITDA from continuing operations for the prior eight quarters (calculated for purposes of the Credit Agreement), which will be used in the calculation of rolling four consecutive quarter Consolidated EBITDA under the Credit Agreement, (ii)&#160;temporarily increase the maximum consolidated net leverage ratio required to be maintained by the Company from 4.50:1:00 to 5.00:1:00 for the second and third quarters of 2020 and 4.75:1:00 for the fourth quarter of 2020, before returning to 4.50:1:00 for the first quarter of 2021 and beyond, (iii)&#160;require that the Company maintains minimum availability under the Credit Agreement of $300.0&#160;million through the third quarter of 2021, (iv) provide for a weekly repayment of borrowings under the Credit Agreement through the second quarter of 2021 using unrestricted cash on hand in excess of $300.0&#160;million, plus a reserve for certain payables, and (v)&#160;temporarily restrict the Company&#8217;s ability to make restricted payments under the Credit Agreement for the remainder of 2020, subject to certain exceptions. At June&#160;30, 2020, the Company believes it was in compliance, in all material respects, with the financial covenants and other restrictions applicable to the Company under its Credit Agreement, its 5.25% senior unsecured notes due 2023<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>and its 6.25% senior unsecured notes due 2027. The Company believes it will be in compliance with these covenants for the next twelve months.&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2020, the Company had no outstanding principal balance on its Credit Agreement. The Company had outstanding letters of credit of $0.2&#160;million which reduced the amount available on its Credit Agreement to $899.8&#160;million at June&#160;30, 2020, after giving effect to the temporary reduction of the capacity of its Credit Agreement described above through September&#160;30, 2021. </div></div></div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CARES Act </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On March&#160;27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) into law. The CARES Act is a relief package intended to assist many aspects of the American economy, including providing up to $100&#160;billion in aid to the healthcare industry to reimburse healthcare providers for lost revenue and expenses attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> The remaining $70&#160;billion in aid is intended to focus on providers in areas particularly impacted by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> rural providers, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for the treatment of uninsured Americans. It is unknown what, if any, portion of the remaining healthcare industry funding on the CARES Act the Company and its affiliated physician practices will qualify for and receive. The Department of Health and Human Services (&#8220;HHS&#8221;) is administering this program and began disbursing funds in April 2020, of which the Company&#8217;s affiliated physician practices received an aggregate of approximately $12&#160;million during the second quarter of 2020.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The Company has applications pending for certain affiliated physician practices for incremental relief beyond what has been received.</div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due December&#160;31, 2021 and the remaining 50% due December&#160;31, 2022. The Company intends to utilize this deferral option throughout 2020.</div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company currently expects that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation will materially impact its financial results, but due to the rapidly evolving environment and continued uncertainties surrounding the timeline of and impacts from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the Company is unable to predict the ultimate impact on its business, financial condition, results of operations and cash flows. The Company, however, believes it will be able to generate sufficient liquidity to satisfy its obligations for the next twelve months. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extraordinary Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263621208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Equivalents and Investments: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2020 and December&#160;31, 2019, the Company&#8217;s cash equivalents consisted entirely of money market funds totaling $1.7&#160;million and $16.8&#160;million, respectively. Investments consisted of corporate securities, municipal debt securities, federal home loan securities and certificates of deposit. All investments are classified as current. </div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at June&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; padding: 0px;"/>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">55,677</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,831</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,537</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263337080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements: </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance establishes a fair value hierarchy that prioritizes valuation inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.&#160;Each fair value measurement is reported in one of three levels: </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/>Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,676</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,549</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,696</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 7.4pt; vertical-align: top; line-height: 5.476pt;;display:inline;">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments were measured at carrying value as of December&#160;31, 2019. See table below. </div></div></td></tr></table><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">744,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value due to the short maturities of the respective instruments. The carrying value of the Company&#8217;s line of credit approximates fair value. If the Company&#8217;s line of credit was measured at fair value, it would be categorized as Level&#160;2 in the fair value hierarchy. </div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263611880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock', window );">Accounts Receivable and Net Revenue</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable and Net Revenue: </div></div></div></td></tr></table><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,386,562</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,943,664</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,040,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,444,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">345,682</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">498,869</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient service revenue is recognized at the time services are provided by the Company&#8217;s affiliated physicians. The Company&#8217;s performance obligations related to the delivery of services to patients are satisfied at the time of service. Accordingly, there are no performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period with respect to patient service revenue. Almost all of the Company&#8217;s patient service revenue is reimbursed by government-sponsored healthcare programs (&#8220;GHC Programs&#8221;) and third-party insurance payors. Payments for services rendered to the Company&#8217;s patients are generally less than billed charges. The Company monitors its revenue and receivables from these sources and records an estimated contractual allowance to properly account for the anticipated differences between billed and reimbursed amounts. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, patient service revenue is presented net of an estimated provision for contractual adjustments and uncollectibles. The Company estimates allowances for contractual adjustments and uncollectibles on accounts receivable based upon historical experience and other factors, including days sales outstanding (&#8220;DSO&#8221;) for accounts receivable, evaluation of expected adjustments and delinquency rates, past adjustments and collection experience in relation to amounts billed, an aging of accounts receivable, current contract and reimbursement terms, changes in payor mix and other relevant information. Contractual adjustments result from the difference between the physician rates for services performed and the reimbursements by GHC Programs and third-party insurance payors for such services. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collection of patient service revenue the Company expects to receive is normally a function of providing complete and correct billing information to the GHC Programs and third-party insurance payors within the various filing deadlines and typically occurs<br/>within&#160;30&#160;to&#160;60&#160;days of billing. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the Company&#8217;s hospital agreements require hospitals to pay the Company administrative fees. Some agreements provide for fees if the hospital does not generate sufficient patient volume in order to guarantee that the Company receives a specified minimum revenue level. The Company also receives fees from hospitals for administrative services performed by its affiliated physicians providing medical director or other services at the hospital. </div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">428,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">486,368</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">919,431</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">956,799</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,138</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">129,698</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">136,008</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,925</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,442</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">509,203</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">561,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,071,054</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,104,249</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableAndNetRevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable and net revenue disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableAndNetRevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264089800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discontinued Operations: </div></div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px; background: none;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of Anesthesiology Medical Group </div></div></div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;6, 2020, the Company entered into a securities purchase agreement with an affiliate of North American Partners in Anesthesia (&#8220;NAPA&#8221;) to divest&#160;the Company&#8217;s anesthesiology medical group, and the transaction closed on May&#160;6, 2020. Pursuant to the terms and conditions of the agreement, at the closing of the transaction, the Company received a cash payment of $50.0&#160;million, subject to certain customary adjustments, as well as a contingent economic interest in NAPA with a value ranging from $0 to $250&#160;million based upon the multiple of invested capital returned to NAPA&#8217;s owners upon exit of the investment. The Company will begin to receive a payment on its economic interest at an exit multiple of 2.0, with such payment reaching $250&#160;million at an exit multiple of 5.0. In addition, the Company retained the accounts receivable of the anesthesiology medical group, which net of various other working capital items, approximated $110.0&#160;million at March&#160;31, 2020. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The operating results of the anesthesiology medical group service line were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020 and 2019. </div></div></div></div><div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-size: 10pt; line-height: 115%; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The preliminary loss on sale recorded during the three months ended June&#160;30, 2020 was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$644.2&#160;million. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">Upon completion of a valuation for the contingent economic interest and working capital true-up, final net proceeds will be determined, and the Company will adjust the loss on sale at that time. As a result of the sale, the Company currently estimates that it will generate an approximately $1.68&#160;billion capital loss carryforward which expires in 2025. Based on management&#8217;s determination that it is more likely than not that the tax benefits related to this loss carryforward will not be realized, the Company has provided an approximately $419.0&#160;million valuation allowance against this deferred tax asset in its financial results for the three months ended June&#160;30, 2020. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology medical group for the three and six months ended June&#160;30, 2020 and 2019 (in thousands): </div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,894</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">307,072</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">374,961</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">615,243</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">95,398</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">247,759</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">348,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">498,930</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,350</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,700</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,287</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,964</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">39,571</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,034</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,030</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,308</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,258</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,771</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,616</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,634</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,721</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">644,162</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">640,154</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">773,002</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">285,959</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,059,938</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">568,180</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(682,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(684,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(682,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,099</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(684,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,111</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,561</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(677,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(679,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">34,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/>  <div style="text-align: center;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Divestiture of MedData </div></div></div></div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and six</div> months ended June&#160;30, 2020, the Company recorded a net incremental loss on the sale of MedData of $3.0&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;and </div>$5.6&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">million, respectively, primarily for the finalization of certain transaction related expenses, a working capital true-up and incremental reserves related to indemnification matters, partially offset by the completion of its preliminary valuation for the contingent economic consideration. This incremental loss is reflected as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2020. The operating results of MedData were reported as a component of discontinued operations, net of income taxes, in the Company&#8217;s Consolidated Statements of Income for the three and six months ended June&#160;30, 2019. </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263588904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align: center; border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Payable and Accrued Expenses:&#160;</div></div></div></div> </td> </tr> </table> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">48,982</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">38,598</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131,739</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">223,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,130</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,466</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">44,869</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,679</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,956</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51,788</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">360,909</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">453,110</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net decrease in accrued salaries and bonuses of $92.1&#160;million, from December&#160;31, 2019 to June&#160;30, 2020, is primarily due to the payment of performance-based incentive compensation, principally to the Company&#8217;s affiliated physicians, partially offset by performance-based incentive compensation accrued during the six months ended June&#160;30, 2020. A majority of the Company&#8217;s payments for performance-based incentive compensation is paid annually during the first quarter. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263605880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Common and Common Equivalent Shares</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common and Common Equivalent Shares: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the period. Potential common shares consist of outstanding restricted stock, deferred stock and stock options and is calculated using the treasury stock method. </div></div></div></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June&#160;30, 2020 and 2019 is as follows (in thousands): </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,061</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,623</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">455</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,745</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,061</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,335</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">923</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,092</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">713</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the six months ended June&#160;30, 2020, no incremental shares are included because the effect would be antidilutive. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623262011640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans and Stock Purchase Plans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive Plans and Stock Purchase Plans: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-align: center;"> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;A&amp;R 2008 Incentive Plan&#8221;) provides for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. </div></div></div></div> </div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than the fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. The Company issues new shares of its common stock upon exercise of its stock options. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. Deferred stock awards generally vest upon the satisfaction of specified performance-based conditions and service-based conditions. The Company recognizes compensation expense related to its restricted stock and deferred stock awards ratably over the corresponding vesting periods. During the six months ended June&#160;30, 2020, the Company granted 1.1&#160;million shares of restricted stock to its employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan. At June&#160;30, 2020, the Company had 6.3&#160;million shares available for future grants and awards under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">A&amp;R</div> 2008 Incentive Plan.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Under the Company&#8217;s 1996 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Employee Stock Purchase Plan, as amended (the &#8220;ESPP&#8221;), employees are permitted to purchase the Company&#8217;s common stock at 85% of market value on January 1st, April 1st, July 1st and October 1st of each year. Under the Company&#8217;s 2015 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Qualified</div> Stock Purchase Plan (the &#8220;SPP&#8221;), certain eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers are permitted to purchase the Company&#8217;s common stock at 90% of market value on January 1st, April 1st, July 1st and October 1st of each year.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Each of the ESPP and the SPP provide for the issuance of an aggregate of 2.6&#160;million shares of the Company&#8217;s common stock less the number of shares of common stock purchased under the other plan. The Company recognizes stock-based compensation expense for the discount received by participating employees and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> service providers. During the six months ended June&#160;30, 2020, approximately 0.4&#160;million shares in <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>aggregate were issued under the ESPP and SPP. At June&#160;30, 2020, the Company had approximately 0.7&#160;million shares in <div style="letter-spacing: 0px; top: 0px;;display:inline;">the </div>aggregate reserved for issuance under the ESPP and SPP.</div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three and six months ended June&#160;30, 2020 and 2019, the Company recognized stock-based compensation expense of $6.6&#160;million and $14.3&#160;million, and $9.9&#160;million and $20.9&#160;million, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263380904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockRepurchasesTextBlock', window );">Common Stock Repurchase Programs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Stock Repurchase Programs: </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In July 2013, the Company&#8217;s Board of Directors authorized the repurchase of shares of the Company&#8217;s common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under the Company&#8217;s equity compensation programs. The share repurchase program allows the Company to make open market purchases from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">time-to-time</div></div> based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of the Company&#8217;s common stock to offset the dilutive impact from the issuance of shares, if any, related to the Company&#8217;s acquisition program. No shares were purchased under this program during the six months ended June&#160;30, 2020. </div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company announced that its Board of Directors had authorized the repurchase of up to $500.0&#160;million of the Company&#8217;s common stock in addition to its existing share repurchase program, of which $107.2&#160;million remained available for repurchase as of December&#160;31, 2019. Under this share repurchase program, during the six months ended June&#160;30, 2020, the Company withheld approximately 159,000 shares of its common stock to satisfy minimum statutory withholding obligations of $3.0&#160;million in connection with the vesting of restricted stock. </div></div> <div style="text-indent: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs. The amount and timing of repurchases will depend upon several factors, including general economic and market conditions and trading restrictions. </div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockRepurchasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of common stock repurchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockRepurchasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264411224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies: </div></div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expects that audits, inquiries and investigations from government authorities and agencies will occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. The Company has not included an accrual for these matters as of June&#160;30, 2020 in its Consolidated Financial Statements, as the variables affecting any potential eventual liability depend on the currently unknown facts and circumstances that arise out of, and are specific to, any particular future audit, inquiry and investigation and cannot be reasonably estimated at this time. </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the ordinary course of business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by the Company&#8217;s affiliated physicians. The Company&#8217;s contracts with hospitals generally require the Company to indemnify them and their affiliates for losses resulting from the negligence of the Company&#8217;s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant costs. The Company believes, based upon a review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition, results of operations, cash flows and the trading price of its securities. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability risk, the Company generally self-insures a portion of this risk through its wholly owned captive insurance subsidiary. Liabilities in excess of the Company&#8217;s insurance coverage, including coverage for professional liability and certain other claims, could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, cash flows and the trading price of its securities. </div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264076328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 14pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New Accounting Pronouncements</div></div></div><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, accounting guidance related to income taxes was issued with the goal of enhancing and simplifying various aspects of the income tax accounting guidance, including requirements related to hybrid tax regimes, deferred taxes on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">step-up</div> in tax basis of goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intraperiod tax allocation exception to the incremental approach, deferred tax liabilities on outside basis differences, and interim-period accounting for enacted changes in tax law and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss limitations. The guidance becomes effective for the Company on January&#160;1, 2021, including interim periods therein, with early adoption permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company does not believe the adoption of this new guidance will have a material impact on its Consolidated Financial Statements and related disclosures. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623261933544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held at June&#160;30, 2020 and December&#160;31, 2019 are summarized as follows (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; padding: 0px;"/>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="width: 10%; vertical-align: bottom; padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/>
<td style="padding: 0px;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">55,677</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">32,962</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Municipal debt securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">20,831</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">29,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal home loan securities</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,537</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">8,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of deposit</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">4,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263459768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are accounted for at fair value on a recurring basis at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value<br/>Category</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,676</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,775</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term investments</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">90,642</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">74,510</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mutual Funds</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,549</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">14,264</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent consideration</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">Level&#160;3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,696</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock', window );">Financial Instruments Measured At Carrying Amount</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial instruments that are not carried at fair value at June&#160;30, 2020 and December&#160;31, 2019 (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/>Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">744,375</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">750,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">766,875</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2027 Notes</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,025,600</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263299528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable, net consists of the following (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross accounts receivable</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,386,562</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,943,664</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for contractual adjustments and uncollectibles</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,040,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1,444,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">345,682</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">498,869</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenue</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company&#8217;s net revenue by category (in thousands): </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net patient service revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">428,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">486,368</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">919,431</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">956,799</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hospital contract administrative fees</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65,138</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">69,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">129,698</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">136,008</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other revenue</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">15,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,925</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">11,442</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">509,203</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">561,237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,071,054</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,104,249</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Net Revenue</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The approximate percentage of net patient service revenue by type of payor was as follows: </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six&#160;Months&#160;Ended</div></div><br/><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contracted managed care</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">67</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">26</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other third-parties</div></div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Private-pay</div> patients</div></td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">100</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="font-family: 'Times New Roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623261863080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the results of discontinued operations related to the anesthesiology medical group for the three and six months ended June&#160;30, 2020 and 2019 (in thousands): </div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;width:;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';;width:;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">90,894</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">307,072</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">374,961</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">615,243</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service salaries and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">95,398</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">247,759</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">348,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">498,930</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of service supplies and other operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,350</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,216</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,700</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,287</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">19,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">30,964</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">39,571</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">2,034</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,030</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">6,308</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">12,258</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Transformational and restructuring related expenses</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">16,771</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,616</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">28,634</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,721</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%; font-size: 10pt;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Loss on sale, net</div></div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">644,162</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">640,154</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">773,002</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">285,959</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,059,938</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">568,180</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income from operations</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(682,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(684,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-operating</div> (expense) income, net</div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Loss) income before income taxes</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(682,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">21,099</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(684,926</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">47,066</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit (provision)</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,111</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(5,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">5,561</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(12,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 63%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(677,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">15,469</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">(679,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">34,576</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 63%;"/>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263263656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses consist of the following (in thousands): </div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">48,982</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">38,598</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued salaries and bonuses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">131,739</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">223,815</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll taxes and benefits</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">43,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">61,130</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional liabilities</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">57,466</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">44,869</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,679</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">32,910</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">46,956</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">51,788</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">360,909</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">453,110</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263566680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share</a></td>
<td class="text">The calculation of shares used in the basic and diluted net income per common share calculation for the three and six months ended June&#160;30, 2020 and 2019 is as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); white-space: nowrap;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Six Months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common shares outstanding</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,061</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">84,623</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of dilutive common share equivalents</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">255</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">455</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">464</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of common and common equivalent<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>shares outstanding (a)</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,745</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,689</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">83,061</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">85,087</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antidilutive securities not included in the diluted net income per<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>common share calculation</div></div> </td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,335</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">923</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">1,092</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">713</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: 'Times New Roman';"/>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: bottom; font-family: 'Times New Roman';">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="font-family: 'Times New Roman';">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="clear: both; max-height: 0px;"/> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to a loss from continuing operations for the six months ended June&#160;30, 2020, no incremental shares are included because the effect would be antidilutive. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623267210408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember', window );">Unnamed Corporate Joint Venture One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember', window );">Unnamed Corporate Joint Venture Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method ownership percentage in joint venture</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=md_UnnamedCorporateJointVentureTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623336888024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Mar. 25, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 899.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member', window );">Senior Unsecurd Notes 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member', window );">Senior Unsecurd Notes 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt Instrument Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letters of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Estimated EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member', window );">Forecast For Second And Third Quarters Of 2020 [Member] | Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.50:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member', window );">Forecast For Fourth Quarter Of 2020 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.75:1:00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member', window );">Forecast For First Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_SupplementaryLeverageRatioRequired', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member', window );">Forecast For Second Quarter Of 2021 [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit Facility Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue', window );">Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes', window );">Deferred Payment Of Social Security Taxes | %</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Rural Area [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ContributionsInAidOfReimbursementOfLostRevenue', window );">Reimbursement of Lost Revenue</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember', window );">COVID-19 [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageIncreaseDecreaseInSalaryAndWage', window );">Decrease In Salary | %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ContributionsInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contributions In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ContributionsInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Earnings Before Interest Taxes Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageIncreaseDecreaseInSalaryAndWage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Increase Decrease In Salary And Wage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageIncreaseDecreaseInSalaryAndWage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfDeferredPaymentOfSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Deferred Payment Of Social Security Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfDeferredPaymentOfSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_SupplementaryLeverageRatioRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementary Leverage Ratio Required.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_SupplementaryLeverageRatioRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_Seniorunsecurdnotes2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondAndThirdQuartersOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=md_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=md_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFourthQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForFirstQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=md_ForecastForSecondQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_ExtraordinaryItemsAxis=md_CovidNinenteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_ExtraordinaryItemsAxis=md_CovidNinenteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=md_RuralAreaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=md_RuralAreaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623261984136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CashEquivalentsAndInvestmentsLineItems', window );"><strong>Cash Equivalents And Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CashEquivalentsAndInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CashEquivalentsAndInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623340099992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 90,642<span></span>
</td>
<td class="nump">$ 74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember', window );">Corporate Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">55,677<span></span>
</td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">20,831<span></span>
</td>
<td class="nump">29,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Federal Home Loan Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">8,537<span></span>
</td>
<td class="nump">8,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 5,597<span></span>
</td>
<td class="nump">$ 4,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AllOtherCorporateBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264741512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of fair value on a recurring basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 16,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MutualFundsFairValueDisclosure', window );">Mutual Funds</a></td>
<td class="nump">13,549<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">90,642<span></span>
</td>
<td class="nump">74,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value Of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MoneyMarketFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of money market funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MoneyMarketFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MutualFundsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mutual funds fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MutualFundsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623337118680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember', window );">2023 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">744,375<span></span>
</td>
<td class="nump">766,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember', window );">2027 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable Fair Value Disclosure</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,025,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=md_TwoThousandTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623267274520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Gross accounts receivable</a></td>
<td class="nump">$ 1,386,562<span></span>
</td>
<td class="nump">$ 1,943,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for contractual adjustments and uncollectibles</a></td>
<td class="num">(1,040,880)<span></span>
</td>
<td class="num">(1,444,795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 345,682<span></span>
</td>
<td class="nump">$ 498,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623268149800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 509,203<span></span>
</td>
<td class="nump">$ 561,237<span></span>
</td>
<td class="nump">$ 1,071,054<span></span>
</td>
<td class="nump">$ 1,104,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Net patient service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">428,473<span></span>
</td>
<td class="nump">486,368<span></span>
</td>
<td class="nump">919,431<span></span>
</td>
<td class="nump">956,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember', window );">Hospital contract administrative fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">65,138<span></span>
</td>
<td class="nump">69,619<span></span>
</td>
<td class="nump">129,698<span></span>
</td>
<td class="nump">136,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Disaggregation of Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 15,592<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
<td class="nump">$ 21,925<span></span>
</td>
<td class="nump">$ 11,442<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=md_HospitalsContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=md_HospitalsContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264256424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember', window );">Contracted Managed Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember', window );">Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Other Third-Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Private-Pay Patients [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems', window );"><strong>Health Care Organization, Receivable and Revenue Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor', window );">Percentage of net patient service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_PercentageOfNetPatientServiceRevenueByTypeOfPayor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net patient service revenue by type payor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_PercentageOfNetPatientServiceRevenueByTypeOfPayor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=md_ContractedManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_GovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623336314264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations -  Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 06, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net incremental loss on the sale of MedData</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (680,036)<span></span>
</td>
<td class="num">$ (28,292)<span></span>
</td>
<td class="num">$ (684,999)<span></span>
</td>
<td class="num">$ (293,710)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Preliminary and incremental gain loss on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase decrease in valuation allowance deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccountsReceivableRetained', window );">Accounts receivable retained</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Tax Year Two Thousand and Twenty Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CapitalLossCarryForward', window );">Capital loss carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember', window );">North American Partners In Anesthesia [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_MaximumConsiderationReceivable', window );">Maximum consideration receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember', window );">Divestiture of MedData [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net incremental loss on the sale of MedData</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccountsReceivableRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable retained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccountsReceivableRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CapitalLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CapitalLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_MaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_MaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_NorthAmericanPartnersInAnesthesiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=md_TaxYearTwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=md_DivestitureOfMeddataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623336684200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net (loss) income</a></td>
<td class="num">$ (680,036)<span></span>
</td>
<td class="num">$ (28,292)<span></span>
</td>
<td class="num">$ (684,999)<span></span>
</td>
<td class="num">$ (293,710)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-sale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net revenue</a></td>
<td class="nump">90,894<span></span>
</td>
<td class="nump">307,072<span></span>
</td>
<td class="nump">374,961<span></span>
</td>
<td class="nump">615,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits', window );">Cost of service salaries and benefits</a></td>
<td class="nump">95,398<span></span>
</td>
<td class="nump">247,759<span></span>
</td>
<td class="nump">348,662<span></span>
</td>
<td class="nump">498,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses', window );">Cost of service supplies and other operating expenses</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">5,216<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">13,287<span></span>
</td>
<td class="nump">19,321<span></span>
</td>
<td class="nump">30,964<span></span>
</td>
<td class="nump">39,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">12,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses', window );">Transformational and restructuring related expenses</a></td>
<td class="nump">16,771<span></span>
</td>
<td class="nump">9,616<span></span>
</td>
<td class="nump">28,634<span></span>
</td>
<td class="nump">10,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale', window );">Loss on sale, net</a></td>
<td class="nump">644,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">640,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">773,002<span></span>
</td>
<td class="nump">285,959<span></span>
</td>
<td class="nump">1,059,938<span></span>
</td>
<td class="nump">568,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(682,108)<span></span>
</td>
<td class="nump">21,113<span></span>
</td>
<td class="num">(684,977)<span></span>
</td>
<td class="nump">47,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense', window );">Non-operating (expense) income, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">(Loss) income before income taxes</a></td>
<td class="num">(682,115)<span></span>
</td>
<td class="nump">21,099<span></span>
</td>
<td class="num">(684,926)<span></span>
</td>
<td class="nump">47,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax benefit (provision)</a></td>
<td class="nump">5,111<span></span>
</td>
<td class="num">(5,630)<span></span>
</td>
<td class="nump">5,561<span></span>
</td>
<td class="num">(12,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net (loss) income</a></td>
<td class="num">$ (677,004)<span></span>
</td>
<td class="nump">$ 15,469<span></span>
</td>
<td class="num">$ (679,365)<span></span>
</td>
<td class="nump">$ 34,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents disposal group, including discontinued operation, operating expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation other income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation transformational and restructuring expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264254728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 48,982<span></span>
</td>
<td class="nump">$ 38,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and bonuses</a></td>
<td class="nump">131,739<span></span>
</td>
<td class="nump">223,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_AccruedPayrollTaxesAndBenefitsCurrent', window );">Accrued payroll taxes and benefits</a></td>
<td class="nump">43,087<span></span>
</td>
<td class="nump">61,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent', window );">Accrued professional liabilities</a></td>
<td class="nump">57,466<span></span>
</td>
<td class="nump">44,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">32,679<span></span>
</td>
<td class="nump">32,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">46,956<span></span>
</td>
<td class="nump">51,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses, total</a></td>
<td class="nump">$ 360,909<span></span>
</td>
<td class="nump">$ 453,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_AccruedPayrollTaxesAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll taxes and benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_AccruedPayrollTaxesAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623263486856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses', window );">Net decrease in accrued salaries and bonuses</a></td>
<td class="nump">$ 92.1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_IncreaseDecreaseInAccruedSalariesAndBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued salaries and bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_IncreaseDecreaseInAccruedSalariesAndBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623264216424">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,490<span></span>
</td>
<td class="nump">83,234<span></span>
</td>
<td class="nump">83,061<span></span>
</td>
<td class="nump">84,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average number of dilutive common share equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">255<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common and common equivalent shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">83,745<span></span>
</td>
<td class="nump">83,689<span></span>
</td>
<td class="nump">83,061<span></span>
</td>
<td class="nump">85,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the diluted net income per common share calculation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Due to a loss from continuing operations for the six months ended June 30, 2020, no incremental shares are included because the effect would be antidilutive.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623337130616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Vesting period of options, maximum years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of market value of common stock at which employees are permitted to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants and awards under Stock Incentive Plans</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember', window );">Amended and Restated 2008 Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember', window );">1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, aggregate shares authorized</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Aggregate number Shares issued under Stock Purchase Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for issuance</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_AmendedAndRestatedTwoThousandEightPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139623337142280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Repurchase Programs - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Company's Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_md_CommonStockLineItems', window );"><strong>Common Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Amount withheld to satisfy minimum statutory tax withholding obligations</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_md_CommonStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">md_CommonStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>md_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (   X_E '04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "   ./Y0.^KF;.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.FUA0-3E N($$A*30-RBQ-LBFC9*C-J]/6G8.B%X (ZQ_WS^
M++G57N@AX',8/ :R&"\FU_51:+]F>R(O *+>HU.Q3(D^-;=#<(K2,^S *_VA
M=@@UYRMP2,HH4C #"[\0F6R-%CJ@HB$<\48O>/\9N@PS&K!#ASU%J,H*F)PG
M^L/4M7 &S##"X.)W <U"S-4_L;D#[)B<HEU2XSB68Y-S:8<*WIX>7_*ZA>TC
MJ5YC^A6MH(/'-3M-?FWN[C</3-:\Y@6_+AJ^X2MQ=2LN;]YGUQ]^9V$W&+NU
M_]CX)"A;^'47\@M02P,$%     @  #C^4)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7'<NF/GWP*]X67:>C(X?6Z>+W3V[@=/C%^^_]Y,WD[ECBE_)\E]1Z/7%@BY
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MJ_YPS9D1WAF8ZRLI]<M)]U5J]Q7R\G]02P,$%     @  #C^4,Q6D\ZU @
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MW/:5"$JP9&J^CP:0^1U@O]I5JII?N.*Y7FS.H?<YM8#AXL2VRVL,!S;=SO>
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M]5>(2O9_@Z?!-HE707&4G:C'QJ"@YLWP/_\V!F+6 /JQ-\!C [QL0!T-R-B
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M?;P=/O?0W0Q?G_R2MS N$A"WA2[##PE$M!T^Z!A..G'HOXEX$%TGZOYPSW*
MN3* W[<"%E7CB;K!]%G-U7\!4$L#!!0    (   X_E!J1T+2[04  &D/   8
M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULS5?;;ALW$/T50D4+%+!U\R4W
MVX#M-'!:.''MM'TH^D M1UHF7')#<BVK7]\SY&J]:F4%"-"B+])RES-S9N;,
M#'FR=/Y3*(FB>*B,#:>#,L;ZY6@4BI(J&8:N)HLO<^<K&;'TBU&H/4F5A"HS
MFH['QZ-*:CLX.TGO;OS9B6NBT99NO A-54F_NB#CEJ>#R6#]XE8ORL@O1F<G
MM5S0'<5?ZAN/U:C3HG1%-FAGA:?YZ>!\\O+BD/>G#;]J6H;>LV!/9LY]XL5;
M=3H8,R R5$36(/%W3Y=D#"L"C,^MSD%GD@7[SVOM;Y+O\&4F UTZ\YM6L3P=
M/!\(17/9F'CKEE?4^G/$^@IG0OH5R[SWZ'@@BB9$5[7"0%!IF__E0QN'GL#S
M\1,"TU9@FG!G0PGE:QGEV8EW2^%Y-[3Q0W(U20.<MIR4N^CQ54,NGEW(H(-P
M<W'C*9"-,L?**O$.$3TO"M?8J.T"WYW%<T'(2 PGHPCCK&)4M(8NLJ'I$X:.
MQ;6SL0SB!ZM(;<J/ +I#/ETCOYCN5/AC8X?B8+PGIN/I>(>^@RX2!TG?P1/Z
M^KXZHPM-0?Q^/@O1@SE_[#!PV!DX3 8.__U0[S8T&8JOM/52?"@)E5*XJI9V
MQ1L:*QNE(REQZ6Q 8)3DQ1MMI2VT-.(.RK,TVXN0O\S2R1ROK8N()9X\12?J
MC @ZM,5+P.3R$I/Q_L_)^EH:'Z2HI8\K 2DI/CIMH[B':..)99>E+DJAHW!+
MRWL/G@V/OA54P*%*%]@183#$!$.*P!_4E[4<OAB.MV@9;F"3.8!!H"NR8X$V
M%0>$35'Z).ASH^%#1;%TBD,D'Z,_HT(V$.Y'C1[(%SI 1] +J^>ZD%"L[=PT
MA#P)=T]^3\R:*)3#)@17 &STSNRU4(!!1] W8R[Z:0,TM*N4*?1UGVC1>9&=
MU97 %^U4Z*5*^I1&8:F@$*37!@FR"MBXJ:X3O]:.?,T XX'U,&;566!H4#77
MH0!U5B3]4+P%,14H!BC)@Z_GWW;"A=(U1C$BGEJ<<X3D(SB?:F*I8]G&_^O4
M:UN81JWIW.7QNV^>3R?/7@51.7#0(V[(XKFU#73>4NT\&&<[ZO^4?EAF.GGU
M?8K)^R*Z&3@T'4]>[&TP1"'D(1400%728G@R0%#<WVOD1V!&2ZO_E#FDF>$Y
MW9S*(*Y)\;#82X5E,)<WU./EW&'T,#ZV4#ADK"Y7 3U1VD<KLR:@\8269BV=
MD+$>QUI#B3X^.9T!*.3?<0DT6/>(^$0(-U*SV6_>6G"%.G[%TA.E1 7]@-"G
MB4,\<03F!;7S8O)B*.ZP[QT2*8Y%LC-Y)<Y#(&B](I,)>R=-UO6Z#_?]9MVL
MJ8NTHD;300&KE,%KN4K#:4?V) +(1:N=<0MN$EQ21BR\:^H=<=T6I%VJ_F\)
MF([3EIR)6RJ,#"%UNHRBE.@I,R(+=BMB0A;D(TZ8Z$@:AG)_0A=9%VG8+-*Y
M<Y&+-+EI7$@=&5IPX./38.YU\!"/\.")6/PG%$DQ^2='I,U#6;5M&>)Y@O/X
M0! <=V'V*),I4<E+U::^J]!-#BS+%%#_B=+$R)A"HH:LH1.Q1129 LZGX94"
MECH!HUB7.]-'XN";FC\0UGB2T>LBQ][AQ$1YV6]#0W'EEI1&5VJ< E.-6[)%
M!PI(D.31%DL9\Y%@[>)2&],2GX%)@=.8#;+(*C]LH>H7PP#M725P\\_S@#/'
M1?:WJ8CNN&T:AFY.M8.\\)I')S*4I#)+RC5+ K-D*?.PQD& %2"3&P4QW'TR
M8[*\QA"I'D="S_RB06UR!#V9E)0\E[@PHWQ "-BX1IQ;GQ/\A4-, (-LR64$
M-;ELJ]KH>9J]]QCTKN&,URB;KO,\:MZ&8:^=B+EEX?#C6P]ZV,K5S&N5-'A:
MX)(7]O@J1=Z3:A$CE"!2O8^,\3%A/[I];C_;SN&CWO6G(K](ESR>6T"6;T+=
MV^X>>9ZO3X_;\R7T6OJ%1NX-S2$Z'CX[&@B?+W9Y$5V=+E,S%W$U2X\E3A7D
M>0.^<^M9+]A =[L^^PM02P,$%     @  #C^4(O,\?C4!   O H  !@   !X
M;"]W;W)K<VAE971S+W-H965T."YX;6RM5DUOW#80_2N$FA8-L-[5RG9B)[:!
MM>.@+A#$L-/T4/3 E482$8I426K7VU_?-]1'UHCM4P_V4A3GS9N9-R.>;:W[
MYFNB(!X:;?QY4H?0OELL?%Y3(_W<MF3PIK2ND0&/KEKXUI$LHE&C%UF:OEDT
M4IGDXBSNW;J+,]L%K0S=.N&[II%N=TG:;L^393)NW*FJ#KRQN#AK947W%/YH
M;QV>%A-*H1HR7EDC')7GR6KY[O*(S\<#7Q5M_=Y:<"1K:[_QPTUQGJ1,B#3E
M@1$D?C9T15HS$&C\,V FDTLVW%^/Z!]C[(AE+3U=6?VG*D)]GIPDHJ!2=CK<
MV>UO-,1SS'BYU3[^%]O^[.%1(O+.!]L,QF#0*-/_RH<A#WL&)^DS!ME@D$7>
MO:/(\H,,\N+,V:UP?!IHO(BA1FN04X:+<A\<WBK8A8LKZZR1&^4Z+VZE*:A1
MN?@UN?K\]>;#P?(T>7VV"'##AQ?Y 'G90V;/0+X1GZP)M1?7@"L>VR] ;^*8
MC1POLQ<!?^_,7!RF,Y&E6?H"WN$4\V'$.WP&[_HA.&E=H0QD*&X"-5[\M5I[
M[.;A[Q<<'$T.CJ*#H_\SJ2]#9G/Q-.HO/YUD6?I^Q(Z/R_>OWXEQ!ZHI#CY)
ME]?"6'/0N8I,V%^.!^=[)R?C+S7!<=-*LQ.J:36A(0,50@K3-6MRPI:QLZSQ
M(EB!P>#);4B42*[)E=2BU/2@UDJKL!-@+5KI O;U#NZ"JF0@$>#$J\JH4N42
MC/"G<M5*=@2GP&<WWWE^7W$8.7(%._V(J]3>B@(-[R-(\ #%NB9,$VTK.*<B
M&E7.=JU01GR2NRBPF=C6Y$A@[CD9E*DP>SQZW(LM;^_QU+N!'3RL=WNL;GA>
M^18Y(4X*A_=R2&(5!%1.D\IGT6@,II8%(A68J3X@A<RI=<HPGL9,TL@T^)H8
MYI5#8$&L*D>Q5O-':6&D?1A-(9#SS"7O#;%ZE<XS%$=K'IO;6D$/>-?EH!Y#
M:6S'1=I(I>5:/^N90W]U<GHZ/YG Y ]ARA+^1:4VS(;*$L-Z3!GZLK6.6S1Z
MCT,<[/A5+I%!%A2>GW1=D,^=6K-0UW;#"D.9JUK<4PM8UNU 80DUK>ZN[\4*
MCC^S"EC^V=N1WRT*J0J&_.*ZIHWE'_*PWX\K5<S$'6E%Y2RJ_#JWQG*#WE/>
M.:;*#J9N'5V.[0H!(FHMMT.Y)DH*PD7\#(S.R;_A0\EGB4<K)TIZKWS %X$U
M[UNDSX])6C7D6*>"(I?=#(:Y[@;YV(V**XB?Z[1,4[$>JH1FD*H8RU"3U*'.
MI6/'!;Y(* A>.5+-NG/^T8$>E@6%ZX+0%LP<;<AT%)-"#[A+>$)((: Z78CR
M =B/K3WC)I(%J@I&0S=,28G-/?CJ7>$[3 XB0(YV40!##B A;7<H-Y0T"LC;
M.)?\6)@@'X R*B1:@2L.#M- A5H<IS^/D).KH0\*!/>!\D%5RUY5,5P^[8AO
M1IQHAGCJ;/:X0_OBQF':!4S-?UF\4$'O%KQM&P,9^**9(\_'((C,41Q0G'+6
M1*C1>S&+X\B9,OW4!V^Q=Z. C*IX;_(BYXC[R\6T.UW-5OV-Y/OQ_EZ'CJH4
MO@Z:2IBF\[?'B7#]7:E_"+:-]Y.U#;CMQ"4D!17Q ;POK0WC SN8+JP7_P%0
M2P,$%     @  #C^4%'M=*8F P  )@<  !@   !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6RM5=UOXS8,?\]?07C%L %&_)7/+@F0IG>X&U"@N&+;P[ 'Q:9C
MH;+DD^3FLK]^E)QX+M9F>]B++8KDCS]2(K4Z*OUL*D0+WVHAS3JHK&UNH\CD
M%=;,C%6#DC2ETC6S).I#9!J-K/!.M8C2.)Y%->,RV*S\WJ/>K%1K!9?XJ,&T
M=<WTZ0Z%.JZ#)+AL?.&'RKJ-:+-JV &?T/[2/&J2HAZEX#5*PY4$C>4ZV":W
M=Q-G[PU^Y7@T@S6X3/9*/3OA<[$.8D<(!>;6(3#ZO> .A7! 1./K&3/H0SK'
MX?J"_M'G3KGLF<&=$K_QPE;K8!% @25KA?VBCI_PG,_4X>5*&/^%8V<[I8AY
M:ZRJS\XDUUQV?_;M7(>!PR)^QR$].Z2>=Q?(L[QGEFU66AU!.VM"<PN?JO<F
M<ERZ0WFRFK2<_.QFQTP%'[ZV_(4)E-8 DP5\EB]H;.WD560IBK.-\C/B78>8
MOH,X@P<E;67@@RRP>.T?$;N>8GJA>)=>!?RYE6/(XA#2.(VOX&5]RIG'R][!
M&V07PCWNK<_9U<">X GS5G/+T<#OV[VQFJ[-'U>"3OJ@$Q]T\C_6^3IB-H9_
M [V%K0%5 E40^PIZHWO,L=ZCABQQN\DR!%LA[%3=,'GZ_KM%FLQ_,I"[ #@(
MD"MJ1V.Q !*Y1G%R^+62>*);J9]IBI2M+ Q891DQ/L!-,I[3Q17"]R"%ODEF
MX\5E)Z3&-@WZUA2G\9#\(!:%R)5NE&86P?0G%$+=2I[SA@EJ1#K'H:K$ C4I
M*E4C",7D0.MYY*@M+WE.F+Y(!3;*<#N&K1# !SR81L@%,X:LB0PC9JW6I'I-
MMT)!2OM?BNTANS'(_^P@2R5H/AKX@4LZ"=4:<C0_WHY>H_T#:;1[HRYP ]-I
M.)O/:9&EX7*6CA[>*Q2AA(LL@709QK/9Z..UJBW":3:G;YQDH]W;U8-I.%W.
M81).9LO1#2SC<#9)B<9\$DZ3-YLW&LRN&O7!3VAW^*VTW1CK=_M'8-O-OK_-
MNQ?D@>D#EP8$EN0:C^?3 '0WE3O!JL9/PKVR-%?]LJ*'#+4S('VIE+T(+D#_
M-&[^ E!+ P04    "   ./Y0Y"AQX9T%  #G#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6R]5UMOVS84?O>O(+QA: '5EN5;XB8&DK3%.C1#T6S=
MP[ '6CJVN$JB0E)QW%^_[U"R+"^7;GO80V*)/.<[W[F2.MMJ\\6F1$[<YUEA
MS_NI<^5B.+1Q2KFT UU2@9VU-KET>#6;H2T-R<0KY=DP"L/9,)>JZ"_/_-I'
MLSS3E<M401^-L%6>2[.[I$QOS_NC_G[AD]JDCA>&R[-2;NB&W*_E1X.W88N2
MJ)P*JW0A#*W/^Q>CQ>6$Y;W 9T5;VWD6[,E*ZR_\\CXY[X=,B#**'2-(_-S1
M%649 X'&;8/9;TVR8O=YC_[.^PY?5M+2E<Y^4XE+S_LG?9'06E:9^Z2W/U+C
MSY3Q8IU9_U]L:]GQI"_BRCJ=-\I@D*NB_I7W31PZ"B?A$PI1HQ!YWK4AS_*-
M=')Y9O16&)8&&C]X5[TVR*F"DW+C#'85]-SRG51&?)991>*:I*T,(>+.G@T=
MP%ED&#= ES50] 303%SKPJ56O"T22H[UAR#5,HOVS"ZC9P%_JHJ!&(>!B,(H
M? 9OW'HZ]GCC;WOZ1MDXT^RL%;]?K*PS*(X_GK$Q:6U,O(W)O[+Q6#"?Q>%.
M7-A2QG3>1ZM9,G?47TX&XHEL+<0O*:' 8UT53A4;L:E4(HN8!%DG5YE"?5@A
MQ9K5[[QZJLA($Z<[X5+I1&F4-LJIKY!C >E;1A5EY2Q^G(:8(1(9W5%F?1\D
M A(.=NG>@82 S#95<;K7JEA$%2+W1)E5Q[PT)/2*'0,]8C%&PECX0FX@WDK
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M2Z"9?T,5[L<F?Y2LSMW]9.E#C^Q>]3![N9/X<M_?!0W/<CBT,9B)'H^E7TJ
M=O1.0<.D>HLF<?+)*,RP/+;2<#7B@?FY&L,TF2ZBV?F4KS#*3K,%KI;),II-
M$[Z:9YA EZ-/.W[L6]I3NE$VCY+I@K)EE,&#),7_Y8*2:1;%\6+T:]_2.LO)
M/)HO4YI'Z1Q^8GA.YY3PR)MBV)W'RRB-V:EYED3I]#S,U_$Y_N:S<)W$LRB=
M+4>,@&B XD,X\QCV'('BW9H+3+\0.H^]VT9V'8A;[[T PJ['T_V1".P:-O->
M:/B&9L1S4G9./U*6#1]S^G'T<1CS*,V&WSYY^W:D.-UTSG^C&XN#Q\O7W!$2
M_*24CI(XAL8GGZ?>]R8';]*UQ'3&WQ<X"N=:]U(]K Y?25QW;^)[\>[[C%\P
MW*%-HIK7V!J?G<_'9+OO"+H;;YKP7KXR'F_YX1(C+'H("^#YVAB_NV$#PQ<U
M5[\#4$L#!!0    (   X_E" NSJ]^@<  /03   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;-5877/;N!5]UZ_ J)Z.,L.5^"W)L3UC.]MM.IO$L\FV
M#YT^0"0D84,2+$!:]O[Z/1<@*<JQW6W[M"\2">!^XMQS 5X<E/YJ]D(T[*$L
M*G,YW3=-?;Y8F&PO2F[FJA859K9*E[S!J]XM3*T%SZU062Q"WT\7)9?5].K"
MCMWIJPO5-H6LQ)UFIBU+KA]O1*$.E]-@V@_\)'?[A@865Q<UWXG/HOFYOM-X
M6PQ:<EF*RDA5,2VVE]/KX/PFIO5VP=^E.)C1,Z-(-DI]I9?W^>74)X=$(;*&
M-'#\W8M;412D"&[\N],Y'4R2X/BYU_X7&SMBV7 C;E7Q#YDW^\OI:LIRL>5M
MT?RD#G\573P)Z<M48>PO.[BU23)E66L:57;"\*"4E?OG#UT>1@(K_P6!L!,(
MK=_.D/7R'6_XU856!Z9I-;31@PW52L,Y6=&F?&XT9B7DFJMWTF2J:F35BIQ]
MJH7FE"QSL6B@G)8LLD[1C5,4OJ H91^@9V_8]U4N\E/Y!9P:/ M[SV["5Q7^
MK:WF+/(]%OJA_XJ^:(@TLOJB_RY2QJN<8:Y6AA?L!ZW:VK!_7F],HX&8?[UB
M.!X,Q]9P_/^G^%5%5)_GIN:9N)RB (W0]V)ZE<[9"P;.,7$O3".;5@NFMNRZ
MPMM>H)X*M7MD'T0NLSYF]JEB'_@C2UV^/8:%[%:5-:\>F:@:H:%;5HUBG!F1
MM5HV4AA6MSK;HR@8WVDA4*P-\-OLD53&MUM92-Y8TQ^5QNAU*31,5NR.ZZ82
MVD#CT2O.9G_^TRH,_;<?K^^N[6/P]@V#R=S&,7:)9H/E6]J]DYC*+J8=Q>39
MO24I[&5EN..!K% &L:B3>.?LKM6FY? ?]JR(T*4#!W*;2X<51$)S0["PX-PB
MI;+:]0M&]DXSJ44F$$R.+&;<[%G-'VW2('>6^',?)5X45LJTFU_ 7.1.)G0#
M>NWH -3)>/X+GDG2P 7##F U^N?, 6%'.@6>52DSVC9L'Q(('93:;HO8/2]:
MP>#JCES?:E6R,Y\,GH7)X(GEO)RU-1XIDA)T)^O"[JJL:%\PF_%:-DB[%L!:
MA0$HZ3?1;I,ZV.VV6L2#;/I$.0T4R)Q]&>7I .-L(^ 8J>JR!I>'?%5,-N:9
M$+$?O#,Q]C2< ](V;--FQ[2CC65["OXDXA=T)'/ Y#VF<P>'ISM+>R0<WGB6
MJ1:;TWG.-TZ#G7H5L(>]A'N5L FZYUJJ%LG#>FV[&[G:YUHVHJ3=KVNM'B3Z
M$VR?!<$(1!3(!XX"95'0PYR2K!Q%0!=2A@#-[_&-$=_(3#!B)0 .E*)%C;(F
M,#ODE=C=#LSYF)+40$E>'YJLL!QUPA\$!F7U;&W?0D(5,K>A?6[P9Q%/\N^=
M/ XEKM[V*$A;K$8^L-(U(D&-B*&-B*&-V"6A'ZQ=(L"BA413I9)" 1N"%;H
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MTO3:_IU>A.?I8!X>^<_<% +O%@E;=$T&5Q^C,)J=X'3M'ZN-=OCT^66)OS7
MD 'N;[5VG4 ']+]>YM\ 4$L#!!0    (   X_E"0":,9#P0  '()   9
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M\86;8KJ;<]W&JHV?+2ME:5+Y94V_!JB= -U7BL+9;YR!_F=C_C=02P,$%
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MXD7KQ25^V7#M-N#Z7"F['S@#P[?2]!M02P,$%     @  #C^4%6=M1HP!
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M463YP!Q;SHT^@ G:A!:$&&JT)G)<A:*LG:%33G9N>:^E#,E1-73BXW?/7YA
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M;S0^P-UOM*8GQR^4[G.P^ E02P,$%     @  #C^4-4E 3*-!   8A(  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULO5C;;N,V$/T50M@%LD#7DNA[
MX!APK 1-L>FF<;)]*/I 2V.;6$ET22I.@/WX#F5%<A")5MJT#XFIRQR=.1P=
M#C79"?E=;0 T>4SB5)TY&ZVWIZZKP@TD3'7$%E*\LA(R81H/Y=I56PDLRH.2
MV*6>-W 3QE-G.LG/W<CI1&0ZYBG<2**R)&'RZ1QBL3MS?.?YQ"U?;[0YX4XG
M6[:&!>C[[8W$([=$B7@"J>(B)1)69\[,/PWHR 3D=WSCL%,'8V)260KQW1Q<
M16>.9QA!#*$V$ Q_'F .<6R0D,=?!:A3/M,$'HZ?T2_SY#&9)5,P%_'O/-*;
M,V?DD A6+(OUK=C]#$5"?8,7BECE_\FNN-=S2)@I+9(B&!DD/-W_LL="B(,
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M#)!JKU=K&%GY"5U)8^?=+TO[(H%R =:_EM+L##?T_1N7_0%02P,$%     @
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MSCLJ"U\>;98+R4IS.I@PJ<X:YC95QT'@.D#M3QF3[PM]X&@.F(/_4$L#!!0
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M>LC89:Z_ T"8 /T\XUR];LRDJ;\L)G\!4$L#!!0    (   X_E"8NA60K0(
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MC9>"'99X;8,T!;B^%D(_3\S-T'\(LK]02P,$%     @  #C^4-M-YR)G P
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M*0P7.2;PYP85LP77\!Y@E"3<#E@*7.S7L%T+;R=H&$_?4<B7^PF\??,.WE
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MRY(&'8T/H/V=UNYL^ /Z7T?V!U!+ P04    "   ./Y02;I(UM0#   0#
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RE5]N.VS@,_17!3[M =^S8
MCG-!$F!RPW:!+@:=[?:AZ(-B,XE064HE>3+[]TO)CB<7)0BF+Q.).B3%0XKF
MC/92_=!; $->2R[T.-@:LQN&H<ZW4%+]('<@\&0M54D-;M4FU#L%M'!*)0_C
M*,K"DC(13$9.]J0F(UD9S@0\*:*KLJ3JOREPN1\'G> @^,PV6V,%X62THQMX
M!O-E]Z1P%[96"E:"T$P*HF ]#AX[P^7 XAW@7P9[?;0F-I*5E#_LYF,Q#B)[
M(>"0&VN!XL\+S(!S:PBO\;.Q&;0NK>+Q^F!]Z6+'6%94PTSRKZPPVW'0#T@!
M:UIQ\UGN_X0FGJZUETNNW5^R;[!10/)*&UDVRGB#DHGZE[XV/-RC$#<*\9D"
M.O8K)(U"<JZ07E%(&X7T7@_=1J%[KX>L4<@<]S59CNDY-70R4G)/E$6C-;MP
MZ7+:2# 3MK">C<)3AGIF,I-E:1,L"M(L%S\K]D(Y"$.>MU2!)G^09ZSGHN)
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M+8[LH"P S]=2FL/&.FC_"9C\#U!+ P04    "   ./Y0$:L6@A(%  ")%@
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M."I%)2$X)\((3DD)CID3YE3H;1%LL/5' QOO)]CI;TB8I.]>A3$046@;,"]
M- \84(:@.JT14[JH%4?K/'B-638C&?3:MOV+R:FR^SOF]@\$WGN1Y)_-;=E\
M'?=$<ELV::=_,KDU(QG:AW);-GK'W(\G$#'8ZZ;;=]U0B48'VX9!/:? >XU\
M:,)0]G%G>!JYQF7WQ[:9_/,]W 8.*&014@3'%K1,5 )97 $HE1UXB%Y=H@1"
M*%#CN:AI:Y2O7=VHN9VFK=\1@G7_2BK!!ZCDZ+3_#,OBDC\P/I'4EZR".X=3
M_QY(9^CZ1\+4#DH!0I?H"8GN50 EH@(([OU^*_5K5DAPY)V_R>4YV&H).(ZI
M!$JJPF:"^*_4K4OE_V,"7+(/[IU(B93DA,U'@W>=_'+;M6.:V_CU'Q:LXR^9
M#)OY8U(@CA.=*)2W.R9E M&KMK/Z94YCA?9?P>R:4);4A,W45(\RX*-B ^AT
M)]9 "33:QO@.7N'I-X;WH%R&VZK<E$54K-([30E\G\0JN[TH1HM[TTEZ6_AB
M_,JYF#H-XS/GXCJ[%2W-9Y>T=T2L6"Q12)>PE-WN UB1W7MF+XJOTWNZ!5>*
M1^EC0 ED3PO _))SM7_1"Q2WS^-_ 5!+ P04    "   ./Y0 "[RX.H"   8
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6RU5EUOTS 4_2M6-(E-
M@B9-/[9.;:5N!3%$T=1I\(!X<)/;Q)H_BNVL*[^>:R?-NI&%/<!+XX][3LX]
M-[[N>*OTG<D!+'D07)I)D%N[.0]#D^0@J.FH#4C<62LMJ,6ISD*ST4!3#Q(\
MC*-H& K*9# =^[5K/1VKPG(FX5H34PA!]>X"N-I.@FZP7UBR++=N(9R.-S2#
M&["WFVN-L[!F29D :9B21,-Z$LRZY_.1B_<!7QELS<&8N$Q62MVYR54Z"2(G
M"#@DUC%0?-S#)7#NB%#&SXHSJ%_I@(?C/?L'GSOFLJ(&+A7_QE*;3X*S@*2P
MI@6W2[7]"%4^ \>7*&[\+]E6L5% DL)8)2HP*A!,ED_Z4/EP $">9D!< >+G
M@/X+@%X%Z+T6T*\ ?>],F8KW84XMG8ZUVA+MHI'-#;R9'HWI,^G*?F,U[C+$
MV>FE$@+MO[$JN2-+V!0ZR=%&<JU5IJDPY!V9I2ES-:*<7,GR0W,5.YZ#I8R?
M8,3MS9P<'YV0(\(D63#.<=^,0XOZW%O"I-)R46J)7] R) LE;6[(>YE"^A0?
M8EYU<O$^N8NXE?!3(3ND%[TE<11'#7HNV^%S2!#>=?#NJ $^;X?/BJR&G[5D
MTZM+U?-\O=>4ZOMGW"57%H3YT<+=K[G[GKO?SFT\-RULKC3[!2G!<N/AWG\5
M31Z4O$//ZWK,_700H=?W#6(&M9C!W\1LJ-R],>2)K$<=:5,M2\[1@9!N=-J)
MFZ4,:RG#5BE+,%:SQ*(5E>\+$"O0;9Z?UMRG_[R>9S7W6:ON+X532=2:F)QJ
M,-A5;)X#3XE5Q. !-NN=:R=,% +MI;:P2N^(I0]EI.(IDQE1*\XR?]P;CW.I
M87!H^6 4O53^4:U]U*I])E0A[?]1//KC:^T]$QL>]%(!.O-WDB&)TU2VU7JU
MOO9FOMN'C^'EG;F@.F/2$ YKA$:=4W1*E_=0.;%JXSOS2EGL\WZ8X]4-V@7@
M_EHINY^X%]1_!J:_ 5!+ P04    "   ./Y0O-J]LC@"  !\"@  #0   'AL
M+W-T>6QE<RYX;6S55EUKVS 4_2M"&:.%4=O)DM'5-FR%PF ;A>9A;T6QKVV!
M/CQ9SIS^^DF6XCAI,T(?MNS%NO=<W7.//O!5W.@-@X<*0*..,]$DN-*Z_A@$
M358!)\V5K$&82"$5)]JXJ@R:6@')&YO$63 -PT7 "14XC47+[[AN4"9;H1,\
M&R#DAB]Y@J/%>XP<W:W,(<&/%V]_ME+?O$%NG+R;3,+'RYM#_*(/7.+@1=+Y
M":17X7%>$SM&O3B)^@_,/7'@-R>-"RGV]\@"IC+A@-:$)?B6,+I2U&85A%.V
M<?#4 IED4B%M#L=(B2S2/+EPY#Q[;IZ'4R%57]M5<-^5GWX0V'I6(&5L$#C%
M#DCCFF@-2MP9IY_<@\]"R-O+36T4EHILHND<[Q+ZP119296#&LI$> NE,8/"
MRE&TK.RH91W8H-:2&R.GI)2"]!JV&=XPM!DP]F O]8]BC[LK1F<:VA,5@VD$
M>=/1.,?RC]D<]Y@V?!4OJNE:ZL^M68[H?7M7X%Y!0;O>[XI!P#'VZ#@[J6NV
M^<1H*3BXQ9]<,(W)-@]54M$G4\U>E<P H#!:@](T&R._%*F7T.GM=>J*XYJG
M_Z'FO[O/)0A0A(U%F[M_SKO\:L6S#_]*<O]7.13\HD;?J<Y=Y/S\1<ZNSU^C
M[_-G)S+P76?4VO8:VX B^X!(\'?[5&&[HFC54J:I\%Y%\QS$L_YFZ#59F:?@
M'K^9GT-!6J:70S#!._L;Y+3EU\.L>[L1?M;._FJ7%RWZ@KOW9OH;4$L#!!0
M   (   X_E"7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%
MT)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI
M&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17
MB%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)
MT:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L
M?@!02P,$%     @  #C^4,^HN%*? P  @!L   \   !X;"]W;W)K8F]O:RYX
M;6S%F<M2VS 40']%XT6'#4UL)^%1P@PDT&:FA0RA;#N*?)-HL*4@R>'Q]95L
M G(+M]T(KV)+BGQ\+=TCV4?W4MW.I;PE#T4N]#!:&;,^['0T6T%!]6>Y!F%K
M%E(5U-A3M>SHM0*:Z16 *?).TNT..@7E(CH^VO8U51W_1!I@ADMA"UW!#8=[
M_5KO3LF&:S[G.3>/PZ@ZSB$B!1>\X$^0#:-N1/1*WG^3BC])86@^8TKF^3"*
MZXH;4(:SOXIG#O*:SG558NC\BEJ0833HV@X77&E3M:CZIY9Q [9Q?58:><YS
M VI,#7Q5LEQSL73=V+OH>+=1Q6'[6P?Q4/U/&.5BP1F,)2L+$*:.HX+< 0J]
MXFL=$4$+&$8CN0%%IG0)[J;L5299?8/&DGGA4H?<5JA)5C&&Y!%:YCRS5\_(
M*<VI8$"J.&JR\U-XD D"F;0(^2OQ(%,$,OU R)F#<'_01"[(1##I0?80R%YK
MD&=W)?<@^PADOS7($=4K#W* 0 ["0IY2S2NDJ0)MFU8M"!49N; I\,2#W$,@
M]T)'4DE!-UR5VN8<D4'!&=GY=%=*\V5T>3,9[\8''ND^0KH?F-0^V&H(;FA>
M/6P7R8G8@#;NGQ[D 0)Y$!;RG')%;FA> OD!5)>J'IA^)N]BJ;P;%N^$,5FZ
MV%T! QM(>_7G 6ELT<;'1(T36#ECKIG5/A>EG=Z7:U!U$Q\/<TT<6#8O49S2
MQY<0VD+E<,\>?$S,-G%PW13%<\)Y/GR=/=:-/B;FFSBP<&9&LELG0-O,KLC(
MU,J[GMQ5C8^)&2<.KIPJA#7M%:Q+Q5946UPEEXH6/B;FG#BP=!PF-\5+@AQ5
M\V@)@G%H3"#,.7%@Z:!F;*S68DPX<9O&:6)BRHG;<0[9N7;)R7_H">:>I$WW
M-**98.Y)VG'/6]%$]SMM.J@93<Q!29L.:F)B#DH".PA/2*F/B3DH">Z@?RW6
MFR'%1)2$%A&:/!LAQ524A-[_H)@]'Q-341)81>_E^%TRL[UG/B:FHJ0E%568
MS=<PF(K25E7DC\T44U$:6$4XIC\V4TQ%Z4>IZ$W,OH^)OGP+K*+WQ+Y+R$F6
M^2^V4DQ%:6 5O8_YYTQ/,16E@56$KS\:4PBS4!K80CAF8PIA%DJ#OX7#EDF-
M:&(62@-;"-VJ-],[9J$TL(70K7H#LX=9J%=9J+/]XI/!@@O(+NPEM"UG-&=3
M1=Q/_4*JUW>[P$69YR-;=BF^2YIM/R!M/WX=_P902P,$%     @  #C^4#QA
M]1J- 0  3Q@  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W938Z"
M0!"&X:L0#F!;5?@W45>S<3OQ D1;,8(0NB>CMQ^C"_W,+&9C^EN1;D+QKAX(
MS+]\7<9#>PK5H0O9N:E/89%7,78?SH5-Y9LR#-K.GZYG=FW?E/&Z[/>N*S?'
M<N^=#H=CUS_/R)?SYYG9^M+Y_TQL=[O#QG^VF^_&G^(?@]U/VQ]#Y7W,LW79
M[WU<Y.Y</[:#NQUD<)V<9ZOM(N]76\E=ZB"%($T?9!!DZ8,*""K2!XT@:)0^
M: Q!X_1!$PB:I ^:0M T?= ,@F;I@V2(,@X)DEZP)M!:D&LA\%H0;"$06Y!L
M(3!;$&TA4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%M?7K8)]%;4
M6PGT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT-M3;"/0VU-L(]#;4
MVPCTMI>/)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z%ZAW\4Z]
M0[S4/CQZ[FN\_SNICM=K_>/VM^5]$Y\7Q0UG!_\/EK]02P,$%     @  #C^
M4)C$(26B 0  IA@  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;H,P$(1?
M!7&-@F,[37^4Y-+VVN;0%W!A"2B +=M)D[>O(3]2JQ0U2J7.!0N\.S-XI>\
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M[XGY)U!+ 0(4 Q0    (   X_E '04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @  #C^4#OJYFSO
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @  #C^4)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "   ./Y0K@3]OAX%  !H%0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @  #C^4+HDR;>V!@  D1P  !@              ("!8@T  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (   X_E#,5I/.M0(  )<(
M   8              " @4X4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "   ./Y0HVLC:JH'  #D(0  &               @($Y%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @  #C^4%39/\N9
M"0  'CL  !@              ("!&1\  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    (   X_E#7J$WH_P<  &(C   8              "
M@>@H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "   ./Y0
M:D="TNT%  !I#P  &               @($=,0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @  #C^4(O,\?C4!   O H  !@
M     ("!0#<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M   X_E!1[72F)@,  "8'   8              " @4H\  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "   ./Y0Y"AQX9T%  #G#0  &0
M            @(&F/P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    (   X_E#S0D6*(P<  +01   9              " @7I%  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @  #C^4("[.KWZ!P
M]!,  !D              ("!U$P  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "   ./Y0X,'A]Y(#   '"   &0              @($%
M50  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (   X_E#R
M![.[MP,  &0)   9              " @<Y8  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @  #C^4%GL/XG* P  R0@  !D
M     ("!O%P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (   X_E#*794=AP,  '@(   9              "
M@9EP  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @  #C^
M4,RJ91#R P  -PD  !D              ("!5W0  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "   ./Y059VU&C $  "]"   &0
M        @(& >   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   (   X_E#F3EC0P@(  /8%   9              " @>=\  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @  #C^4("1UWQC P  F@<
M !D              ("!X'\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "   ./Y0I22B;E("   :!@  &0              @(%Z@P
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (   X_E#5)0$R
MC00  &(2   9              " @0.&  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @  #C^4"2 +7(? @  [P0  !D
M ("!QXH  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "
M./Y0KB#6P/<"  !L"@  &0              @($=C0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (   X_E *V;9:Y (  &4(   9
M          " @4N0  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#
M%     @  #C^4)BZ%9"M @  10@  !D              ("!9I,  'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "   ./Y0O$_.X80"   4
M!@  &0              @(%*E@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;%!+ 0(4 Q0    (   X_E#;3><B9P,  .D+   9              " @069
M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @  #C^4/DB
M9]5R P  -Q   !D              ("!HYP  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    "   ./Y0Y@H31=\#  "_#0  &0
M    @(%,H   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M   X_E!>[I/K.@4  &,4   9              " @6*D  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @  #C^4.)<S?[U @  N @  !D
M             ("!TZD  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "   ./Y0+U:6QAX"  !&!   &0              @('_K   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (   X_E!)NDC6U ,
M ! ,   9              " @52O  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @  #C^4!&K%H(2!0  B18  !D              ("!
M7[,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "   ./Y0
M "[RX.H"   8"   &0              @(&HN   >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    (   X_E"\VKVR. (  'P*   -
M      "  <F[  !X;"]S='EL97,N>&UL4$L! A0#%     @  #C^4)>*NQS
M    $P(   L              ( !++X  %]R96QS+RYR96QS4$L! A0#%
M  @  #C^4,^HN%*? P  @!L   \              ( !%;\  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    (   X_E \8?4:C0$  $\8   :
M  "  >'"  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M   X_E"8Q"$EH@$  *88   3              "  :;$  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     P #  !PT  'G&      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>296</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Coronavirus Pandemic ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Accounts Receivable and Net Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</Role>
      <ShortName>Accounts Receivable and Net Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Common and Common Equivalent Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentShares</Role>
      <ShortName>Common and Common Equivalent Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Common Stock Repurchase Programs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchasePrograms</Role>
      <ShortName>Common Stock Repurchase Programs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CashEquivalentsAndInvestments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables</Role>
      <ShortName>Accounts Receivable and Net Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsReceivableAndNetRevenue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/DiscontinuedOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Common and Common Equivalent Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables</Role>
      <ShortName>Common and Common Equivalent Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CommonAndCommonEquivalentShares</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail</Role>
      <ShortName>Coronavirus Pandemic ("COVID-19") - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mednax.com/role/CoronavirusPandemicCovid19</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of fair value on a recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail</Role>
      <ShortName>Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - 	 Discontinued Operations -  Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations -  Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations - Schedule of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail</Role>
      <ShortName>Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d919859d10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail</Role>
      <ShortName>Common Stock Repurchase Programs - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="d919859d10q.htm">d919859d10q.htm</File>
    <File>d919859dex101.htm</File>
    <File>d919859dex311.htm</File>
    <File>d919859dex312.htm</File>
    <File>d919859dex321.htm</File>
    <File>md-20200630.xsd</File>
    <File>md-20200630_cal.xml</File>
    <File>md-20200630_def.xml</File>
    <File>md-20200630_lab.xml</File>
    <File>md-20200630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d919859d10q.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 128,
   "dts": {
    "calculationLink": {
     "local": [
      "md-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "md-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d919859d10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "md-20200630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "md-20200630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 376,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 10
   },
   "keyCustom": 30,
   "keyStandard": 266,
   "memberCustom": 22,
   "memberStandard": 24,
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.mednax.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Fair Value Measurements",
     "role": "http://www.mednax.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Accounts Receivable and Net Revenue",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenue",
     "shortName": "Accounts Receivable and Net Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Discontinued Operations",
     "role": "http://www.mednax.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Common and Common Equivalent Shares",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentShares",
     "shortName": "Common and Common Equivalent Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Stock Incentive Plans and Stock Purchase Plans",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Common Stock Repurchase Programs",
     "role": "http://www.mednax.com/role/CommonStockRepurchasePrograms",
     "shortName": "Common Stock Repurchase Programs",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CommonStockRepurchasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Commitments and Contingencies",
     "role": "http://www.mednax.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Basis of Presentation and New Accounting Pronouncements (Policies)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies",
     "shortName": "Basis of Presentation and New Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Cash Equivalents and Investments (Tables)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Accounts Receivable and Net Revenue (Tables)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables",
     "shortName": "Accounts Receivable and Net Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.mednax.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Common and Common Equivalent Shares (Tables)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables",
     "shortName": "Common and Common Equivalent Shares (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail",
     "shortName": "Basis of Presentation and New Accounting Pronouncements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_UnnamedCorporateJointVentureOneMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
     "shortName": "Coronavirus Pandemic (\"COVID-19\") - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Cash Equivalents and Investments - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_CashEquivalentsMemberusgaapCashAndCashEquivalentsAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail",
     "shortName": "Cash Equivalents and Investments - Schedule of Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of fair value on a recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "md:MoneyMarketFundsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "role": "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails",
     "shortName": "Fair Value Measurements - Schedule of financial instruments that are not carried at fair value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "md:FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020_TwoThousandTwentyThreeMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Accounts Receivable, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "md:AccountsReceivableAndNetRevenueDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020_HealthCarePatientServiceMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "role": "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail",
     "shortName": "Accounts Receivable and Net Revenue - Schedule of Net Patient Service Revenue by Type of Payor (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "md:PercentageOfNetPatientServiceRevenueByTypeOfPayor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - \t Discontinued Operations -  Additional information (Detail)",
     "role": "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
     "shortName": "Discontinued Operations -  Additional information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020_NorthAmericanPartnersInAnesthesiaMemberusgaapDisposalGroupClassificationAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Details)",
     "role": "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
     "shortName": "Discontinued Operations - Schedule of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020_DiscontinuedOperationsHeldforsaleMemberusgaapDisposalGroupClassificationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
     "shortName": "Accounts Payable and Accrued Expenses - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "md:IncreaseDecreaseInAccruedSalariesAndBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "role": "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
     "shortName": "Common and Common Equivalent Shares - Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn06_30_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail",
     "shortName": "Stock Incentive Plans and Stock Purchase Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Income",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P04_01_2020To06_30_2020",
      "decimals": "-3",
      "lang": null,
      "name": "md:PracticeSalariesAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Common Stock Repurchase Programs - Additional Information (Detail)",
     "role": "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
     "shortName": "Common Stock Repurchase Programs - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "md:CommonStockRepurchasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn08_31_2018",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Equity",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2019To03_31_2019",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure - Basis of Presentation and New Accounting Pronouncements",
     "role": "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements",
     "shortName": "Basis of Presentation and New Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Coronavirus Pandemic (\"COVID-19\")",
     "role": "http://www.mednax.com/role/CoronavirusPandemicCovid19",
     "shortName": "Coronavirus Pandemic (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "md:CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Cash Equivalents and Investments",
     "role": "http://www.mednax.com/role/CashEquivalentsAndInvestments",
     "shortName": "Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d919859d10q.htm",
      "contextRef": "P01_01_2020To06_30_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "md_AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts payable and accrued liabilities excluding accrued income taxes current.",
        "label": "Accounts Payable and Accrued Liabilities Excluding Accrued Income Taxes Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccountsReceivableAndNetRevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable and net revenue disclosure.",
        "label": "Accounts Receivable And Net Revenue Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable and Net Revenue"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_AccountsReceivableRetained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts receivable retained.",
        "label": "Accounts Receivable Retained",
        "terseLabel": "Accounts receivable retained"
       }
      }
     },
     "localname": "AccountsReceivableRetained",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AccruedPayrollTaxesAndBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued payroll taxes and benefits current.",
        "label": "Accrued Payroll Taxes And Benefits Current",
        "terseLabel": "Accrued payroll taxes and benefits"
       }
      }
     },
     "localname": "AccruedPayrollTaxesAndBenefitsCurrent",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_AmendedAndRestatedTwoThousandEightPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amended and restated two thousand eight plan.",
        "label": "Amended and Restated Two Thousand Eight Plan [Member]",
        "terseLabel": "Amended and Restated 2008 Plan [Member]"
       }
      }
     },
     "localname": "AmendedAndRestatedTwoThousandEightPlanMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_BasisOfPresentationAndNewAccountingPronouncementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis of Presentation and New Accounting Pronouncements [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationAndNewAccountingPronouncementsTable",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value Of contingent consideration liability.",
        "label": "Business Combination Contingent Consideration Liability Fair Value Disclosure",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CapitalLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capital loss carry forward.",
        "label": "Capital Loss Carry Forward",
        "terseLabel": "Capital loss carry forward"
       }
      }
     },
     "localname": "CapitalLossCarryForward",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CashEquivalentsAndInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents And Investments [Line Items]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsLineItems",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CashEquivalentsAndInvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents and Investments [Table]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsTable",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Line Items]",
        "label": "Common Stock [Line Items]",
        "terseLabel": "Common Stock [Line Items]"
       }
      }
     },
     "localname": "CommonStockLineItems",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_CommonStockRepurchasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entire disclosure of common stock repurchases.",
        "label": "Common Stock Repurchases [Text Block]",
        "terseLabel": "Common Stock Repurchase Programs"
       }
      }
     },
     "localname": "CommonStockRepurchasesTextBlock",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchasePrograms"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CommonStockTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common Stock [Table]",
        "label": "Common Stock [Table]",
        "terseLabel": "Common Stock [Table]"
       }
      }
     },
     "localname": "CommonStockTable",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ContractedManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracted Managed Care [Member]",
        "label": "Contracted Managed Care [Member]",
        "terseLabel": "Contracted Managed Care [Member]"
       }
      }
     },
     "localname": "ContractedManagedCareMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ContributionsInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contributions In Aid Of Reimbursement of Lost Revenue.",
        "label": "Contributions In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ContributionsInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_CoronavirusPandemicCOVIDNineteenDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "label": "Coronavirus Pandemic COVID Nineteen Disclosure [Text Block]",
        "terseLabel": "Coronavirus Pandemic (\"COVID-19\")"
       }
      }
     },
     "localname": "CoronavirusPandemicCOVIDNineteenDisclosureTextBlock",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_CovidNinenteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Covid Ninenteen [Member]",
        "label": "Covid Ninenteen [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "localname": "CovidNinenteenMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DeferredTaxAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Axis]"
       }
      }
     },
     "localname": "DeferredTaxAssetsAxis",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DeferredTaxAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetsDomain",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Cost of Salaries and Benefits",
        "label": "Disposal Group Including Discontinued Operation Cost of Salaries and Benefits",
        "verboseLabel": "Cost of service salaries and benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostOfSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Cost of Service Supplies and Other Operating Expenses.",
        "label": "Disposal Group Including Discontinued Operation Cost of Service Supplies and Other Operating Expenses",
        "verboseLabel": "Cost of service supplies and other operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostOfServiceSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Gain or Loss on Assets Held for Sale.",
        "label": "Disposal Group Including Discontinued Operation Gain or Loss on Assets Held for Sale",
        "negatedLabel": "Loss on sale, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainOrLossOnAssetsHeldForSale",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents disposal group, including discontinued operation, operating expenses",
        "label": "Disposal Group Including Discontinued Operation Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation other income (expense).",
        "label": "Disposal Group Including Discontinued Operation Other Income Expense",
        "terseLabel": "Non-operating (expense) income, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeexpense",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group including discontinued operation transformational and restructuring expenses.",
        "label": "Disposal Group Including Discontinued Operation Transformational and Restructuring Expenses",
        "terseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransformationalAndRestructuringExpenses",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_DivestitureOfMeddataMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divestiture of MedData.",
        "label": "Divestiture of MedData [Member]"
       }
      }
     },
     "localname": "DivestitureOfMeddataMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "label": "Estimated Earnings Before Interest Taxes Depreciation And Amortization",
        "terseLabel": "Estimated EBITDA"
       }
      }
     },
     "localname": "EstimatedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ExtraordinaryItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Abstract]",
        "label": "Extraordinary Items [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAbstract",
     "nsuri": "http://www.mednax.com/20200630",
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Axis]"
       }
      }
     },
     "localname": "ExtraordinaryItemsAxis",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_ExtraordinaryItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extraordinary Items [Axis]",
        "label": "Extraordinary Items [Domain]"
       }
      }
     },
     "localname": "ExtraordinaryItemsDomain",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at carrying amount.",
        "label": "Financial Instruments Measured At Carrying Amount Table Text Block",
        "verboseLabel": "Financial Instruments Measured At Carrying Amount"
       }
      }
     },
     "localname": "FinancialInstrumentsMeasuredAtCarryingAmountTableTextBlock",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "md_ForecastForFirstQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For First Quarter Of 2021 [Member]",
        "label": "Forecast For First Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For First Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForFirstQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForFourthQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Fourth Quarter Of 2020 [Member]",
        "label": "Forecast For Fourth Quarter Of 2020 [Member]",
        "terseLabel": "Forecast For Fourth Quarter Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForFourthQuarterOf2020Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondAndThirdQuartersOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "label": "Forecast For Second And Third Quarters Of 2020 [Member]",
        "terseLabel": "Forecast For Second And Third Quarters Of 2020 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondAndThirdQuartersOf2020Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ForecastForSecondQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Forecast For Second Quarter Of 2021 [Member]",
        "label": "Forecast For Second Quarter Of 2021 [Member]",
        "terseLabel": "Forecast For Second Quarter Of 2021 [Member]"
       }
      }
     },
     "localname": "ForecastForSecondQuarterOf2021Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_HospitalsContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospitals Contracts [Member]",
        "label": "Hospitals Contracts [Member]",
        "terseLabel": "Hospital contract administrative fees [Member]"
       }
      }
     },
     "localname": "HospitalsContractsMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents Income (Loss) from continuing operations, per basic and diluted share",
        "label": "Income Loss from Continuing Operations Per Basic and Diluted Share [Abstract]",
        "terseLabel": "Income (loss) from continuing operations:"
       }
      }
     },
     "localname": "IncomelossFromContinuingOperationsPerBasicAndDilutedShareAbstract",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "md_IncreaseDecreaseInAccruedSalariesAndBonuses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in accrued salaries and bonuses.",
        "label": "Increase Decrease In Accrued Salaries And Bonuses",
        "verboseLabel": "Net decrease in accrued salaries and bonuses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalariesAndBonuses",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term debt and capital lease obligations excluding long term line of credit.",
        "label": "Long Term Debt and Capital Lease Obligations Excluding Long Term Line of Credit",
        "verboseLabel": "Long-term debt and finance lease liabilities, net"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MaximumConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum consideration receivable.",
        "label": "Maximum Consideration Receivable",
        "terseLabel": "Maximum consideration receivable"
       }
      }
     },
     "localname": "MaximumConsiderationReceivable",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MoneyMarketFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of money market funds.",
        "label": "Money Market Funds Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_MutualFundsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mutual funds fair value disclosure.",
        "label": "Mutual Funds Fair Value Disclosure",
        "terseLabel": "Mutual Funds"
       }
      }
     },
     "localname": "MutualFundsFairValueDisclosure",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan And Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan and 2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanAndTwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1996 non-qualified employee stock purchase plan.",
        "label": "Nineteen Ninety Six Non Qualified Employee Stock Purchase Plan [Member]",
        "terseLabel": "1996 Non-Qualified Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "NineteenNinetySixNonQualifiedEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_NorthAmericanPartnersInAnesthesiaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "North American Partners In Anesthesia [member].",
        "label": "North American Partners In Anesthesia [Member]"
       }
      }
     },
     "localname": "NorthAmericanPartnersInAnesthesiaMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_PercentageIncreaseDecreaseInSalaryAndWage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Increase Decrease In Salary And Wage.",
        "label": "Percentage Increase Decrease In Salary And Wage",
        "terseLabel": "Decrease In Salary | %"
       }
      }
     },
     "localname": "PercentageIncreaseDecreaseInSalaryAndWage",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfDeferredPaymentOfSocialSecurityTaxes": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage Of Deferred Payment Of Social Security Taxes.",
        "label": "Percentage Of Deferred Payment Of Social Security Taxes",
        "terseLabel": "Deferred Payment Of Social Security Taxes | %"
       }
      }
     },
     "localname": "PercentageOfDeferredPaymentOfSocialSecurityTaxes",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PercentageOfNetPatientServiceRevenueByTypeOfPayor": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of net patient service revenue by type payor.",
        "label": "Percentage Of Net Patient Service Revenue By Type Of Payor",
        "terseLabel": "Percentage of net patient service revenue"
       }
      }
     },
     "localname": "PercentageOfNetPatientServiceRevenueByTypeOfPayor",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "md_PracticeSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Practice salaries and benefits.",
        "label": "Practice Salaries and Benefits",
        "terseLabel": "Practice salaries and benefits"
       }
      }
     },
     "localname": "PracticeSalariesAndBenefits",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_PracticeSuppliesAndOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of supplies and other operating expenses directly attributable to the physician practices.",
        "label": "Practice Supplies And Other Operating Expenses",
        "terseLabel": "Practice supplies and other operating expenses"
       }
      }
     },
     "localname": "PracticeSuppliesAndOtherOperatingExpenses",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_ProceedsFromContributionInAidOfReimbursementOfLostRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue.",
        "label": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue",
        "terseLabel": "Proceeds From Contribution In Aid Of Reimbursement of Lost Revenue"
       }
      }
     },
     "localname": "ProceedsFromContributionInAidOfReimbursementOfLostRevenue",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_RuralAreaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rural Area [Member]",
        "label": "Rural Area [Member]",
        "terseLabel": "Rural Area [Member]"
       }
      }
     },
     "localname": "RuralAreaMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_ScheduleOfFinancingReceivablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of financing receivables.",
        "label": "Schedule Of Financing Receivables [Line Items]",
        "terseLabel": "Schedule Of Financing Receivables [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFinancingReceivablesLineItems",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_Seniorunsecurdnotes2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2023 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2023 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2023Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_Seniorunsecurdnotes2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SeniorUnsecurdNotes2027 [Member]",
        "terseLabel": "Senior Unsecurd Notes 2027 [Member]"
       }
      }
     },
     "localname": "Seniorunsecurdnotes2027Member",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period shares stock swaps.",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "md_StockIssuedDuringPeriodValueStockSwaps": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock issued during period value stock swaps.",
        "label": "Stock Issued During Period Value Stock Swaps",
        "terseLabel": "Stock swaps"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockSwaps",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "md_SupplementaryLeverageRatioRequired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary Leverage Ratio Required.",
        "label": "Supplementary Leverage Ratio Required",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "SupplementaryLeverageRatioRequired",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "md_TaxYearTwoThousandAndTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax year two thousand and twenty five [Member].",
        "label": "Tax Year Two Thousand and Twenty Five [Member]",
        "terseLabel": "Tax Year Two Thousand and Twenty Five [Member]"
       }
      }
     },
     "localname": "TaxYearTwoThousandAndTwentyFiveMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandFifteenNonQualifiedStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "label": "Two Thousand Fifteen Non Qualified Stock Purchase Plan [Member]",
        "terseLabel": "2015 Non-Qualified Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenNonQualifiedStockPurchasePlanMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Seven [Member]",
        "terseLabel": "2027 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentySevenMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_TwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Two Thousand Twenty Three [Member]",
        "terseLabel": "2023 Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unnamed Corporate Joint Venture [Member]",
        "label": "Unnamed Corporate Joint Venture One [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureOneMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "md_UnnamedCorporateJointVentureTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unnamed Corporate Joint Venture Two [Member]"
       }
      }
     },
     "localname": "UnnamedCorporateJointVentureTwoMember",
     "nsuri": "http://www.mednax.com/20200630",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r133",
      "r170",
      "r172",
      "r264",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r165",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r134",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableGrossAllowanceAndNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued expenses, total"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Gross, Current",
        "terseLabel": "Gross accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r27",
      "r44",
      "r135",
      "r136",
      "r171"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail",
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r39",
      "r236",
      "r252"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r32",
      "r33",
      "r59"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued salaries and bonuses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r190",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherCorporateBondsMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in corporate fixed maturity debt securities classified as other.",
        "label": "Other Corporate Bonds [Member]",
        "verboseLabel": "Corporate Securities [Member]"
       }
      }
     },
     "localname": "AllOtherCorporateBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r178",
      "r187",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r50",
      "r137",
      "r144"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for Doubtful Accounts Receivable, Current",
        "negatedLabel": "Allowance for contractual adjustments and uncollectibles"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfAccountsReceivableNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r102",
      "r222"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Antidilutive securities not included in the diluted net income per common share calculation"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r131",
      "r234",
      "r251"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r29",
      "r31",
      "r69"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r18",
      "r20",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 25.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "verboseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r139",
      "r146"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r26",
      "r51",
      "r104"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For the entity and the disposal group, cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents.",
        "label": "Cash and Cash Equivalents, at Carrying Value, Including Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r219"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in financing activities - discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r17",
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by (used in) investing activities\u2014discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r17",
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net cash provided by operating activities - discontinued operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "verboseLabel": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, aggregate shares authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r43",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock; $.01 par value; 200,000 shares authorized; 85,536 and 84,248 shares issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r235",
      "r237",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r61",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "verboseLabel": "Schedule of Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 31.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r102",
      "r105",
      "r197",
      "r198"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r194",
      "r196"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r102",
      "r128"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 11.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Net Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans and Stock Purchase Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r78",
      "r260"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "(Loss) income before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r21",
      "r195",
      "r200"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "negatedLabel": "Income tax benefit (provision)"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r18",
      "r20",
      "r151",
      "r156"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 32.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "verboseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "verboseLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r102",
      "r152",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Preliminary and incremental gain loss on sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r25",
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r80",
      "r108",
      "r112",
      "r115",
      "r116",
      "r117",
      "r120",
      "r246",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average common shares:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r80",
      "r108",
      "r112",
      "r115",
      "r116",
      "r117",
      "r120",
      "r246",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Common and Common Equivalent Shares"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method ownership percentage in joint venture"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r212",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r212",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r212",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r212",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Measurements, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 28.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicDistributionAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Axis]"
       }
      }
     },
     "localname": "GeographicDistributionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeographicDistributionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.",
        "label": "Geographic Distribution [Domain]"
       }
      }
     },
     "localname": "GeographicDistributionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r148",
      "r149"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 27.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization that is the governing authority of a community.",
        "label": "Government [Member]",
        "terseLabel": "Government [Member]"
       }
      }
     },
     "localname": "GovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]",
        "terseLabel": "Health Care Organization, Receivable and Revenue Disclosures [Line Items]"
       }
      }
     },
     "localname": "HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Health Care Organization Revenue and Expense [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueAndExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Net patient service revenue [Member]"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r108",
      "r232",
      "r243",
      "r263"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r74",
      "r80",
      "r112",
      "r115",
      "r116",
      "r241",
      "r244",
      "r246",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r74",
      "r80",
      "r112",
      "r115",
      "r116",
      "r117",
      "r246",
      "r259",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]",
        "terseLabel": "Loss from discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r21",
      "r80",
      "r260"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      },
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Loss from discontinued operations",
        "presentationGuidance": "Net incremental loss on the sale of MedData",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Loss from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r78",
      "r80",
      "r114",
      "r115",
      "r116",
      "r246",
      "r260",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r77",
      "r102",
      "r129",
      "r142",
      "r242",
      "r258"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity in earnings of unconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r105",
      "r130",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r66",
      "r240",
      "r257"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "verboseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable / receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in liability to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Increase (Decrease) in Liability for Claims and Claims Adjustment Expense Reserve",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Weighted average number of dilutive common share equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r127",
      "r220",
      "r222",
      "r247"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r33",
      "r34",
      "r59"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r82",
      "r84",
      "r85"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "verboseLabel": "Investment and other income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r233",
      "r248",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letters of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r49",
      "r238",
      "r255"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r18",
      "r20",
      "r153",
      "r156"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r18",
      "r20",
      "r151",
      "r156"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "verboseLabel": "Liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r40",
      "r237",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Line of credit outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Credit Facility Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "verboseLabel": "Line of credit remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Current",
        "terseLabel": "Accrued professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).",
        "label": "Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent",
        "terseLabel": "Long-term professional liabilities"
       }
      }
     },
     "localname": "MalpracticeLossContingencyAccrualUndiscountedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash used in financing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r99",
      "r100",
      "r103"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities \u2013 continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r72",
      "r73",
      "r79",
      "r103",
      "r119",
      "r245",
      "r261"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r40",
      "r237",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes Payable Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 30.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use\u00a0assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107",
      "r109",
      "r126",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and New Accounting Pronouncements"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/BasisOfPresentationAndNewAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r59"
     ],
     "calculation": {
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesScheduleOfAccountsPayableAndAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 29.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized holding gain (loss) on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "negatedLabel": "Payments of contingent consideration liabilities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payments for credit facility amendment and financing costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "terseLabel": "Amount withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition payments, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Payments to Acquire Other Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $.01 par value; 1,000 shares authorized; none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r28",
      "r30",
      "r147"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from issuance of senior notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r92",
      "r106"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on credit agreement"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Proceeds from maturities or sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "verboseLabel": "Proceeds from sale of business, net of cash sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "verboseLabel": "Other revenue [Member]"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r72",
      "r73",
      "r98",
      "r131",
      "r132",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r36",
      "r37",
      "r154",
      "r256"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 26.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r94",
      "r106"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedLabel": "Payments on credit agreement"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r102",
      "r160",
      "r161",
      "r162"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 12.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "verboseLabel": "Transformational and restructuring related expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r46",
      "r168",
      "r254"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained (deficit) earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r169",
      "r170"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "verboseLabel": "Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r19",
      "r22",
      "r23",
      "r24",
      "r157",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "verboseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r180",
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Calculation of Shares Used in Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r217",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Percentage of Net Revenue"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Private-Pay Patients [Member]"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants and awards under Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r177",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Vesting period of options, maximum years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of market value of common stock at which employees are permitted to purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, Shares",
        "periodStartLabel": "Balance, Shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid for Tax Withholding for Share Based Compensation",
        "terseLabel": "Number of shares withheld to satisfy minimum statutory tax withholding obligations"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r65",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsPayableAndAccruedExpensesAdditionalInformationDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity",
      "http://www.mednax.com/role/CoronavirusPandemicCovid19AdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail",
      "http://www.mednax.com/role/DiscontinuedOperationsScheduleOfDiscontinuedOperationsDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFairValueOnARecurringBasisDetails",
      "http://www.mednax.com/role/FairValueMeasurementsScheduleOfFinancialInstrumentsThatAreNotCarriedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Aggregate number Shares issued under Stock Purchase Plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/StockIncentivePlansAndStockPurchasePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Forfeitures of restricted stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeitures of restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r42",
      "r43",
      "r168",
      "r179",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Gross",
        "terseLabel": "Issuance of restricted stock and conversion of restricted stock units to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized for repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Company's Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchased common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r42",
      "r43",
      "r167",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchased common stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r43",
      "r47",
      "r48",
      "r138"
     ],
     "calculation": {
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r201",
      "r202",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonStockRepurchaseProgramsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Other Third-Parties [Member]"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/AccountsReceivableAndNetRevenueScheduleOfNetPatientServiceRevenueByTypeOfPayorDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r173",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "verboseLabel": "Federal Home Loan Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r173",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "verboseLabel": "Municipal Debt Securities [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CashEquivalentsAndInvestmentsScheduleOfInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase decrease in valuation allowance deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/DiscontinuedOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted average number of common and common equivalent shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r117"
     ],
     "calculation": {
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.mednax.com/role/CommonAndCommonEquivalentSharesScheduleOfCalculationOfSharesUsedInBasicAndDilutedNetIncomePerShareDetail",
      "http://www.mednax.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r272": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r273": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r274": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r275": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r276": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r277": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001193125-20-203325-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-203325-xbrl.zip
M4$L#!!0    (   X_E"=$;Y=21D! #<A$0 /    9#DQ.3@U.60Q,'$N:'1M
M[+UI<]M(LB[\_4;<_U"AF3['CH!D@COMMF^PM72KCRUI)'E.S_O%40**(J9!
M@(U%R_SZ-ZL D" )4ERP%("<F)8E$DM5YI-K967]_/]>)B9Y8HYKV-;G(_6D
M<428I=FZ83U^/O*]T7'_B/R_+__W__P\]N!"N-AR/T[TST=CSYM^_/#A^?GY
M9,)TB[Z<:/;D0[/1;#2Z+7A(<*5I6'\N7/ORX)@GMO,(5S9:'_C7#]1ET>7\
M6]V8W1"_N/LA^')VZ<JCGUOB6G4P&'P0W\XN=8VD"^&AZH<_OGV]T\9L0H\-
MR_6HI2V,Q=@P]N7K=;8T<)=I)X_VTP?X NY0!\<-];BE1I<;KMUNJKU-+PBN
MF#]_ZC"->DQ?>\_@ W4TQS;9A_G%T>V:[5N>\YH\Q/!+/LS>XC UWW$ #^ON
M"[]-F!][T<;)-_%O$FZPJ*&YR7>(KQ(&YQI:\@WP!;]<7;K<FSIKKH=O^ W]
MQ1M\]_B1TNGLGA%U'P2MPR\29O%B;N#H'U]CJ/0]9P,CX=O9L!UO=03P81*H
M7M8]4N6 !:%@?_QR^W5^N9=\_?S2#YY#+7=D.Q/J@8;@3^H<-YK'S6Y<3C9-
M>EG&X:7'0/>%.R(^O/7>_GRNZT6?*ZHCH;$8U?F_GN&9[(O:./['SQ^"W^'#
M"?,HT6S+8Q80P6,OW@=^XR>BC:GC,N_S]_L+KOOX6X[97[[Q]/GH-+C\^/YU
MRHX^\*=\B-[Q8.NOQ/5>3?;YB+^<_*P;3^$'_ZT;[M2DKQ^)95OLO[_\;+Q\
MY/<Q)_C5T'5FB5_A^RM_PAQ#(Q:=P*- =WP<3IBEPW_>A4D?CXC!Y5_<HK8&
MJMII#8Z">;QXMVST^>BFH?Z _W--?&\WNC]:#?'[T9<1-5WV\X>%UT1OO7"H
MQND<OC;$]\<;AXT8B+A^Y]G:GS?4N7;N/*Y5_DE-G]TPYPZ(Q9;>/W2OK=A[
MB6\9P3??X9<?W^_.?DR9\R.\4V>:,8&!?3ZZO+HX^M(X::C1$*,QI33&!;IU
M&OUF,V'<:O-'B]-.'60^[E-[,K&M70?=*I;86PTZ%ZJNRLF9K?E"3 Q7HR8,
MQ[#U"_C,7969=F=+F?E'<XW K+[^W +=\GH* W"H>6GI[.5_V&O"JWM;OKH!
M_^L/6H/V8.LAG IS'!+@7XPZYY9^!@Q*&,6V2N/X6&V"TMV1"G? 1/,7WP5E
M[JZ0O]7K+*-XH\HB.[[\'#Y^!/?U5\=^]L: V"FU5A@!@UB6_]T',;)MS[(]
M)IY]<?6CT^RV W_MHTFY_\RLX^]W1U] 1;G %Z:39\,;&Q9QP/@ ;70"/+)@
MJ"X!2?/&C _(M4U#YU)%'JC)'4SBCAGS"'7%%=&'ADN,"1A'& PU3\3H9L-9
M.[A^PN#.?$8\FU!BVJY+1HX]$60Q+!\&1FR03F&!X2O;$2-PC1<"2L ;NQ I
MZ##.WWV+D59#(9Q>"A@Y8EB:P[@L4A-&#Z+M$OC!/S9]?L<#^*8^$)4_CHU&
M3//(L^V;_ M"X=VZ8?J>\<1.R/+$/BP:3*'[P0-E[I>?N:/QT17./#"4B!#@
MHP>F^O.1:TRF)O= Q&=CA_-[HA]'T<K)BPM^\H?P$9'#LN-#?H#'?0+4C2[@
M?O@&MTBXZ=, &(+ 7^>OC1X1>O.;HQQX"&>29S!W-9[:/DC:.E([E$PZ&^U*
M)KC% &M1(R*9]&%7(L$MS*P+?<"^[4H?N$7SS;*)VH<E)2?^=&W?$7^)',7'
MT(H)1;_.BI$O)+R:"2,Y^]/0^0<C@SE$Z$Z6&)B=7O[/HD>R?#,\[T/B\Z?"
M#YO]Z7K4\;A/\H4/BT>OW,5;_FX^5CUV;?>XU9B_10^O_+#TG@\+1$FDD7":
M^Z%/VI>&-D%&R?L2)"+ZPNU:_&:OV3;:I4)$NPA$1#12!W,:\6A%0AKQG,^V
M-.+7ID<CM50TVE:SI$JCY7!<$MK,-<NRU!RD699C>^EF"[P-P]<T]&@<_RWI
M9GT(_ELQ&J6B(X2M"6DDD1P<XGVD1B.A(WH_FFVY:+.H(WK'S7;Z.D)27RL]
M'1'7_Q+IA@6-F*[^EU 3+LZVE2IOY=-IBW*;[FQGGLP/L0C%]*&EWS)7)/WO
MG^W[L>V[U-+/C<>Q=V-2ZQN;/##'=_E: ?_[BD[8\,5P?YQ#.&^_,B96#JZG
M/ B/7SM\IH[.5]7XQ7E0-E3Y[)$G*<._=7C?R]0T-,,+QD9T [X."B-FJTVQ
M6<% )_K'72CS\X?$%^TR@&5219^OI?#Z=WY8ID+1OF0,;U>&Q3S&+/'OZYWQ
M<F5;__"IR1FH+\SUQG>T,749IS(P(4;\"V,D'A&[<^6.=8@M&0CS)5<Y(?7=
MXBM%^JGM3&T'Y/1WV["\?\+(?(==6RR8@^MXO!Y(]TUV/3K_RX=1?V/>V-8O
MK2<0;SZKU4\9DQHV,*>/!TX*(+85^:J'#! 01,;^R)B1KYS(.*7NF!/@B9HP
M'#=N+?A7H$"7KI"6U;,*CDW#CE^T,NUR<O#*=KSQ4*S94^L&0GP+1/D23!\
M><Q<@\9Y>F:X4]NEYJ^.[4]/3>JZ0&]-K!D)-_:>OO"RBIC1%"84YOEZ83RQ
M^*/@TJ $17I$O#'IT,'8CHPI.+C+A(.7;T7V<L)S:)K70$!GICQ_L2U]0<_,
M-7$I J3$X<Z"EPVS+2?_OM^)$C@7 'ECFX8'XF'>^0^Z\61PNE26D]O-NZP\
M_=5^8H[%1W8WY159#@11<+TS=0R7N6?LP;MCFN\8O!*@NAS>G0KEY/<I+^D0
M)H^YUZ,S!M8P&GGUV+IALN7DW@4U'%& ?&E-?<_]RIZ8J<:Y-[O@E]?9K[\!
MB:FCC5_%Y<*WFWWWC5'7#\H7W5L.<,>P'M<\,';MA</^\OEF&.GQL1U!8IC9
M0.(4'+[MR+ER]08V50?(301RUD!N(I!S '(+@9PUD%L(Y)2!'$LX!-F&^['#
M%K(\W F^A#<Z8N>1]#A+'"Y/L&R8:$58=P<B8M6!=;&)EI-UI_:3H?.%3(LO
M1P9#_G9V_N(YU'9TPZ+.ZZ7')O*FVH$K:T<+WR7-KYR<^LH\CSG7HU.'Z8L1
M<_#)!=4,$T8I+:=F07'2<*,ODV99(G[-"W1Q-2N7U:Q4BXZ7.(C+!=DO%V3)
M/UPN*&:Y(%N>XG*!;,L%6?(;EPO*S#U<+L#E@MR24WD#&9<+<+F@$D#&Y0)<
M+B@=D#'G7!W6X4J/M*Q+[M7QXS=&36]\2AUV0R'$A"B4.4^&-M_7<^/8NJ]Y
MUT[XA;0\Y+LRU@PV8N_FR:;-2#G:CZQAN^U.#8^:+F_.RGM$NI5B.(CLNAG6
MB<LA=8:6'I)'Y(4KQ>EY/]OU4ZT3RV_#'IGG88O,N#$6R60^T6!S&N_Q:5NE
M6+!Z:^31=<FSKQ/_(VW']&_4HH],Y]8N#H*Y#;QV'JEE_$=L6;KEKJC/[H(6
M>=+C88=)B-*!M32I$S3F*PUUQD-TRS(UZH2$^['AZ'P[XNL-?;4=A,/T8R))
MZH2).V:.8.J(!? VXJ2H$P9BYQ34RV]<F7B=N#[4==$EG)HWU- OK5,J N=Z
M(6 C$>J$AC/##0\R8/KU[!B#WYBICVS'I>9B>O?-)@CR(N/ML<>NW(8DE4;)
M8AML3!OGDS8NO+/W,MLQ;5P#+F/:N'8LQ[1QOFECV?B/:6-ITL:R00/3QD6E
MC65# J:-BT\;RX8)3!OGGS:6#0.8-LXC;2P;US%M7&3:6#8T8-I8QK2Q;"A)
MLZUTR5&21G?HZ@'DS."[:@UQ.L+H&]-UZM4+$^L)4$T8))Z.B<M+^>U**.3
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M_"A-U94F21GY?__/SY[PU#5FFE.JZ_"@ST<0:_&_PP>+O\,Q!%04+R":[SC
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MN> "PB^A,N40U.S)E%JO"E?\,$90E)P0CP1,[K,WCKX^ 3O Q(1U-C(LT8I
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MWWV+!5QJ-925Y$SM %M;J-X9+PC4_=""%B,?B]&L@1CRY6FIP%WXJVO&?G6
M[*\Q^U'Z:\U^R:3_$,\FI7K!S=/G!8-D(6&RF@ZL;>/^*^81ASTQRV>+J;[M
M8;5])FR>A%GOR6U74[;5Q?ML[164N'#L"5_.XA?]K^&-3WT7GL><V?&:0]=E
M\'_]GKXLU9DUVC\:JB@@O+<S.,N[,5":C59RM=EVW#JXW"Q[4%00#NI@#H<4
MMX!W5:79ZB$<2@,'-4OMH/*6#TJCTT9 E T0V>@'55$;O+/BH%A K/,0XQ7*
M&:%F[0*9',[,@B-:JBU&.SB(59MF>95AM?A0DVDBW.3@0TVFB7"3@P\UF68J
MCF0JC74PB;AW$O%ZRAS*S_LD[&7*+ AV/I8AF;CECL<*/2LS[5N.Z2,II7P6
MDG+-LW!IK<SMDV]$LDUCQ*4F=:+&' _,8B/#<ZMA('=]XO8YUHG^,2+@74B_
MH:7_$E(OUU6W5GN@-#M)Q]/4,ZM>.EADDUUO\=4W7(PM(2PR787KM?M*3UUS
M[A'"0GY89*,M>BU5Z:SKR%_T2EQ=$RCRN8K^=&I&KJ+MC9E#[)7D"KJ.VTM]
M2$^0^FM.S5FFZCRD9:Z.9%-5VBUT&"J"D6SL1).?TX48*3M&,G4QVUVEWRJX
MJ <QDA9&LM$C[9ZB-@HN#<7\99F=TE\A3.(-S;@K2O6)81FNQP']Q- 3W;%0
M-"0E:(;A B%#S9"K$]KK*=T>E@B7'Q[9V U^%+N*OD6)X9'M'H-N1VFVUC0S
M1WR4"!\9;3D ?/0&:\YRJH#?B1[E 1[E&9LZ !0J,"S<RHD-Y/N/^ !]R>VD
M/4Y$^!UX +]PV8_1,E>'4FTKK0%FK"J"D8S,0DOI]="K+#M&,G4MFWWP'-"S
MK A&,EH=Z2F=?L')"\QJEMD'O7>HY08( ^2$Z4V'0<SD:Y[O\'5VAYGBN ;,
M<NZZ'3Y&Q=,Q<#_G]75553K8#J.LF,C(\^PI_>Z:<X81$])B(E-/L]4 +Z+@
M4CS$Q+Z8R,BS;"BM1L%5N]@HI1Z;GFLRS;+JPZKQH2;31+C)P8>:3!/A)@<?
M:C)-65*4I4P^]F1)/MH>-7%'S]Y18K';=]J]MM(<X,[.,B(BHP;,#57I=PJN
M=D)$[(:(K'LP-QN*VL%:AS)B(ALM,1@TE59'TKTXF%NL5IQ0DVF651M6C0\U
MF2;"30X^U&2:"#<Y^%"3:<J26ZQP^:,L&<A+2[,GC(P<>Q+E(6T+\X^[QI$!
M&;_:;MZ=*)5! QM1EA,2&:4@!TJKCS6O)8-$ICG(3D/IXS)%22&1416TJ@(F
M"MY<A:O2<A[?<6D],=>;P.3G;2<#OAD"K>@=;B?D<SH&4G[%O'R]0Z7?P:KV
M<B(BJP- L9=/Z1"1[=871>WA'NMR(B*CC2_%[X_#E&*YW4>X'" <53.BNQ@)
M_KNW)#\@7!%=()M]I=E-/4=P].5]K35]*@S/Z+0:56ET4^_2A P_A.'99@$[
MRJ"5>CB(#$^!X=E(>%=5>MW4>^,L,1QS>'(Z8>=_^8;W2@R+,.I8<(M+[!$
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MG?H5W&;N-%U;=TSS'<,SF#MT#!>^.H,_K<<;YABV#@[6]>B>OI3,&Q>=""^
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M2,*83'-*=9X$_'S4.!)_AP(F_@Z?%TBPF#G1?,>!F0@1F&OI1N.G/2I50LT
MSS+IU(6/H]]F7RU(^]%2=FWK+A[A*-LPQJ2JG7@R55!]4?&L:)9#M-)*/4U
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M?DY\=/362W?/%"[0(-(W>Z(V?(R@Y-LZ*4N,?SL_NQK^H9#+J],D-23&8NA
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MMWBUPLL,M+%(][I<].%JT"2/<!4\*Y!E;TP]_@#>-H),QZ\NA O4XELRGPR
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M:5WY-]%WC*RA1O+12X/4XN/LS>$CZB4\&Z)Q.EDC;#W( H"CFP1\U45,XBI
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M1'1<T/>U2=Y*'QFOQ1AM[:V._Q^1Q+Z7#G"S+IJ-YH<I_;[.!'-H[&;[A+W
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MWU?Q$& P2*29%0<5R?Z\-#MPK;>:;N?<>G'V8_LWX']ONI<-J\M;9BV9-35
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M:[>S"G_F>FLK2N+61?2-Y7Q5LI)^J]36:$X",<RJD"I-"''%)^>#WQF.TJX
M;H:.TO#)&Z>&U3_0;M623U>M0@M';#2@;+3!!E;_O/OPYB_+H1DT6B?-"P/
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M 4[I'8&O!D$WT!TZ<.+&9=VQKN9B?9)#K=)+-R7&*$G<=:C\@)-OM-@BPLQ
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MG\ SJ:K%2#9@1YO7#4CUQ=*/J8HE]$,.04CY"GC"<#SV"(V6LM@D3?BQ!I$
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MYM"IE,VUV.2A*9(9)H%HT$XPI80]E"\XE-]%+T1_45_;8\=ZZ*97HH#^40T
ME"8!1P,K=*B_P6SP_WX<9]@ @"0IXYNI: RE?BCH,PXFJ,=)P2:]*0K_@1S^
M? )#(=W=!<3+0N'>%90R+B=8$IIE(8GCGB'X[?EZP?GZE3MB%;[?:X/3PEK?
M4/&70A:OT=F[*9"W=.\_D1!"#[)FV<:UC.(41X727$B4$^=3X1IB77"!#NBJ
M]B&842T+]E"DJ4('A8^G7,A,W=J_B!$L%%A%(^+WA/$3H]%5=DH3H) VE'[]
M[1H#[O2E-IA\P<E/,%GJM8) :V4PMR7GA6KCY^GEJ4XE5$/Z^\G=B1Z*1/I#
M7R!F]"$.7 %]O"V,-N5N-N!1-!Q9"8J0W#*<2U5 UX&F'?0QY3-&:'K'7'%T
MZG*7C[1H#5UXEA&;DU,I49>0R-@/0GWEA'&O,%#8VUD!U&L&/*@R2&:V!=B:
MDMU>.B)*5&1^5QB*L@LJ]N'#"'Y"[%^6^>B6<V 02VRCPG@E*[$T:^K54,)G
M"U'308Z,!:E@9!HDGW+ZWZCZN<98BKYW<"VPEHDD3C,PS&T%J3LJ 741R)3O
MR",BAD$^+('A*,@L#4A&#KV4%%5LWVIL-H<9T'Y31W6B;ZQ:?[3$$'VUJV/6
M*BE-I3N D)7OHQ_')7^QQAJU-4:UJ3%JVQJC_:LQVJQ2M[%><]O5Z>Y+6(6J
M#Y>!5/A5&NA@B]=)I=LV(IO4!AY%"(ID&>XR17 $\4#.U6*M#"P[TU> ,ILR
M CG?9D!ZEQ:(?=DM3KH;3+65*R,23^V-<)7K]B'&D%!?-JPE>036%.@*TGR3
MOD+9SY:[]\A ;.(Q6(1.65CXUB+PV4UB#Y.P#$.,(2RQP#?%4/B0WMVGM"6\
MV$&GR@.#6YNI&K*MO)FPI$1L;]S#"E^-%8G+5U!K)GJ#J.CZ,* @M&[>5PQ5
M WE29$].5A<F%#VB>AZW@Y=FJX.NO2'W2C$@/G4?\4>4X-1DO>A/1>#DV&EI
MOF>95)@J"O!UA)V5$/(/*\QJ3.*@G94I+CUJ2.8ZN6RFG!23Y_H*@6B8@4)4
M]F4X45V,[>R$OM"LH9#T0XH4.[NEE6*:32:%&X:U@0(^EWC-XZ21(<T[&!-2
M*L?"8S1OSE(K(,5E-ZJY,79Y4O1+@%' SL;JYD0\8(J+C!? XKA%Z[Z*LQ7&
MT<-[C :5IV>>.':8J#P')&7G@5)@DXD"=F,)BXI\T]EAA(-EV0Q6VA,@O>RR
M9IR']Q/G@<%8BHA*:FZM)I\I<]@8% EH:CFDB(Q8E\0@"&6^D_S#.'A7)4!0
M&25'W\YB9%P#5E=&<4K8NO.#?-)4HH"/ZBA2H#C38G8QO^)1,ZM*YCW9J4\>
M9 510'1)?3@?921-'E"X#V25H$ .'AK];)8 /:;5'EA":4",%X;]E TP]2<E
M8P;-?6F8H0,<AHJ=T[&*K4]551G3. ?KT*TM[U.K PSFAQB GH&Q-4[:EN.6
M><G*A*2<-]!*</R4"21[3VE<75U',]M1MKT491 9\#W9DYRCK+?/H!9V1M(>
M%=UG,JS73%5^A';3>[IQ*VY5%\Z#R]#CJM>%F7#T)#2,,24$]>#<*U:43:M/
M97)6Y&NJ!GD42ABGL<-)7<5O-41ZMC[2%?3IWPJ7W'=!GO%C59HQ>G\KO2RW
M$O]+=0/&6FF?+$8"'*+48:-7[-5UD>.AVW":*C<=D)1!YJ?;0N<DTUPN!D'Q
M ])3I8""D!?8NP^=.P6[B.7->"LZ6F6H_CG3/4XPC)Z>2'AXX_52M63-,L5<
MWR =J%R.22<:<"_E%,3,6ZYT58#W.E\&;N3DS$"[>%GFN!*+!SLNJVQ5$!$/
MTGGEJ@ZL_R%^HWUFIMM+><U(7(,<2@R-!1M11,R%D,T8'6\-P6&XG+N@$_4#
M%!'L^#=6A?9##[;@FLP?/=6813A?9-N;:^#BH?/%"U,L#_,"&.Z5K/%A+<;L
M0I9X.0M8#\8H,*L<&_. &AL3<W]2GMJN01.(?Q=GDIL:FX"PVM@I93*W_/K*
M]*X:-\@UYGH?(R]7+3<'H6&_>E*U*K8*UR.=']P]Q"S.>UY/F0*9EK*9"N4D
M!/&;AI[N$3!AHO;#_%DZLE5!SYB,J.9IX]Q%KQ/5*L//17TTYG>C&I!QL)'V
MQ'1/4WZ[N>6L[6EE"[1+W/@@'?*)T >6E02UX]2 A.L69'&T]ER7]I\I TA5
M#Q:9D/= 2<(9=DV@@1*D?FF8F,E#>J5)AVK(\J7]G*WS*WW L0GU-2GP/'J5
M%B]SNKTA: 9Z;%.9V]??[HQ033JQ'80[]DB=2&>P948%PWP-\8.Q*Q_9N"@8
MD&DBZ(E)Q8UM,G:8/.1@/M.]:&U$A!U&''9BZD=UJ*ZR<IIRZ1"PD).<%XG<
MI'$2F)+Y^]S*! OT@;N#T&%>KS,W:1,#$L#3PHQ/!%JCF?>,J>\((.<Z7-K@
MI3*=3ST9G3CH!:%#2\%'.2AXC]Q]\HVI)#6<TP4BIJC.:+[J5 O,/:'-OQ?/
M'C=AX^@E3@Q;B\A$[_+)%L2E)]%(*%AY<D=GDO*XM(XB\W4HPS5(Y%E#>0_&
M5^";$<H3.#UF(S3,.%++STWBZ$RX4LB69GAISI GQM4) O<B'U%"@P1G,&:O
MTRAA/B"C)$0#6@X3FTW%)CUC;O :+*9,J#>@1 3OPQ-1Q@JT*Q6RGI#. W.O
M9 YZ;VIAACE045>HU4&+1^E*W+&=O V"82 (N3SX(5U-6@FCM U3VRJ2)OLR
M5;A@TV @=[%R$GT.X:.TM[5H*'>XH%24$]0GB"ADCZNIQ<88)79SS3D]94!@
M^Z@? 6WDQ:J60]NL:!33-F@OH7;+Q:A/$,>9F-Q$W#!3.J5>(7XJ*[6Z2'9&
M(:A&R<$^>=QH+9#E$3CY.$T#JC]#ZI@(JQ<F-/E<193$8:@XJZ'<%%HK#TP&
MQ8^,XY*N(?,Y8%$4#>K&C9'T[\I6E-HVX363]@4[J+A\7 6B$W)?8); B.GN
MAGH8*=(I*C2K*-"E P0;Q_A1"3OH8+^0PZ0R(,=2@;DY]M*C.U4PFC-+" @:
M4XZE&H;Y7<#8,/49!+1/Q$V0.Y&J;YH_+D<FI8PX#SY]$F(TH4EKWFN06CH&
MYCPT56^V(O"3D0*#A6'E_!=#+(VD(_HJ&I>T2NI]4%(J>3"3N6NFJ<'I<#@!
M&MB,DPG*C< B4?:BJQ.ZV0+M8SM])9FF%1Q#>I7S3H:QSP8TL/M_Y=@R$ZW^
M^>2@"C2P(J]?M%_2V<FZHF_*5B1J]X,PISPF7\#0>7#2ZO!5K$YJU[I$%0_2
M51BJ9L H F$Y0IGIHH\#A9RTZX*FUI/#2OAUI&P;( K;P@G@QHHS40R*M$YD
M//-G(-7YZ76O,,BYI Z?5A2.3&J:M(]3#_.J5QA^S"= #X[L@)7[QI/EH!TF
M"A>CL#MUJKORM!B,G3TV9F*8I&"N2BHQ71T1+"JW _^D++3HE<91A1%R^UIM
MW -E(QA38<_*<K1N&/=^.# $=OY1S(958>UK'&%0CJJ5,$#(D@;^5CF3+D:O
M,%Y*<\)0Y(-V Q9F2]]LUN:J1$%L[1@I]]Y#[N$PA%3%4-$=H\C&FG2@./;C
MR:1EJBE6;CCI97.>Z*$R20X?.935:/BUWBI@?0_4!INE,(*R>7DVB!.9;4;1
M"3R=)<=A+\^*%VE [R#CX# Z1! &@,,/(Q&/^*"SPCCI<T@GC"$B$H($X_@>
MZCQ86S>M#02)484_13ELLDJHH6 4J("FB!ZD\\5(;T1EWL][*LJJ@T2J+L[7
M?:V-=:#I<6]/GW%G$!*/)CGQ6O8& ;]/A$KA\Y2CU67)@D5YS#?I6Y59**OG
M"(X!"\N6ZX5AD_VVF.S7L<E^^YWLMT[Q7!.BO"HL=PYP8!5=IE4M65@]+M6;
M&1A2RC!1-C^&3%2P6KHB#%:L,[*Y]* LR+%9.]:W&?GHDR]FQ]F8360<YG+V
MTO94UB]L,G!G^7Z >5"@\@&)<><MUG;P4RFY'2=>MEY+R@L^JW3]7MB*-I(_
M,S-6@P)1A+JGM-'KW[[>.M^%U*HXJ[-N:%];C^^MM% JQO3MZOI[$>B7(8FT
MR.#CG)Y!'*=2RT(TJF"D"GDE7OJ39EBHE@WST$/P23ALV?N/I&M]57%M5<+B
MW+$S1X_CZVT1["*#7+;8,6[Y%H.16H3'KFZ_Z:JJ$^>CF3K$3D)\)CJ \91J
MW;X\,Z7*Z[A[P7BUDDC%D+T!9JRII +EA5!I6VP$($8:ER:7+9:A\*A6TY4(
M2SJ5B?$!<&G1 F$+'KB]3 0D31TCDVDFKTJ]H5"O8!-!/AGT?\*5]HI5<\V9
MHK"8N8EX'T<&?0?65")N%3>KL:%S&\;4S\/B"3*W&;="U5+S@G;C*$^+Q20G
MNR;0T02N!V'2$26RT[PB2HVA3K2C(L/.*OLPNF-ML98P.*A C&T'BF?&U,_=
MR+O0*2/LJ;K^=L>59AJ3$QU:<KE(L,X"O9)+8*:T=$5!>0:Y3:R.I%@=>2TV
M2&+&X2(A-6-/>R %!9"D[!F"40<+;>*QN-0H^HM\/1J0$H,TRZD1&PFU#'I4
M2K5!!P'O$YK(F)B2L@"7#L )X0P;RY:8D?&B@LJI;EQ?20Y'Y?CYYY0V6:4Z
M*JVN<'OP]I%Z0\ZS955#=#$8NUI;)=&J3"NK3-I[\UFE.M5)*5)Y2,3FI6B6
M3JJBS=T,-Y1FCRK<IQD=T33&H]AS)+W1/?E9UH0JEW55VIY"&$)O8<;"RN-Q
MZ2C_($A!= 2]TFTA5D_0T!NMEH:FT^/#8)FZZL2YCQUTB;M.ZUP[YN1!^*0R
M"\B>#_-A-_ F$O@JATUN5\Z5)&A'S6;7GH\,._6>%ZG<Y&$*JI-5GAF.1R/]
M[JH(S,N+S3)K9ARP5@.=+A[")OIC.5]0QT(?Q+/./Z)N/82SA!UJ@KY&_'Y
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ME*;'./"G-GK&8!U)ZL5I.VEKMYL:Q7__.X^S#Q-CX2^-PS2U5)M^Y?2+X6C
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M0 S@A:W\L<RSIK":PFH*>YDK?RSS?(3B]Z<:!-;/([@>)@ALC8&]P7)ZJ\;
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MS\J$1 YA4W!^>=F'AK8']A-5[1:!7E4&NCN5N?HT[@Q><1$'?XD=5MX#ZT)
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M)WRZHW!PV[UG;"@C[?4Z&6_QTW(K37@XB#95<\".<+V5J36@X1,*&.,?HJE
M&2['CHK92AZ=-7-]&@;0\*Y9=6S-1-R&FK;9L&=PQ:<-'@Y=D^ $T!?J)1D
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M\]'?S+*CYE]2\C9?T'@K;T<-*!.!CN4MEQ(.D:.JYJ$$^>1HA@GK;8MNXM5
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M;U4)A@_N ^J1<D?+[_#OPQ=:U2G_[<NRQ.UN,LX3@]LL)9LLUB(O))TISQ"
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M))M%(Q!M9.[2X.I"#'NWQ^899BT,R,71B)VEF-GW^0]2]VJ^>Q70DSPHI2:
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MZ?  4R#X!K(65+1B-BXK.%CF\QB;L]'NVVJ'V)[/AG0HF6QZ'?DN9AS7<ST
MM"USV)BJW<YM@VZ?*Y#WO8L6F''7V^K/N(P,F1$S"2?/UFI##&)FN*J!U7QE
M>]4K)[*0= &#\"^:8::E<=+H'WUB_M+U[9+E8E4X3A5I-'&?HAIA;TFY,ARG
M1>4))F--V4U=,DN$O"T:P^>@'3^:5IB<>4MGDDTDX\AC\S<4W#]8_!-<J&#.
MU4P?*A_;"6NI/^TV?EN:"Q?89YLI1C_1VX*Q( P-:[?)DU(;S5%,.).3I6U2
M&&1(,>^@'/0D8J("?L,X2RIU0''U>FXQ1(?5PO90<[CXG*/[XC-JP?I 1YO
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MFXT^PRSUMQI%/+CW/8IXFR@B>OJ"#YQTSJ(A>Z"6YW++T><T1! 'G5-;\?5
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M"#92-[Y(C9\9#>;&1V\-LMWF.29;OA<=:1]+_V!LUHA/YA3?59\AV%J'=I=
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M)&J8M(\A!,U\T*@UV.5(#LJG[T/+K 0OBZK.TR3:$AWM\+L.%SXM<FJKCH\
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MV9J/MV;W(,@/O 0<5T]32,G#W_DQCN)4U?OU]UQXQ:[KBPK<V0)*W'<>;.\
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M2AS^^:[H]:IXP^^TU]QQUBYJU#F_8QVB5T'^V_.]^]C7^<[M^]M!$ _#)BW
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M#3)"5F)*6TM:T->'PG= B0!E&2-8V=*J6@Y-73<E@(LN6:&JO@;S 0*<"9:
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M?[P>'8_>O:1+[1,8Q=Q;@$'(XXQT"W DP2UG0B";7 N1M=3BQ#I:T[QN6AO
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MT:ZG5SX-?^MT/10;]:W2/P%02P,$%     @  #C^4*_0./DV!   UP\  !$
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M?8WR]6N[.*0;^F6.POQ!_P=02P,$%     @  #C^4+[ ]0T,#P  ^9,   \
M  !M9"TR,#(P,#8S,"YX<V3M7>MOX[@1_]P"_1]4?]H"=1QO;G<OP>4.>=[Y
MD(<OR6ZO*(H#+=$VL1+I(ZG$;M'_O4-*LF1+U,N*DE;YLBM+\_C-#$G-D!3S
MW0]+S[4>,1>$T>/><&^_9V%J,X?0V7'/E]/^M[T?OO_3'[_[<[__(Z:8(XD=
M:[*RSB]'-]:OIW=7UH@*B:B-K7-F^QZFTNI;<RD71X/!T]/3GC,E5##7EZ!
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M0H6J2J6U]I2IM0YZ"HUE$OQIK1$](<[M] X3;^)SH>ENIU=,Q*?S/OND9E5
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M&%> XM8U)?9_MBL,66'_X9!QK<#"K;=H[:1PU:TU<"C*^X^(@G$%*&X]0KE
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M!%\M)WU%W2,$W4)J!=1^W(EF QFSVXRPS0^UA]JB\C%B;2&V FS7UYZE5OH
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MS>4:%2.ER*60!?S%KP;71_8-G:;1V.O'_BT3V>ZXPWD< 0I__C]02P,$%
M  @  #C^4%XZ@HA2(0  I. ! !,   !M9"TR,#(P,#8S,%]D968N>&UL[5WI
M;^,XEO^^P/X/V<SG5)P[*4S-P+FJ,TABCY/JGL5B83 6'6M;%MV4E,2SV/]]
M>?B0;5Z22).I7:#1G4Y(ZOW>X_4>W_'GOWZ,DYTWB+,8I=]V#[ZT=G=@.D!1
MG+Y^VRWRX=[Y[E__\J__\N=_V]O[#E.(00ZCG9?ISO7MW>/./RY[]SMW:9:#
M= !WKM&@&,,TW]G;&>7YY.O^_OO[^Y=H&*<92HJ<?"#[,D#C??+W7_D'=WI'
M7UKD?\E/1ZV]OQ7)=.^P==C:^8_6P==6Z^OAR7_N_'?WX7_V]B@%29S^_@(R
MN$,H3K-ONZ5O?+S@Y O"K_N'K=;1_KSA+F_Y]2.+5UJ_'\W;'NS_X^'^:3""
M8[ 7SV L>M%A1/T.+BXN]ME?2=,L_IJQ_O=H '+&0RU=.](6]/_VYLWVZ*_V
M#@[WC@Z^?&31@B[2)LH7GRD/<++/_[A+V851 GMPN,,H_9I/)_#;;A:/)PE%
MR'XWPG#X;7<<,9ZW3H]:]#-_ND)47'%$!?V4DW]3D6:=X<T?19Q/=W?HN#]Z
M=RLXQS!*P0<3+OWSOFZ,_28$7H(L)F-U,<S(J(SI[31ZA._MP0 5:4YF;A>C
ME/PXX-]M1U%,6X'D+ATB/&9=KF$.XL0,CMTO-@)_A<B'P%N,BZP+T@B.X\$5
M>HNC@XO&*&L.W0P.R$9T4KR!A/$MC>[2-YCE=N16?W1WH.AN$Q4)[ Q+O[0&
M2CEZ(U"W(,:_@J2 #Q!D!89KGUO\N9.V>W!08$P6!5LW_.N9&;CF7W$*,D[)
M"1'3&9/EF)UUV?,(Y&T,'U%^!0@Y,&KGBU&L0J_[[48,F6UP&6$V)#/N)8%L
MX\M[\ VF!5R2M_Q=E;G<8/BMP>J2C8$P^PGBMW@ 9RTNI\_D8^1( %.$72$V
M_W(C9ES'V0#10ZR 46=";WCTIM9X\ZTQK ,82X:*_UYIB3;\A)4I2^0^FS7D
M-YA\Z.9C M,,-A=8LR\T O>4H\'O=^3V1)CW!KL)2.FYQG[;+?!@1&[#_)=-
M,5KY4,,+W'B,4O;%'IS,OXG1*P9C"S>>VJ,W!$4TR"YXA:94+II;X"41(/]A
M>2MZ&@%R5U\NS"N0#(J$X>T,^1]_9)!<G.C=84 &N(Z)@@KI1DPF!QK#+L2L
M677>;X,:MQN)I=W"-9G/]->VB)T/YG(Z6IE%;DFLPE/#H;9R+MC=_%WN\!:V
M<0ODQ3,5F J/F2\@42VJ"%XZ@,MKN94;MEL2ZVQ*FJ$:"EMLB./G2C-CWGP,
M:P1>@H0:8)]&$.;9CQ04Y+H"HR[93=)\!/-X (Q/XHJ#.N$Q-=3<)NC=>%EI
MA]F.SKO9D+1RHN,JO^3V]K!)A+2I51VJQG<=KR];2\J%Z:V!Y<P%.55V=^4
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MJ?9I/ ;GGA>S4;VK<GV$:I]0QWIBO=R\GRSZ[O3\M-7R\L)1+R*$T;M%Y="
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M=459$:"CVJT/15Z I.(24_;A%'LU"S5976;8;)1VM96P!KS0U"LQK'E^F0W
MD0>744]YB%5$YJA<[&61$7JS[ J-7^*4>7G1-*EQ^DJ?!A%1C,EW /?6X?1.
MC5>BG;$Y![Q$WM44U<:RM<P(35U;SSY7!&!*$[,N<PIFSR.0MS%\1"SB,(91
M.U_B^[2>6.<M#QMJ T^L\Y:/^#HYZ\3;HH3N__?$6G'0.&\%$#TG$Y5:KE(X
M/Y,GUGG+=SR<GM]B.2GP_$R>6 10**\*UB45H"=6X^J_!-A!@&4!E5N> D<P
M;E56Z\E2<+Z*"1HPW41* CC!.$G9EU4H6Z!MH5EU>1)HS<_OZ'F$B@RDT?,[
M(6#Z3)K*$_]H>G"BO994T2Z"#9W6") %ER03[C_1DBV5N%_JP8GU^E!I@?LB
M0,'X#I7L)]5,?F73RGDKN 342D56!2,<MYY'6B^Z"Z8::T*Y&9]?7E\U5+P5
M2T,((!QGFBW:R<\/O+Y^-%E')LC"<:DI3[EJKXJ:GARKU]>.BD+1KTD53(U?
MC6-[=WLP0 5WNX;Q&Z6UG4:/<%XG;FGY7O[.0E+^#8-Z^KHD0)>5W[!S__#$
M1RZY. .OKQB^L@</6H*/\<Q@C]/T)'"\W*&K,ERBT9B "\:@/:-N45614/A;
MG(^NBBQ'8XCOTD%21(0+]*V;_!,]@P^%8&N,UC\\]7H#,1*76-*UT09C("^E
MF)AMCFPKOT<@I4F9!&M ^UI5;T3"9C>>:[*J'186>B.H%I_!FMOMC5(B=S&*
MBD'>P4\0O\4#5>IO45,".X27KD8R6YD&:J"N#/951$41S0C+I 9&97N"Q=?S
MEYJ]4E'(,'A-E6]5'KY-O58%H[/O>C#._P)!0@YQ@&&77 EH:CI.M=;K7MV1
MG/Q>U'6#M2$^WDS@N#'*_X*R29R#))O?JN2YV!2M"85>-.O*#-=B""8>> 9K
MB8KEA],N#%6W_M'%R>'9YQ!4)3Q>TZE5,76LKNY9B\LI31K8&7;!%&$_B?F7
M^T\'OX)TEKEP!='<2K.P-!EEZF\V,%F2E0XE9?%Y0P&(-[[*P_0/_59/ML'X
MC:VS)A>",< LU^)\<:*"(,K$S#)7OXU'(WQU\QZG=">U/Q<:L\"B2N[!E"-C
M:)D%&G<MTR$(N]QHA355^:IRUEQW3< 'XT%I0K;6N<A\$(+>482IL5]8-4'5
M%W89<##NEQ[$[=O>X$_N.N-$T^#CN;('HP>0D@M,1 E3J;J*#N16X]4;H.J*
MVKC':;$%8R!:%BW0:K[K3?N>5%T[4E*C"B8GW1-,Z$U?*YR5=@2#(X?G;4I&
M "D8X]'S*,91%^!\RM0PK7B$[0DFKP&D=L2D@.;5;$15+1;.6L"H,YE%LF;M
M*(HY/7?I$.$Q^ZVG8HT-@SV/3\^//+G*3% &DN\8%9-'E L9_9W,FGN499UT
MWESM0E-GQ/[)V?&I(^VMOM_@7"SBU=(4:CBFGIHAOXP];A[/JX;\JB4EH=N7
M845PY;Z&0X@Q<\7AV3LD)A%94X;I/ 3KAX35Z]=J-0H+9@P3)DLU4GEC3J(O
M6X.6<7H^K\&P8$%PRVG?:KYMEEM5WAW< EC0+R^11IFL":15]V0.UL?AE701
M[TI5006C^"L(UL=OZOIRN+[+OIC*I+)$UT &8RS8ADQ];ZW;%:YNXVT:-/J(
M<#YJCR$F'T^I$IU"G-VE[11F^0AF,5!94 T[]\\.SD]=5<(V]DLW7$L;!V-5
MD!;"2T5WDY@F'(SS L/.\ %&$<B5HI&W[Y^1Q7OHU3S70!H&N)Q%D1IYI_9
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MLG =U8UGT1MUNOM:7HR5K1(DR9I;_VQ%L6<0+/(TB7DV6;39)&E"?PS(H V
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MVDH2O3!-Y(;.T'.V21;Y&'5ZR6-^7C?<KC)UI0DR5FX%..DT:86V,,S'=#/
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M_BSP![WVRJ;9HBZ)&*4V,Y>V%^R550WWDDN8O'5;Y9.V#V3NL1@'R95*TR"
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M5&VN#OL?RNE.Y)QJIGRL/N;D.S0]P5V&3@JMVD7'6ME!N0<HF>!=@1%S<@\
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M E[>4+<,%L]\C\P41;E6% 2_E@7+F?J2M; +U?D@RZEV")V6NHU-J!$Q]J&
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M=-XHJ=F&Q=)C4 Z9TJ-;]!;(@!\6:S!"_<)@"[C;MI ER5[HIPPVD.W&@@K
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MRM=B5";;T"VX[S(.I1[PZ>LJ#.[HFMKW+X1LI&C,"O-"28=L.ZVS%2R[4>H
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M_2CS(ILB<I<.DG)(Z<<"ONC_AB_QN_9-P'DT>EP"F]FM6"V7DMIX.YRQU\4
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M&ZH(XT??,GQ$$!\P;+,]F6V16+Y<MSLCJM>( AM@(1B4.M.,%%4*"3]BJOF
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MP5;I064QR0C^.])MHII>E#3 #QKM"I41NL+=KE.V:N&YG><E&E[SZB!B)Q>
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M8&ZV__+_ 5!+ 0(4 Q0    (   X_E"=$;Y=21D! #<A$0 /
M  "  0    !D.3$Y.#4Y9#$P<2YH=&U02P$"% ,4    "   ./Y0(ZL/$96H
M  #03@, $0              @ %V&0$ 9#DQ.3@U.61E>#$P,2YH=&U02P$"
M% ,4    "   ./Y0XPEJ%_ '  "7*@  $0              @ $ZP@$ 9#DQ
M.3@U.61E>#,Q,2YH=&U02P$"% ,4    "   ./Y07<W9).('  !<*@  $0
M            @ %9R@$ 9#DQ.3@U.61E>#,Q,BYH=&U02P$"% ,4    "
M./Y0K] X^38$  #7#P  $0              @ %JT@$ 9#DQ.3@U.61E>#,R
M,2YH=&U02P$"% ,4    "   ./Y0OL#U#0P/  #YDP  #P
M@ '/U@$ ;60M,C R,# V,S N>'-D4$L! A0#%     @  #C^4'O"!<>Z#@
M7M@  !,              ( !".8! &UD+3(P,C P-C,P7V-A;"YX;6Q02P$"
M% ,4    "   ./Y07CJ"B%(A  "DX $ $P              @ 'S] $ ;60M
M,C R,# V,S!?9&5F+GAM;%!+ 0(4 Q0    (   X_E"*@8^L0%4  /73!  3
M              "  786 @!M9"TR,#(P,#8S,%]L86(N>&UL4$L! A0#%
M  @  #C^4#^U[UMS.@  Q)$# !,              ( !YVL" &UD+3(P,C P
A-C,P7W!R92YX;6Q02P4&      H "@!Z @  BZ8"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
